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Summary 
The pathophysiology of traumatic brain injury (TBI) includes perturbations to energy metabolism. 
Improving our understanding of cerebral energy metabolism will lead to strategies that improve 
clinical outcomes. For the studies in my thesis I used microdialysis to deliver carbon-13 labelled 
substrates to the human brain. I combined this with nuclear magnetic resonance (NMR) spectroscopy 
of interstitial fluid sampled from the brain to interrogate glucose, lactate and tricarboxylic acid (TCA) 
cycle metabolism.  
 
Study I: I defined the optimal parameters for quantitative proton and carbon-13 NMR of cerebral 
microdialysates.  
Study II: I measured baseline microdialysate metabolite concentrations for brain and muscle and 
investigated the influence of muscle activity and cerebral catheter placement in grey or white matter 
on metabolite concentrations. 
Study III: I used 1,2-13C2 glucose to measure glycolysis and pentose phosphate pathway activity. 
Glycolysis is the dominant lactate-producing pathway but the pentose phosphate pathway also 
contributes and is increased in some TBI patients.  
Study IV: I used arterio-venous gradients to measure glucose and lactate delivery to the brain. There 
are periods after injury when lactate is imported from the circulation despite relatively high brain 
lactate levels suggesting up-regulation of lactate transport. 
Study V: I followed the metabolism of 3-13C lactate and demonstrated that lactate is metabolised by 
the TCA cycle. This occurs in both normal and injured brain but not in muscle.  
Study VI: I used 2,3-13C2 succinate to investigate the role of the TCA cycle in producing metabolites 
that are exported into the interstitium. The TCA cycle is found to be a source of lactate. Succinate 
delivered to the brain improves redox and enhances glutamate uptake into cells. 
 
The implications of the findings in my thesis on existing knowledge of cerebral metabolism are 
discussed. Strategies that might potentiate cerebral metabolism and improve clinical outcomes are 
suggested. 
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1.1 Traumatic brain injury 
 
Traumatic brain injury (TBI) is a heterogeneous disorder caused by the action of external 
mechanical forces on the brain. (1) It is one of the leading causes of mortality in young 
adults with mortality rates in the USA and Europe ranging between 15 and 20 per 100,000 
per annum. (2,3) TBI incidence is increasing worldwide. In developing countries this is due to 
increasing use of motorised vehicles while in developed nations there is an increasing 
incidence of TBI in the older population due to falls. (4) Moreover, it is estimated that 
approximately 5.3 and 7.7 million people are living with disability due to TBI in the USA and 
Europe respectively. (4) Consequently TBI has huge economic and societal costs. 
 
The primary injurious event is followed in the hours and days after injury by secondary 
pathological processes that can exacerbate damage and are thus targets for therapy. (1) The 
management of TBI centres on the maintenance of adequate cerebral blood flow (CBF) and 
the delivery of sufficient glucose and oxygen to preserve tissue not irreparably damaged by 
the initial physical insult. Cerebral perfusion is maintained, hypoxia avoided and with 
modern neurocritical care management, secondary ischaemia is not thought to play a major 
role. However, despite progress in management of TBI patients many still suffer long-term or 
lifelong disabilities, so placing heavy demands on carers and healthcare resources, and there 
is scope for better treatments. 
1.2 Energy metabolism in the brain 
 
Energy metabolism, the fundamental process through which living systems acquire and 
utilise the energy they need to function, is achieved through the oxidation of 
carbohydrates, lipids and proteins coupled to endergonic reactions, which results in the 
synthesis of high-energy phosphate compounds, specifically adenosine triphosphate 
(ATP). Glucose is a ubiquitous fuel in nature and is recognised as the principle energy 
substrate for human cells.  
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1.2.1 Glucose and glycolysis 
 
Glucose is the preferred substrate for the brain, although the brain can take up lactate, 
other monocarboxylic acids and ketone bodies under certain circumstances, for 
example, during the perinatal period. (1,5) Once it enters cells, glucose is metabolised 
through glycolysis to pyruvate. Glycolysis is the series of reactions that results in the 
breakdown of glucose, generating pyruvate, ATP and nicotinamide adenine dinucleotide 
(NADH). See Fig. 1.1. Glycolysis is a truly fundamental pathway, found throughout 
nature and proceeds without the need for oxygen. The ten key enzymatic steps, in 
which 2 ATP molecules are consumed early on but then paid back later with the 
generation of 4 ATP molecules per glucose molecule, takes place in the cytosol. There 
are three key regulatory points catalysed by the enzymes hexokinase, 
phosphofructokinase and pyruvate kinase. These reactions are essentially irreversible 
whereas the other enzymatic steps exist in equilibrium. (6) Pyruvate is converted to 
acetyl CoA that enters the tricarboxylic acid (TCA) cycle within mitochondria. 
Alternatively, pyruvate can be converted to lactate, which recycles NADH (reduced 
nicotinamide-adenine dinucleotide) to NAD+, a coenzyme essential for glycolysis enabling 
further glucose molecules to be processed by glycolysis. The TCA cycle results in the 
transfer of electrons to electron transport chains (ETC) located in the inner 
mitochondrial membrane. These electrons ultimately deposit on oxygen molecules 
generating carbon dioxide and water. The ETCs pump protons across the inner 
mitochondrial membrane maintaining a gradient of protons across the membrane. 
Protons then flow down their concentration gradient through ATP synthetases (ATPase), 
resulting in the generation of ATP, the cells widely used energy currency. (6) The 
theoretical overall yield of the glycolytic followed by TCA cycle metabolism of glucose is 36 
moles of ATP per mole of glucose. See Fig. 1.1. 
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Figure 1-1 Glycolysis and the tricarboxylic acid cycle 
Glycolysis (also termed Embden-Meyerhof pathway) metabolises glucose to pyruvate, adenosine triphosphate 
(ATP) and nicotinamide adenine dinucleotide (NADH). There are three key regulatory points catalysed by the 
enzymes hexokinase, phosphofructokinase and pyruvate kinase. Pyruvate is converted to acetyl CoA that 
enters the tricarboxylic acid (TCA) cycle within mitochondria. The TCA cycle results in the transfer of electrons 
(from NADH and succinate), to electron transport chains (ETC) located in the inner mitochondrial membrane, 
which ultimately deposit on oxygen molecules. The ETCs pump protons across the inner mitochondrial 
membrane maintaining a gradient of protons across the membrane. Protons then flow down their 
concentration gradient through ATP synthetases (ATPase), resulting in the generation of ATP. Glutamate spins 
off the TCA cycle from α-ketoglutarate (αKG), an intermediate of the TCA cycle. (1)  
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1.2.2 Energy metabolism, neurotransmitters and neuronal-glial coupling 
 
Metabolism in the brain is compartmentalised by the different cellular and subcellular 
location of enzymes and transporters. This is integral to the release, uptake and recycling of 
neurotransmitters, which is coupled to cerebral energy metabolism. As discussed above, the 
mitochondrial TCA cycle is central to the high oxidative demands of the brain and also 
provides the carbon skeletons incorporated into the neurotransmitters glutamate, GABA and 
aspartate. In this way, the release, uptake and recycling of neurotransmitters by neurons and 
glia is intimately related to oxidative energy metabolism. For example, there is a constant 
cycle of glutamate released during neurotransmission at glutamatergic synapses, 
retrieved from synaptic junctions by astrocytes and returned to neurons as glutamine. 
Sibson et al. (1998) have estimated that 80% of total cerebral glucose is tied to 
glutamatergic activity in this way. (7) The exchange of metabolic intermediates between 
cells is not yet fully understood however and controversy exists over the coupling of 
metabolism between neurons and glia and the biosynthetic functioning of their respective 
TCA cycles.  
1.2.3 Lactate metabolism by the brain 
 
Glucose is recognised as the primary energy substrate in most organs, including the brain. 
Increasingly recognised is the potential role that lactate, conventionally regarded as a waste 
product of glucose metabolism, plays as a metabolic substrate in brain.  
 
Evidence from in vitro and in vivo studies indicate that the brain is able to oxidatively 
metabolise lactate. In vitro studies using neuronal and/or astrocyte cultures as well as 
isolated brain tissue demonstrate that labelled lactate is readily metabolised to both carbon 
dioxide and derivatives of the TCA cycle. (8-13) Lactate is able to support neuronal function 
in the absence of glucose and has been shown to be more readily oxidised than glucose by 
neuronal cultures. (11,12,14) In support of lactate's role as an energy substrate in vivo the 
oxidation of lactate has been demonstrated in rat brains to occur in an activity-dependent 
manner and also to spare glucose utilisation. (15) More recent evidence has confirmed that 
the human brain is able to oxidatively metabolise lactate. (16,17) 
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As a result of the evidence for lactate's role as an energy substrate in the brain and in 
particular as a neuronal substrate, a scheme of metabolic trafficking between astrocytes 
and neurons has been proposed by Pellerin and Magistretti. (18) Neurons take up lactate 
(produced from glucose by glia), metabolise lactate to pyruvate, which is transported into 
the mitochondria and converted to acetyl CoA, which enters the TCA cycle. This has become 
known as the astrocyte-neuron lactate shuttle hypothesis. (18) However, despite evidence 
that the brain has the biochemical apparatus necessary to oxidatively metabolise lactate, 
controversy exists as to its exact role as an energy substrate. (19)  
 
1.3 Metabolic changes in the brain associated with TBI 
 
The pathophysiology of energy failure after TBI is not yet fully understood. Animal studies 
suggest an early period of increased glucose metabolism followed by an extended period of 
metabolic depression that may last from hours to weeks. (20-22) The acute increase in 
glycolytic activity is thought to occur in response to the massive ionic disturbance that 
follows the physical disruption of cells. (23,24) Disruption to cell membranes and a failure to 
maintain normal ionic homeostasis results in cytotoxic oedema, which further challenges 
membrane integrity. (25) Excitotoxic release of glutamate and other excitatory 
neurotransmitters further exacerbate the disturbance of trans-membrane ionic gradients. 
(22,23) Mitochondrial calcium accumulation induces oxidative stress and impairs 
mitochondrial function. (26,27) The generation of free radicals, highly reactive oxygen and 
nitrogen species normally kept in check by cellular antioxidant systems, leads to the 
oxidative modification of proteins, lipids and DNA. (28,29) This results in increased 
permeability of the inner mitochondrial membrane, release of cytochrome c leading to 
caspase-dependent apoptosis, and activation of poly-ADP ribose polymerase (PARP), a 
nuclear DNA repair enzyme that consumes NAD+. (30-32) Ultimately, although initially 
potentially reversible, these metabolic and mitochondrial perturbations result in energy 
failure and activation of both apoptotic and necrotic pathways. (31) These and other as yet 
uncharacterised changes may be important in TBI patients' brains. (1) 
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1.4 Evidence from animal studies 
 
The metabolic perturbations that result from TBI have largely been studied using animal 
models of TBI. (1,24,33) In general, for the purposes of metabolic studies, metabolites are 
measured and/or tracers are used to follow biochemical processes at set time points after 
experimental injury. Many of the techniques used require the brain to be extracted and so 
are not applicable in clinical studies. Animal models of TBI produce a relatively homogenous 
injury in comparison to clinical TBI and the majority of studies do not consider co-
morbidities or other systemic factors that frequently complicate clinical TBI. (1) Patients with 
severe TBI commonly have injuries to other organs, such as chest and abdominal injuries, 
with consequent risk of systemic hypoxia and/or hypotension that is deleterious to outcome. 
(34,35) The impact of sedative drugs and other pharmaceutical agents that are also likely to 
influence cerebral metabolism, are also frequently overlooked. Hence, we must exercise 
caution when applying what we learn about glucose metabolism after TBI in the laboratory 
to what actually happens in clinical practice. (1) 
1.5 Evidence from human studies 
1.5.1 Methods for studying energy metabolism in humans – an overview 
 
There are various methods for investigating metabolism after TBI in patients. (1) Measuring 
arterial, jugular and/or cerebrospinal fluid (CSF) concentrations of metabolites provides a 
measure of how much the brain as a whole imports or exports. Microdialysis, which samples 
extracellular fluid, is a focal technique that allows the immediate microenvironment of the 
brain to be sampled in vivo. Autoradiography experiments in animals and analogous positron 
emission tomography (PET) studies in humans, use glucose labelled with a radioactive tracer. 
These experiments allow regional differences in glucose uptake and metabolism to be 
measured. In vivo magnetic resonance spectroscopy (MRS) has also been used to measure 
the combined extra- and intracellular regional concentrations of lactate and high-energy 
phosphate compounds. Our ability to study cerebral metabolism using these techniques has 
improved our understanding of the pathophysiology of TBI and corroborates experimental 
data that indicates changes to glucose metabolism and mitochondrial physiology. 
Importantly, there is also the potential for these techniques to help in the management of 
patients with TBI and improve clinical outcomes, although their role in the clinical setting is 
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still being defined. (1) In the next section I summarise the evidence that provides the basis 
for our current knowledge of energy metabolism in the human bain with a focus on the 
insights gained from human microdialysis and PET studies. 
1.5.2 Microdialysis 
 
Microdialysis allows continuous in vivo sampling of molecules from the extracellular fluid 
from the human brain and permits the longitudinal analysis of certain energy-related small 
molecules. (1) Clinical microdialysis catheters are often inserted alongside brain tissue 
oxygen sensors such that changes in concentrations of small molecules related to energy 
metabolism can be monitored in conjunction with variations in tissue oxygen levels. 
Metabolic features of microdialysates statistically associated with adverse outcomes after 
TBI include high concentrations of lactate and high lactate/pyruvate (LP) ratio, while for 
glucose the situation appears more complex with both high and low concentrations having 
adverse associations. Further details are as follows.  
1.5.2.1 Microdialysate glucose concentrations after TBI 
 
Patients with poorer outcomes after TBI have been observed to have lower average glucose 
concentrations for the monitoring period compared to those with better outcomes although 
the relationship is complex and high glucose concentrations are also associated with worse 
outcomes. (36-39) Vespa et al. (2003) identified three patterns of daily mean glucose 
concentrations in 30 patients with severe TBI. (37) They found better outcomes when the 
glucose concentration was initially ‘normal’ and then later declined as opposed to initially 
low at the start of their monitoring. They also found the lowest overall mean glucose in the 
patients that had the worse outcomes, although no independent effect of low glucose was 
observed using a multivariate model with other known predictors. Similarly, Yokobori et al. 
(2011) found that glucose gradually declines until the fourth day after the onset of 
monitoring and then increases. (36) The largest investigation of TBI patients to date found 
that the total averaged monitoring glucose concentration was a positive predictor of 
mortality in a multivariate model such that higher concentrations of glucose were associated 
with mortality. (39) Hence, the likelihood is that there is an optimum range for cerebral 
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glucose with both low and high glucose having been associated with worse clinical 
outcomes.  
1.5.2.2 Evidence for ischaemia after TBI 
 
Low brain glucose after TBI might be attributable to ischaemia, i.e. a deficiency in supply of 
oxygen, glucose and other blood-borne nutrients. Nowadays, with modern protocol-driven 
therapy, the incidence of gross ischaemia after TBI is low in neurocritical care patients. The 
injured brain may however be at risk from micro-vascular ischaemia, failure of vascular 
autoregulation, elevated intracranial pressure, and systemic problems that result in hypoxia 
and/or hypotension. (34,39-42) On account of the confounding effects of a reduced 
conscious level and sedative drugs after TBI, ischaemic thresholds cannot simply be 
determined by CBF measurements. Instead, an increase in the oxygen gradient across the 
brain is used to indicate a relative supply failure. This can be measured globally using jugular 
venous oxygen saturations and regionally using PET. Coles et al (2004) used Oxygen-15 (15O) 
PET to measure oxygen extraction fraction (OEF) and to define ischaemic voxels. (43) They 
based their OEF ischaemia threshold on a venous oxygen threshold of 3.5 ml/100 ml and 
estimated the volume of ischaemic brain in 15 TBI patients within 24 hours of TBI. They 
found ischaemic volumes of between 1 % to 16 % of the total brain volume, particularly in 
voxels adjacent to contusions or haematomas. Vespa et al (2005), using similar methodology 
and the same OEF threshold in 19 patients found that the incidence of ischaemic voxels 
averaged only 0.14±0.28%, although patients underwent PET imaging at later time points; 
on average 60±30 hours from injury. (44) In summary, the incidence of frank ischaemia after 
TBI appears to be low, although marked changes to CBF induced by hyperventilation, or 
marked reductions in cerebral perfusion pressure (CPP) can affect brain glucose. (45,46)  
 
In support of brain glucose concentrations being more influenced by uptake and cellular 
utilisation rather than ischaemia, a combined 18F-fluoro-deoxyglucose-PET (FDG-PET) and 
cerebral microdialysis study in TBI patients found that the cerebral metabolic rate of glucose 
(CMRglc) measurements in a 2 cm region of interest around the microdialysis catheter tip 
showed significant positive correlations of CMRglc with lactate and pyruvate concentrations. 
(47) Therefore, low concentration of brain extracellular glucose seems a consequence of 
increased substrate demand rather than inadequate substrate delivery.  
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1.5.2.3 Microdialysate lactate / pyruvate ratio after TBI 
 
The LP ratio reflects the balance of cytosolic NAD+ and NADH, the redox status. NAD+ is 
oxidised to NADH during glycolysis and a continued supply of NAD+ is required for glycolysis 
to continue. See Fig. 1.1. In the cytosol NAD+ can be regenerated via lactate dehydrogenase 
(LDH), which catalyses the conversion of pyruvate to lactate and NADH to NAD+. Inside 
mitochondria, NADH generated from NAD+ through several of the reactions of the TCA cycle, 
transfers electrons to electron transport chains which regenerates NAD+. If mitochondrial 
metabolism falls, the NADH/NAD+ ratio increases and there is greater lactate dehydrogenase 
conversion of pyruvate to lactate and an increase in the LP ratio is observed. The LP ratio can 
be described by the following equation: 
 
[lactate]/[pyruvate] X KLDH = [NADH][H+]/[NAD+] 
 
A greater proportion of glycolytic metabolism compared to mitochondrial oxidative 
metabolism, due to either hypoxia and/or a pathophysiological reduction in mitochondrial 
activity (termed ‘mitochondrial dysfunction’) will produce a greater LP ratio. Hence, the LP 
ratio is used clinically as a marker of mitochondrial dysfunction after TBI. (48) An increase in 
the LP ratio in the presence of low pyruvate (and low oxygen) indicates ischaemia whereas 
an increase in LP ratio in the presence of normal or high pyruvate (and normal oxygen) 
indicates mitochondrial dysfunction. (48)  
 
The association of a higher LP ratio with a poor outcome is a consistent finding across the 
TBI-microdialysis literature and is found in the most methodologically robust of studies that 
use patient-averaged data and multivariate statistical techniques. (39,49,50) Timofeev et al. 
(2011) in the largest study to date found that the most consistent trends of all the 
microdialysis parameters measured after TBI were for brain lactate and the LP ratio both of 
which were lower on a daily basis in patients with favourable outcome as compared to those 
patients with a poor outcome. Moreover, the LP ratio was found to be a significant positive 
predictor and pyruvate a significant negative predictor of mortality. The observation of a 
high LP ratio in the absence of ischaemia or hypoxia corroborates experimental evidence 
indicating mitochondrial dysfunction as a feature of the pathophysiology of TBI.  
Introduction 
12 
1.5.3 Autoradiography and positron emission tomography 
 
Autoradiography and PET imaging studies that use labelled 2-deoxy-D-glucose (2DG) as a 
tracer allow the in vivo delivery, uptake and initial metabolism of glucose to be assessed 
both globally and regionally in the brain. Demonstration of this technique by Sokoloff et al. 
(1977) provided some of the first experimental techniques for interrogating regional changes 
in cerebral metabolism in vivo. (51) They used 2-deoxy-D-[14C]glucose as a tracer ([14C]DG), 
which is taken up from the circulation and phosphorylated by hexokinase in the first stage of 
glycolysis. [14C]DG, following phosphorylation, does not continue in the next and subsequent 
steps of glycolysis, essentially remaining trapped. Sokoloff et al. (1977) injected awake and 
anaesthetised rats with the tracer and used quantitative autoradiography of brain sections 
to calculate regional rates of glucose metabolism. 
1.5.3.1 Hypermetabolism and hypometabolism after TBI 
 
Autoradiography and PET studies in animals have demonstrated a stereotyped acute period 
of high glucose metabolism followed by longer lasting metabolic depression. This acute 
period of hypermetabolism is observed in animal models for up to 6 hours and affects both 
hemispheres, but more so on the ipsilateral hemisphere. (20) Following this acute period of 
hypermetabolism, a depression in glucose metabolic activity ensues that may last several 
weeks. This appears to be widespread throughout various regions of the brain and has been 
found to be associated with neurological outcome in clinical studies. (52) 
 
Most clinical reports demonstrate a depression of glucose metabolism following TBI when 
compared to control subjects with only discrete areas of supra-normal glucose metabolism, 
particularly in relation to mass lesions. Bergsneider et al. (2000) observed that 20 of 26 
(77%) patients with a range of TBI severities within seven days post-injury demonstrated a 
CMRglc in cortical grey matter of the whole brain at least two standard deviations lower 
than a value for CMRglc derived from a historical control group (7.3 ± 1.2 mg/100 g/min). 
(53) There was no clear correlation between the severity of injury and CMRglc values 
although patients that were on dual sedative drugs (morphine and a benzodiazepine) 
exhibited lower CMRglc values than those on a single sedative. Some peri-contusional 
cortical grey matter areas demonstrated markedly raised CMRglc values compared to the 
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control value whereas others demonstrated depressed CMRglc. A later study from the same 
group which used aged-matched controls, found significantly lower CMRglc in the whole 
brain, striatum and thalamus in TBI patients compared to control subjects. (54) No 
differences were detected in the brainstem or cerebellum.  
1.5.3.2 Increased anaerobic glucose metabolism after TBI 
 
Although glucose metabolism in TBI patients is found to be relatively depressed compared 
to awake and non-sedated control subjects, PET studies suggest that glucose metabolism in 
TBI is increased relative to the rate of oxygen utilisation. In a subset of six patients 
undergoing 18FDG-PET Bergsneider et al. (1997) used a combination of arterio-venous 
oxygen measurements and intravenous Xenon-133 CBF measurements to calculate both 
oxygen and glucose metabolism. (55) In all six of these patients who underwent FDG-PET 
imaging between days 2 and 8 post-injury, glucose metabolism was found to be 
disproportionately greater than oxygen metabolism, so termed ‘hyperglycolysis’. Wu et al. 
(2013) combined triple-oxygen (15O) PET used to measure regional oxygen utilisation, with 
FDG-PET to explore the relationship between glucose and oxygen metabolism in contusional 
and peri-contusional regions in 8 TBI patients. (56) CMRglc in contusional and peri-
contusional regions was depressed relative to CMRglc measured in the surrounding normal-
appearing white matter of the same patient. Yet, oxygen metabolism was even more 
depressed suggesting a shift in glucose metabolism from oxygen consuming to anaerobic 
metabolism. 
 
The changes in glucose metabolic activity observed with deoxy-glucose studies relate to 
both the rate of glucose transport into cells and the rate of phosphorylation by hexokinase 
(and its subsequent metabolism). Whether the changes in glucose metabolic activity that 
follow TBI are caused by changes in glucose transport, changes in hexokinase activity or are 
due to a combination of both changes in transport and hexokinase activity is not readily 
appreciated by autoradiography studies.  
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1.5.4 Current knowledge of energy metabolism in the injured brain – a 
summary and the context for this thesis 
 
In summary our understanding of energy metabolism in the brain is incomplete. 
Perturbations to energy metabolism are an important aspect of the pathophysiology of TBI. 
Changes to glucose metabolism that follow TBI appear to be largely independent of 
ischaemia. PET studies both alone and in combination with microdialysis suggest that 
ischaemia when it occurs is only detectable to any great extent in the first few hours after 
TBI or when CBF is challenged by hyperventilation or marked falls in CPP. FDG-PET indicates 
that although glucose metabolism is depressed when compared to control subjects with 
discrete areas of supra-normal glucose metabolism, there is a shift in glucose metabolism 
from oxygen consuming to anaerobic metabolism. Microdialysis studies demonstrate 
changes to extracellular glucose and lactate concentrations that relate to clinical outcomes. 
It is likely that these reflect changes in the proportion of glycolytic versus mitochondrial 
metabolism as reflected by the LP ratio and are in part due to mitochondrial dysfunction. 
Developing our understanding of these changes that occur in the cellular utilisation of 
glucose after TBI forms the basis for this thesis. 
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1.6 Objectives 
 
The overall objective of this thesis is to increase our understanding of energy metabolism in 
the human brain after TBI by defining how the cellular utilisation of glucose changes, 
exploring the role of lactate as an energy substrate and investigating mitochondrial 
dysfunction. Complimentary methods have been used to explore the uptake and release of 
lactate by the injured brain and to interrogate the metabolic fate of glucose and lactate and 
the TCA cycle in the normal and injured brain.  
 
1.6.1 Hypotheses 
 
o H1: “1H and 13C NMR analyses of cerebral microdialysates can be used to identify and 
quantify a range of interstitial cerebral metabolites” 
o H2: “Baseline tissue chemistry is the same in brain and muscle” 
o H3: “In TBI patients baseline tissue chemistry is the same in grey and white matter” 
o H4: “The relative contribution of the glucose metabolic pathways glycolysis and the 
pentose phosphate pathway differs for uninjured brain compared to injured brain. 
The contribution of the PPP is less in uninjured brain than in injured brain.”  
o H5: “The brain after injury imports lactate from the circulation.” 
o H6: “The brain is able to oxidatively metabolise lactate.” 
o H7: “Muscle is also able to oxidatively metabolise lactate.”  
o H8: “3-13C lactate metabolism through the TCA cycle differs between the uninjured 
and the injured brain.” 
o H9: “Administration of succinate by microdialysis will enhance energy metabolism 
and have a favourable impact on the lactate / pyruvate ratio.”  
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2.1 Microdialysis 
 
Microdialysis allows the simultaneous delivery of a substance to the extracellular interstitial 
fluid whilst also sampling the interstitial fluid. Microdialysis catheters possess a semi-
permeable membrane that is continuously perfused with fluid, allowing molecules to diffuse 
across the membrane to and from the brain's interstitial fluid. They are used clinically to 
monitor the extracellular chemistry of brain-injured patients. Microdialysis is also used 
extensively as a research method for both the sampling of interstitial fluid and for 
pharmacokinetic studies. 
2.1.1 Microdialysis apparatus 
 
The microdialysis catheter consists of two concentric tubes. The outer tube is connected to a 
syringe pump that delivers perfusion fluid. At the tip of the catheter a semi-permeable 
membrane permits bi-directional diffusion of molecules between the perfusion fluid and the 
brain interstitial fluid. The microdialysate returns up the inner tube to be collected in a 
collection vial. 
 
For the studies in this thesis, CMA 71 microdialysis catheters (membrane length 10 mm, 
nominal molecular weight cut-off 100 kDa) (M Dialysis AB, Stockholm, Sweden) were placed 
either via a triple lumen cranial access device (Technicam, Newton Abbot, UK) or during a 
craniotomy for a traumatic lesion into the brains of the patients. For TBI patients with a 
diffuse injury the right frontal region was chosen; if there was greater injury to one 
hemisphere rather than the other the most injured side was chosen. Lesional areas, such as 
traumatic contusions, and peri-lesional areas were avoided. CMA 71 catheters were also 
used for control subjects who had catheters placed into macroscopically normal brain via the 
cranial opening at the end of a neurosurgical procedure to resect a benign lesion. For 
patients undergoing muscle microdialysis, CMA 60 catheters (membrane length 30 mm, 
nominal molecular weight cut-off 20 kDa) were used and placed under direct vision into 
right quadriceps muscle in patients undergoing fat and fascia harvesting as part of acoustic 
neuroma surgery. 
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Commercially available clinical bedside analysers were used for measuring the metabolites 
glucose, pyruvate, lactate, glutamate and glycerol contained in the microdialysates. The 
analysers are automated to handle the collection vials, use enzymatic colorimetric analysers 
to calculate metabolite concentrations and are designed to handle small sample volumes. 
The clinical microdialysis analysers used for the studies in this thesis are the ISCUSflex, ISCUS 
and CMA600 models all of which are made by M Dialysis AB, Stockholm, Sweden. Each 
measurement uses between 0.2 and 1 μL of the sample for analysis depending on the 
analyte. The leftover microdialysates in the collection vials were then stored for later off-line 
analysis.  
2.1.2 Recovery 
 
The concentration of a substance measured in the dialysate is related to the free 
concentration in the tissue interstitial fluid by the mean relative recovery (the dialysate 
concentration as a percentage of the true interstitial concentration). (48) This reflects 
properties of the catheter and perfusion fluid as well as properties of the tissue. (48) 
 
As perfusion fluid is pumped continuously through the microdialysis catheter equilibrium 
across the semi-permeable membrane is never reached. The slower the fluid flows through 
the catheter, the closer the concentration of the substance measured in the dialysate is to its 
concentration in the interstitial fluid. A flow rate of 0.3 μL/min was used in all the studies in 
this thesis. In human brain this equates to a mean relative recovery of approximately 65 to 
72 % for the molecules measured in this thesis. (57)  
2.1.3 Retrodialysis 
 
Diffusion across the microdialysis membrane is bidirectional and thus microdialysis can be 
used to deliver molecules (‘‘retrodialysis’’ e.g. 13C-labelled substrates) to the interstitium. 
This allows a region of interest around the catheter tip to be micro-dosed whilst 
simultaneously collecting the downstream products in the emerging microdialysate for 
analysis in the laboratory. (58)  
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2.2 Proton and carbon-13 NMR 
2.2.1 Principles of NMR spectroscopy 
 
Proton (1H), carbon-13 (13C) as well as some other nuclei such as fluorine-19 (19F) and 
phosphorus-31 (31P), possess nuclear spin values of ½. This means that these nuclei have 
magnetic dipoles and in essence behave like miniature bar magnets (Fig. 2.1A). In an 
external magnetic field (B0), these miniature magnets line up and rotate, or 'spin', about the 
long axis of the dipole. They come to lie in one of two directions, known as 'spin up' and 
'spin down' (Fig. 2.1B). Spins pointing along the direction of the field ('spin up'), aligned with 
B0, have lower energy than those pointing against it. At equilibrium, there is a small 
population difference between 'spin up' and 'spin down' nuclei, with more in the lower 
energy 'spin up' direction. This population difference between the nuclei produces a small 
amount of net magnetisation that lies along the direction of B0. The equilibrium state can be 
perturbed by the introduction of energy. The energy needed to motivate the nuclei to 
change state takes the form of radiofrequency electromagnetic radiation.  
 Figure 2-1 Principles of NMR spectroscopy: Spin ½ nuclei.  Nuclei such as 13C with a spin value of ½ behave like miniature bar magnets (A). When 
placed in a strong external magnetic field (B0) they line up in ‘spin up’ and ‘spin down’ 
orientations (B) with more in the lower energy ‘spin up’ direction. The nuclei spins precess 
about the direction of the external magnetic field (C). 
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Radiofrequency radiation 'excites' the nuclei, flipping some of the 'spin up' nuclei into the 
higher energy 'spin down' state. The direction and timing of excitation radiofrequency pulses 
is modulated to influence different aspects of the net magnetisation signal resulting from 
the population difference between spins. Importantly, the excitation pulse is applied in a 
different direction to B0 so that the net magnetisation comes to lie in a different direction. 
After this excitation pulse is turned off, the nuclei return back to their equilibrium state and 
there is a decay of net magnetisation in this different direction which can be recorded by 
radiofrequency receiver coils. Complicating this simplified explanation of the NMR 
experiment is the phenomenon of precession. When the nuclei are placed in an external 
magnetic field their spins align with the direction of the field and also spin with an additional 
rolling motion, or 'precess', about the direction of the external field (Fig. 2.1C). Hence, any 
net magnetisation is also precessing. The frequency of precession known as the Larmor 
frequency is proportional to the strength of the external field and also relates to the 
particular nucleus. The change in net magnetisation in a particular direction recovered by 
the radiofrequency receiver coils forms the NMR signal. This takes the form of a complex 
series of sine waves that decay exponentially in time (the free induction decay (FID)). Fourier 
transformation (a mathematical transformation of a function of time to a function of 
frequency) of this signal is then used to provide a spectral output. In summary, to observe 
NMR signals we require a nucleus with a magnetic moment, a homogenous external 
magnetic field, radiofrequency transmitter and receiver coils, and a computer to perform a 
Fourier transformation.  
2.2.2 Chemical shift analysis 
 
The NMR spectra produced following Fourier transformation of the NMR signal consists of a 
series of peaks over a range of different frequencies. The frequency of the peak corresponds 
to the resonance frequency of electromagnetic radiofrequency radiation emitted by the 
nucleus, which has been excited within the external magnetic field. The resonance 
frequency is plotted as the difference between the resonance frequency of the nucleus and 
a standard, relative to the standard, and termed the chemical shift expressed in parts per 
million (ppm). In a molecule, the electron density that surrounds a nucleus creates its own 
mini magnetic field that alters the magnetic field produced by the nucleus itself. This slight 
Generic Methods 
21 
change in the magnetic field of the nucleus alters its resonance frequency of radiofrequency 
radiation in the B0 field. If the nucleus is chemically bonded to another the electron cloud 
will be shared between the two nuclei. This changes the magnetic effect the electrons have 
on the nuclei. Consequently the chemical shift varies depending on the immediate chemical 
environment of the particular nucleus. This is why specific chemical groups in specific 
molecules produce characteristic chemical shift patterns. (59)  
2.2.3 Multiplet peaks 
 
It is not just the electrons that influence the magnetic field of the nucleus. Other magnetic 
nuclei that are close by will also influence the magnetic field and alter the chemical shift. For 
example, if a molecule has one 13C-containing group a single peak is produced. If another 
13C-containing group is added adjacent to the first group two peaks are produced. However, 
there is also an interaction between the magnetic fields of the two 13C nuclei that result in 
splitting the two single peaks into two pairs of double peaks, termed doublets. This coupling 
effect of magnetic nuclei termed scalar coupling, can result in extremely complex spectra 
with numerous multiplet peak structures that may overlap and make interpretation difficult. 
Multiplet peaks also cause a reduction in signal intensity.  
2.2.4 Proton decoupling 
 
1H nuclei are abundant in molecules that contain carbon. Therefore, 13C spectra are usually 
acquired using 'proton decoupling'. Proton decoupling is used to eliminate the coupling 
effects of 1H nuclei on 13C nuclei, and thus greatly simplify spectra and improve signal 
intensity. The basic principle of proton decoupling methods is to use a high power 
monochromatic 1H radiofrequency pulse that irradiates the protons such that the 
populations of the two spin states are equalised. This removes the magnetic influence that 
protons would otherwise have on neighbouring 13C nuclei. The main proton decoupling 
techniques used are broad-band decoupling (BB) and composite pulse decoupling (CPD). For 
the experiments in this thesis I used a CPD scheme known as Waltz-16, which allows more 
efficient decoupling than BB methods requiring lower radiofrequency (RF) power levels. (60) 
The use of proton decoupling with 13C NMR has another effect that must be considered 
when interpreting spectra. A transfer of magnetisation from the 1H nuclei to the 13C nuclei 
Generic Methods 
22 
takes place, termed nuclear Overhauser enhancement (NOE), which increases the 13C NMR 
signal. Maximising NOE enhancement results in an increase in the sensitivity of 13C NMR and 
hence can be a useful phenomenon.  
2.2.5 NMR sensitivity 
 
Compared to other spectroscopic techniques NMR is relatively insensitive. The population 
difference between spin states, which produces the NMR signal, is tiny in comparison to the 
total number of spins. The strength of the NMR signal is also determined by the difference in 
energy between the two spin states. The population and energy differences are proportional 
to the strength of the external magnetic field, B0, and to the gyromagnetic ratio of the 
nucleus being observed. The gyromagnetic ratio (γ) is a property of the individual nucleus 
that describes how big a magnetic field it generates. Compared to 1H NMR spectroscopy, 13C 
NMR is several-fold less sensitive. The gyromagnetic ratio for 13C is a quarter of the 
gyromagnetic ratio for 1H. This means that 13C nuclei in comparison to 1H nuclei have a 
quarter the population difference between spin states and generate only a quarter as strong 
a magnetic dipole. The precession rate of the nucleus also relates to the gyromagnetic ratio. 
13C nuclei precess at a quarter the frequency of 1H nuclei, which in turn, reduces the signal 
detected in the receiver coil to a quarter. The other major factor that reduces the sensitivity 
of 13C NMR is the low natural abundance of the 13C isotope. Overall, these factors reduce 13C 
NMR spectroscopy to approximately 1/5800th the sensitivity of 1H NMR spectroscopy.  
 
Given the inherent sensitivity limitations of 13C NMR it is not surprising that its development 
as an analytical technique is relatively recent. There are several strategies for enhancing its 
sensitivity that work by reducing the thermal and electronic noise of the hardware and by 
increasing the strength of the 13C NMR signal. One of the most significant technological 
developments in NMR spectroscopy was the introduction of helium-cooled coil and 
amplifier hardware that greatly reduce noise, as used for the experiments in this thesis. 
Usually when performing NMR several thousand experiments are performed on a single 
sample and signal averaging is used to increase the signal-to-noise ratio. Increasing the 
strength of B0 will also increase the 13C NMR signal. The development of large 
superconducting magnets has allowed significant gains in the strength of B0. The difficulty of 
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maintaining a sufficiently homogenous field as the B0 strength increases is the major limiting 
factor in developing more and more powerful magnets. Special excitation pulse sequences 
can be used to increase the population difference between spin states, and reducing the 
temperature of the sample will also increase the population difference. Despite the gains in 
sensitivity achieved through these strategies 13C NMR remains considerably less sensitive 
than 1H NMR. Studies on metabolic pathways usually focus on the NMR signals produced 
from 13C enriched substrates (as used in the studies in this thesis) and their metabolites as 
opposed to natural abundance 13C NMR.  
2.2.6 13C NMR for studying cerebral biochemistry 
 
NMR can be performed on intact animal or human brains or on smaller samples of cell 
cultures or metabolite solutions. 13C NMR on solutions with the use of high strength 
magnets, cooled coils and sophisticated pulse sequences, permits high resolution 
spectroscopy with low signal-to-noise.  
 
The ability to discern the specific carbon group of a particular metabolite enables the 
metabolic fates of glucose and other carbon containing metabolites to be traced. 13C NMR 
provides a convenient way to study the interchange of carbon skeletons that takes place 
during the metabolism of glucose. The relative proportion of 13C incorporated at different 
carbon positions has been used in experimental studies to calculate pathway activity. (e.g. 
(61-65)) 
2.2.7 Quantitative NMR spectroscopy 
 
Calculation of metabolic pathway rates or comparison of relative pathway fluxes requires 
some form of quantification of 13C NMR spectra. Quantification of 1H NMR spectra is 
relatively straightforward. The intensity of the NMR peak is related to the number of nuclei 
producing the NMR signal. Hence, NMR spectra can be used to quantify the nuclei of 
interest. However, several other factors also influence the 13C NMR signal intensity. The NOE 
transfer of magnetisation from 1H to 13C influences signal intensity and is not uniform across 
different carbon groups. The NOE effect on the NMR signal is partly determined by the 
magnetic relaxation properties of the 13C nucleus (the T1 longitudinal relaxation time), which 
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in turn is determined by its local chemical and physical environment. Other radiofrequency 
pulsing parameters will also affect the signal intensity recorded, as investigated in Study I. If 
identical pulsing conditions are used 13C peak intensities can be compared and quantified 
across samples by relating the peak intensities to those of an internal standard with a known 
concentration. An alternative quantitative method involves using 1H NMR and identifying 
the peaks of 1H nuclei that are bonded to 13C nuclei and quantifying these. (60,64) 
2.2.8 Acquisition and processing of the NMR spectra 
 
For the purposes of the studies in this thesis 1H and 13C NMR spectra were acquired on a 
Bruker Avance III HD 500 MHz spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany) 
with a dual 1H/13C cryoprobe (CP DUL500C/H, Bruker BioSpin GmbH). See Fig 2.2. 13C and 1H 
NMR spectra were acquired and processed using TopSpin software (Bruker GmbH). After 
acquisition of the FID a series of processing steps were carried out using Topspin to enable 
accurate identification and quantification of metabolites. First, the FID was multiplied by an 
exponential function prior to Fourier transform. This mathematical function is termed line 
broadening and acts to smooth the spectrum and increase signal-to-noise ratio. Secondly, 
manual phase correction was applied. Lastly, manual baseline correction was applied to 
ensure a smooth baseline. 
 
 
Figure 2-2 Spectrometer used for the experiments in 
this thesis. For acquisition of 1H and 13C NMR spectra a 
high strength super conducting magnetic is used (Bruker 
Avance 500 MHz in the Department of Chemistry, 
University of Cambridge) in combination with a helium 
cooled ‘cryoprobe’ that increases signal-to-noise. 
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3.1 Introduction 
 
NMR is an analytical method that lends itself to the examination of biological fluids. 
Chemical modification of samples is not needed and analytes in solution can be analysed 
without prior separation. NMR is highly reproducible and applicable to small fluid samples. 
There is direct proportionality of the signal detected from an analyte and its concentration. 
Therefore NMR can be used for both the identification and quantification of analytes and 
has been used for measuring metabolites in biological fluids including cerebrospinal fluid 
(CSF) and urine. (66-68) 
 
In terms of studying cerebral metabolism, 1H NMR has been used to explore the metabolic 
profile of human CSF. (66) Wishart et al. (2008) used 1H NMR alongside gas 
chromatography–mass spectrometry (GC–MS) and liquid chromatography Fourier 
transform–mass spectrometry (FTMS) to characterise the metabolites found in CSF. (66) 
They identified 53 different compounds, 47 of which they were able to accurately quantify 
using 1H NMR. 1H NMR had the highest yield of the analytical techniques used in terms of 
identifying metabolites. The pathophysiology of TBI includes changes to metabolism and so 
it follows that studying the metabolic profile of the injured brain will potentially lead to 
insights into the metabolic perturbations that accompany TBI. 1H NMR has been used in this 
way to assess the metabolic response to experimental injury in brain tissue extracts from 
rats undergoing fluid percussion injury. (69) 
 
Both 1H and 13C NMR can be used to identify and quantify metabolites in human brain 
microdialysates. 13C NMR has a much larger chemical shift range in comparison to 1H NMR 
and is not as subject to the difficulty of interpreting spectra with multiple overlapping peaks 
which occurs with 1H NMR spectra from biological fluids. Furthermore, 1H decoupling 
techniques typically used when acquiring 13C spectra, eliminate scalar coupling due to 1H. 
Consequently 13C spectra are generally less complex than 1H NMR spectra; individual 
chemically non-equivalent carbons are represented by a single peak. However, due to the 
naturally low abundance of 13C and its lower gyromagnetic ratio compared to 1H, 13C NMR is 
much less sensitive than 1H NMR. Furthermore, unlike 1H NMR the 13C NMR signals are not 
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directly proportional to concentration in a predictive manner due to the differential 
influence of the NOE on different 13C nuclei (see Section 2.2.7).  
3.1.1 Aims 
 
The aim of this study was to use both 1H and 13C NMR to determine the metabolites that can 
be identified in human brain microdialysates collected from TBI patients and to define the 
optimum conditions for the quantification of 1H and 13C NMR spectra.  
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3.2 Materials and methods 
3.2.1 Sample preparation 
 
Samples for NMR analysis were acquired from microdialysates from TBI patients and also 
from stock solutions prepared with known concentrations of metabolites. 
 
For the patients undergoing microdialysis, CMA 71 microdialysis catheters  were perfused 
with CNS Perfusion Fluid (M Dialysis, AB), composed of NaCl (147 mmol/L), KCl (2.7 mmol/L), 
CaCl2 (1.2 mmol/L), and MgCl2 (0.85 mmol/L) in water at a rate of 0.3 μL/min. Microdialysate 
samples were pooled into 24-hour periods for each patient and then stored at  –80°C prior 
to NMR analysis.  
 
Stock solutions of sodium L-lactate (powder, ≥99 % nominal purity, catalogue number 
71718) and L-glutamine (powder, ReagentPlus grade, ≥99 % nominal purity, catalogue 
number G3126), obtained from Sigma-Aldrich (Poole, Dorset, UK), were made up in CNS 
Perfusion Fluid. 
 
Samples were prepared for NMR analysis by adding 20 μL of deuterium oxide (D2O) and 50 
μL internal reference standard from a stock solution of 24.0 mmol/L 3-(trimethylsilyl)-1-
propanesulfonic acid sodium salt (DSS) (Sigma-Aldrich) in CNS perfusion fluid to 180 μL of 
the sample, which was then transferred into a 3 mm NMR tube (Hilgenberg GmbH, Malsfeld, 
Germany).  
3.2.2 NMR analysis 
 
13C and 1H NMR spectra were acquired and processed using TopSpin. In addition, further 
processing of NMR spectra and simulation of metabolites was performed using Chenomx 
software (Chenomx, Edmonton, Canada). The Chenomx software contains a library of 
theoretical NMR signals produced by different metabolites and can simulate the NMR 
spectra that would be observed from solutions of metabolites. The software is also able to 
de-convolute experimental NMR spectra into the individual peaks of different metabolites. 
 
Study I 
30 
1H spectra were acquired using the pulse programmes zgpr and noesypr1d. The observed 
spectral bandwidth was 10 kHz (20 ppm). Both of these pulse programmes are standard 
one-dimensional (1D) experiments that use presaturation to suppress the water signal. For 
the 1D NOESY experiment acquisition parameters included 32 scans with a d1 (relaxation 
delay) of 2 seconds and a presaturation power of -39.05 dBW, which was used to suppress 
the water signal. For the zgpr experiment the d1 time was varied over a range of values in 
order to assess the influence of d1 time on the NMR spectra.   
 
13C spectra were acquired using the pulse programme zgpg30, which has 30-degree flip-
angle on the carbon channel with a d1 of 3 seconds, using 4096 (4k) scans and digitising 64K 
points. The observed spectral bandwidth was 35 kHz (278 ppm). Power-gated broadband 
proton decoupling was achieved using the ‘WALTZ-16’ supercycle. The receiver gain was set 
to a constant value in each experiment.  
 
Line broadening of 0.3 Hz and 3 Hz was applied to the FID produced by the 1H and 13C NMR 
experiments respectively, prior to manual phase and baseline correction of the Fourier 
transformed spectra. Chemical shifts were referenced to DSS. Manual peak picking was 
applied and cross referenced with previously run standard solutions containing known 
concentrations of glucose, lactate, pyruvate, glutamate and glutamine and also with two 
online metabolomic databases: the Biological Magnetic Resonance Data Bank (BMRB) (70) 
and the Human Metabolome Database (HMDB) (71). Both of these databases carry 
information on different metabolites found in the human body and include chemical, 
biological and NMR data.  
3.2.2.1 Integration and peak modelling  
 
The area under the NMR peak is proportional to the number of nuclei (1H or 13C) responsible 
for the NMR signal. I assessed two methods of quantifying the NMR signal. Firstly, I manually 
selected regions of the NMR spectra and integrated individual peaks using Topsin. Secondly, I 
used a Lorentzian line shape function inputting the NMR peak amplitude and peak width at 
half-height to calculate the area under the Lorentzian peak. This calculation was performed 
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using Topspin. NMR peaks are Lorentzian in shape as the FID decay is exponential and 
therefore a Lorentzian line shape function can be used to model NMR peaks. (72)  
 
Metabolite concentrations were calculated from 1H and 13C spectra using the following 
equations. 
 !"#$%#&'(&)"#	"+	+,#$&)"#(-	.'",/	0(1%2	"#	/'"&"#	345	= 	 (8%(9	('%(	"+	.'",/ 3". "+	/'"&"#1⁄ 	)#	.'",/) × [?@@]?@@	/%(9	('%( 3". "+	?@@	/'"&"#1⁄  
 !"#$%#&'(&)"#	"+	+,#$&)"#(-	.'",/	0(1%2	"#	$('0"#	13	345= D8%(9	('%(	"+	.'",/?@@	/%(9	('%( × '%1/"#1%	+($&"'E × [?@@] 
 
The 'response factor' is based on the experimentally determined linear relationship 
between 13C peak area and metabolite concentration (see Section 3.3.4). 
3.3 Results 
3.3.1 Identification of metabolites of interest 
 
Two patients with isolated diffuse TBI underwent microdialysis of radiographically normal, 
non-contused brain, with CNS perfusion fluid. Microdialysates from a 24 hour period were 
subsequently pooled for each patient for 1H and 13C NMR analysis. Fig. 3.1a illustrates a 1H 
NMR spectrum of microdialysate pooled over 24 hours. After careful phase and baseline 
correction, peak lists were manually generated and compared with NMR spectra from stock 
solutions run under identical conditions and with the BMRB and HMDB databases. This 
yielded 15 compounds that could be robustly identified and are listed in Table 3-1 with their 
mean concentrations from the two patients calculated by integrating the 1H NMR peaks. The 
15 compounds were then modelled using Chenomx and fit with the microdialysate spectra 
to confirm the presence of these metabolites. See Fig. 3.1b. Peak lists from 13C NMR were 
similarly inspected and compared with both online metabolome databases and with 
standards of stock solutions run under identical conditions to determine peak identity. See 
Fig. 3.2. Of the 15 metabolites identified with 1H NMR, only D-glucose, lactate and myo-
inositol were identified using 13C NMR and 2-dimensional HMQC.  
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Figure 3-1 Proton NMR spectra of TBI brain microdialysate 
(a) 1H NMR spectra acquired from TBI brain microdialysate pooled over 24 hours showing 15 metabolites 
identified that had concentrations ranging from 27 μmol/L for 2-hydroxybutyrate to 3.6 mmol/L for lactate. (b) 
Chenomx software was used to model the peaks based on the chemical shifts, amplitudes and multiplicity of 
the peaks identified. Abbreviations: 2-hydroxybutyrate (Hyb), aminobutyrate (Amb), Acetate (Ace), Alanine 
(Ala), Citrate (Cit), Creatine & Creatinine (Cre), Ethanol (Eth), Fructose (Frc), Glucose (Glc), Glutamate and 
Glutamine (Glx), Glycerol (Gly), Lactate (Lac) Myo-inositol (Myo-I), Pyruvate (Pyr).  
 
 
Table 3-1 
Metabolites identified with proton 
NMR of microdialysates from 2 TBI 
patients 
Average (mean) concentration 
(μmol/L) 
Lactate 3593 
Glucose 1668.6 
Myo-inositol 177 
Glutamine 132.8 
Fructose 126.9 
Ethanol 124 
Pyruvate 116.4 
Glycerol 112.1 
Creatine 111.7 
Alanine 110 
Glutamate 76.9 
Creatinine 61.6 
Acetate 57.6 
Citrate 35.5 
2-hydroxybutyrate 27 
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Figure 3-2 Carbon-13 NMR spectra of TBI brain microdialysate 
The metabolites identified with 13C NMR are glucose (Glc), lactate (lac) and myo-inositol (Myo-I). The myo-
inositol peaks are mixed amongst the glucose C2-5 peaks and are shown in the expansion from 70 to 80 ppm. 
(DSS, the internal reference standard). Spectra were run from –20 ppm to +250 ppm.  
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Figure 3-3 1H /13C-HMQC spectra of TBI brain microdialysate 
Illustrative example of a 2-dimensional 1H /13C HMQC spectra of TBI brain microdialysate demonstrating 
glucose (Glc), lactate (lac), myo-inositol (Myo-I) and DSS. 
 
 
 
D-glucose results in a complex series of 9 multiplet patterns from 3.2 to 5.2 ppm on 1H NMR. 
See Fig. 3.1. In aqueous solution it exists in equilibrium as an open-chain and ring form with 
the ring form predominating. The ring form exists as two anomers, an α anomer and a β 
anomer, based on the orientation of the hydroxyl group attached to the first carbon (C1). 
This is more clearly defined on the 13C spectra with α and β anomers producing peaks at 
94.8 and 98.7 ppm respectively. See Fig. 3.2.  
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Lactate consists of a methyl group which produces a doublet at 1.31 ppm, and a methine 
group which produces a quartet at 4.09 ppm on 1H NMR. All three carbons of lactate were 
detectable using 13C NMR with peaks at 22.8, 71.3 and 185.2 ppm corresponding to the C3, 
C2 and C1 groups respectively. 
 
Myo-inositol is a cyclic polyalcohol that is an isomer of glucose. On 1H NMR it produced a 
quartet centred at 3.52 ppm and triplet at 3.61 ppm. Its six carbons were represented by 4 
peaks on the 13C spectrum from 73.9 to 77.1 ppm owing to the two sets of identical carbon 
groups within this cyclic molecule. The role of myo-inositol in the brain is unknown. 
Increased concentrations in the human brain as measured with in vivo MRS, have been 
associated with Alzheimer’s disease and Down’s syndrome (73-75) and with TBI (76). 
 
The other metabolites identified were detectable with 1H but not 13C NMR. Pyruvate 
produced a singlet at 2.36 ppm. L-glutamine and L-glutamate are structurally similar amino 
acids with two methylene groups and a methine group and hence they produced 
overlapping multiplet signals. L-glutmate produced a series of 4 multiplets from 2.0 to 3.7 
ppm and L-glutamine a series of 3 multiplet peaks from 2.1 to 3.8 ppm. L-alanine, a 
nonessential amino acid with a high abundance in muscle and known to act as an inhibitory 
neurotransmitter, produced a doublet at 1.46 and a quartet 3.76 ppm. Creatine and 
creatinine which are thought to be involved in energy metabolism produced two peaks at 
3.92 and 3.02 ppm.  
3.3.2 Relaxation delay of proton NMR 
 
One patient with a diffuse TBI had microdialysates pooled from 24 hours of CNS perfusion 
fluid microdialysis. Several 1H NMR experiments were run sequentially on this sample using 
the pulse programme zgpr with the d1 changed between experimental runs to assess the 
influence of d1 time.  
 
A short d1 resulted in an overestimation of the true concentration by as much as 13 % 
relative to the ISCUS calculated concentration at a d1 of 1 sec. The concentrations calculated 
stabilised with a d1 of 16 seconds or longer. See Fig. 3.4.  
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Figure 3-4 The influence of relaxation delay on calculated concentration of lactate. 
The concentration of lactate in a TBI brain microdialysate was calculated using 1H NMR. The relaxation delay 
(d1) time was varied from 1 to 32 seconds. The calculated concentration was stable at a d1 of 16 seconds or 
longer.   
 
 
 
3.3.3 Integration versus peak area modelling of proton NMR 
 
Two methods of measuring peak areas were assessed: integration of the peaks and 
mathematical modelling based on Lorentzian shaped peaks. The values produced by each of 
these methods were used to calculate the concentration of glutamine and lactate in 
standard solutions with known concentrations of these metabolites. Glutamine ranged in 
concentration from 0.5 to 57.2 mmol/L. At each concentration that was tested modelling the 
peak areas as opposed to integrating them produced concentrations closer to the actual 
concentration.  
 
Lactate concentrations in the samples tested ranged from 3.0 to 61.6 mmol/L. At each 
concentration that was tested integration and area modelling produced similar results. Each 
method included the 13C satellites of both the lactate and the DSS peaks, although whether 
or not they were included did not appear to greatly affect the calculated concentrations. All 
of the calculated concentrations were an overestimate of the actual concentration, likely 
due to the low d1 of 1 second used in this experiment. In order to confirm this I ran two 
further NMR experiments with a d1 of 32 seconds. Samples with lactate concentrations of 
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2.96 and 5.92 mmol/L run using the longer d1 resulted in calculated concentrations that 
were 101.9 % and 103.2 % respectively of the actual concentration. See Fig. 3.5. 
 
Figure 3-5 Integration versus mathematical peak modelling for calculating lactate and glutamine 
concentrations. 
Stock solutions with known concentrations of glutamine and lactate were used to assess the accuracy of using 
1H NMR spectra to calculate concentration. The peaks corresponding to glutamine and lactate were integrated 
and modelled using Topspin software and then the areas were used to calculate concentration. (A) Calculating 
glutamine concentration by integrating peaks tended to overestimate the concentration compared to using 
modelled peaks. (B) Integration and modelling faired equally well for calculating concentrations although both 
overestimated the concentration when the 1H NMR spectra were acquired with a d1 of 1 second, as 
demonstrated by the more accurate concentration achieved with a d1 of 32 seconds (orange markers). 
 
 
 
3.3.4 13C peak area relationship to concentration 
 
To assess the linearity of the relationship between 13C peak area and concentration, stock 
solutions of glutamine and lactate (unlabelled) were prepared ranging from 0.6 to 28.4 and 
2.96 to 61.6 mmol/L respectively. Peak areas relating to each of the carbon groups relative 
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to the DSS internal standard were plotted against the known concentrations of glutamine 
and lactate and found to be linear.  See Fig. 3.6.    
 
Figure 3-6 Calibration curves for concentrations of lactate and glutamine 13C nuclei. 
Stock solutions with known concentrations of lactate and glutamine were run using the standardised 13C NMR 
protocol used in all of the studies in this thesis. The 13C response for each of the 13C groups were confirmed to 
be linearly proportional to the concentration of the 13C group. 
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3.4 Discussion 
 
In this study, both 1H and 13C NMR have been used to identify metabolites in human brain 
microdialysates from patients with TBI. 1H NMR is more sensitive for the identification of 
metabolites than 13C NMR. Both 1H and 13C NMR allow quantification of metabolites; the 
optimal conditions for ensuring accurate quantification are defined. 
 
3.4.1 Identification of metabolites present in human brain microdialysates 
 
1H NMR of microdialysate from TBI patients produced complex spectra as illustrated in Fig. 
3.1. with many overlapping peaks and complex multiplet structures. Careful processing of 
the FID including manual phase and baseline correction along with use of DSS as an internal 
standard and chemical shift indicator allowed accurate peak assignment. Peaks were cross-
referenced with the HMDB and BMRB online databases to enable peak identification. The 15 
metabolites that could be reliably identified were those expected to be present in brain 
interstitial fluid i.e. metabolites involved in energy metabolism including glucose, lactate, 
and pyruvate, and amino acids involved in neurotransmission. See Table 3-1. These 
metabolites are common to the most abundant metabolites found in human CSF. (66,77,78) 
 
13C NMR of microdialysates from TBI patients produced much cleaner spectra than 1H NMR 
with clearly defined peaks spread out over a large chemical shift range and without the 
presence of complex multiplets. See Fig. 3.2. However, the baseline noise was much greater 
than the 1H spectra. 13C NMR was sufficiently sensitive to detect glucose, lactate and myo-
inositol; the metabolites with the highest concentration as measured with 1H NMR. Similarly 
the 2-demensional HMQC experiment, see Fig. 3.3, did not reveal any 13C-1H correlations of 
metabolites not detected by 1-dimensional 13C NMR alone.  
 
The current study reveals that the limit of detection using this method is approximately 27 
μmol/L; substances less than this concentration were not detected. The reasons for this are 
the considerable overlap of peaks likely obscuring smaller peaks arising from less abundant 
metabolites and the low NMR signal produced by metabolites of very low concentration. 
Further, the membrane pore size of the microdialysis catheters used to sample the 
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interstitial space had a nominal molecular weight cut-off of 100 kDa limiting any molecules 
sampled to small metabolites and not larger macromolecules such as inflammatory 
mediators. 
3.4.2 Improving NMR sensitivity 
 
The sensitivity of NMR is influenced by many factors including sample factors, the NMR 
instrument including the strength of the B0 magnetic field and by the experimental set up. 
The samples used in this study were pooled samples from 24 hours of microdialysis 
monitoring. The microdialysis catheter was perfused at a rate of 0.3 μL/min which results in 
approximately 18 μL of microdialysate returned to the microdialysis vial per hour. The 3 mm 
NMR tubes used in this study require 181 μL volume to fill the tubes to a height of 40 mm; 
volumes less than this risk introducing the sample/air interface into the coil region resulting 
in field in-homogeneities and thus difficulties shimming. Hence, the pooled samples used in 
this study are currently at the limit of what is achievable in a time frame that is relevant for 
studying pathophysiology; larger volume samples collected over longer periods would 
improve sensitivity but at the expense of limiting biological interpretation in the face of 
more dynamic pathophysiological processes. Smaller NMR tubes are available, including 2 
mm, capillary and Shigemi tubes which allow smaller sample volumes to be analysed. 
Shigemi tubes are specialised NMR tubes manufactured with water susceptibility matched 
glass elements that surround the sample volume and allow very small sample volumes. 
Although the small sample volumes required by these tubes permit more frequent analysis 
of brain microdialysates, this is at the expense of sensitivity. The signal-to-noise ratio relates 
to the number of active nuclei in the coil region and so smaller volumes reduce NMR 
sensitivity. Furthermore, Shigemi tubes are much more expensive than routine NMR tubes 
and require more complicated sample preparation. 
 
Experiment factors that influence NMR sensitivity include the number of scans performed 
and the influence of NOE enhancement (see Section 2.2.4). NOE enhancement is the 
phenomenon of magnetisation transfer from one nuclear population to another due to cross 
relaxation. The degree of signal enhancement or reduction that this causes depends on the 
size of the molecules and also on whether heteronuclear decoupling is used. (79) 
Study I 
41 
Consequently the degree of enhancement is not uniform and so this introduces complexity 
when trying to quantify NMR signals. The signal-to-noise ratio increases as the square root 
of the number of scans (FIDs) that are added together. The number of scans run is usually a 
compromise between improvements in the signal-to-noise and the overall time needed for 
the experiment. The 13C NMR experiments used in this study involved 4096 scans requiring 
approximately 4 hours per sample. Hence, increasing the number of scans beyond this for 
any significant gain in signal-to-noise ratio becomes impracticable.  
  
Instrument factors that influence NMR sensitivity are harder to modify compared to sample 
and experimental set up factors. The coil used to excite and detect the NMR signal produces 
most of the noise associated with an NMR experiment arising from the thermal motions of 
electrons within the coil metal. Cryogenic probes, as used for the studies in this thesis, 
substantially improve signal-to-noise ratio by cooling the coil. Improvements in 
superconducting magnet technology will result in NMR instruments with a greater B0 field 
strength. Currently, the most powerful NMR instrument to date has recently been installed 
in France with a 23.5 Tesla magnetic field. This B0 increases the resonance frequency of 
protons to 1000 MHz, resulting in approximately double the sensitivity in comparison to the 
instrument used in this study. However, the gains in sensitivity achieved come at the 
expense of the size and cost of the hardware. 
3.4.3 Optimal experimental conditions for quantitative NMR 
 
The relaxation delay (d1) is the time inserted between the end of acquisition of one FID and 
the radiofrequency pulse used to excite the nuclei of interest for the next FID acquisition. 
During this time the magnetisation of the nuclei relaxes back to its equilibrium state. If the 
relaxation delay is too short and the next pulse comes before the nuclei are fully relaxed, the 
subsequent FID acquisition will not reflect the true amount of energy from that acquisition 
and the spectra will no longer be reliably quantifiable. In this study a d1 of less than 16 
seconds was associated with an increase in the measured concentration of lactate which 
stabilised at a d1 of 16 seconds or longer.   
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3.4.4 Integration versus peak modelling for quantification 
 
In addition to experimental factors data processing factors also influence the accuracy of 
NMR quantification. Care is taken to ensure a flat spectral baseline and to appropriately 
phase correct the spectra. Peak areas can either be integrated or they can be estimated by 
peak fitting. NMR peak signals are Lorentzian in shape and so easy to model mathematically 
with knowledge of the peak amplitude and width at half-height. This is performed 
automatically by NMR processing software such as Topsin used throughout this thesis. 
Modelling peaks is advantageous over integration when peaks are overlapping making it 
impossible to integrate individual peaks separately. To assess the accuracy of integration 
versus peak modelling, lactate and glutamine concentrations measured by these methods 
were assessed. The methyl group of lactate gives rise to a doublet peak at 1.3 ppm that in 
the brain microdialysate samples is relatively clear of overlapping peaks. Both integration 
and modelling faired equally in terms of calculating concentrations over a range of 
concentrations of stock solutions. Glutamine produces complex multiplet peaks in a 
relatively crowded region of the NMR spectra from 2.1 to 3.8 ppm. Integrating the peaks 
appeared to overestimate the concentration in comparison to modelling. Moreover, in brain 
microdialysates there are likely to be many overlapping peaks reducing the reliability of 
integration. 
3.4.5 Quantification of 13C NMR spectra 
 
13C NMR spectra are typically acquired using proton decoupling which results in a simpler 
spectrum and also boosts the signal as a result of NOE enhancement. Given the relatively 
poor sensitivity of 13C NMR in comparison to 1H NMR this boost in signal is desirable. 
However, this means that the spectra are not directly quantifiable. Furthermore, 13C nuclei 
typically have long T1 relaxation times. Very long d1 times in the order of several minutes 
are needed to ensure quantifiable spectra. This is prohibitively time consuming and it not is 
practical on current NMR instruments. Although 13C NMR is not directly quantifiable each 
peak area should relate linearly to the concentration of the nuclei producing the peak. In 
order to test this the 13C response of stock solutions of metabolites with known 
concentrations was assessed. Glutamine and lactate were chosen as the metabolites of 
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interest due to their importance in cerebral energy metabolism and relevance to the other 
studies in this thesis. This study demonstrates that the 13C concentration relative to the DSS 
concentration, used as an internal standard, relates linearly to the 13C peak areas relative to 
the DSS peak area. Hence, defining these linear relationships in order to calculate a response 
factor enables subsequent 13C spectra to be quantified. 
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3.5 Summary and context 
 
In this study I have been able to determine the sensitivity of 1H and 13C NMR for analysing 
cerebral microdialysates. The NMR experimental set up influences calculated concentrations 
of metabolites. I defined the optimal relaxation delay for accurate quantification of 1H 
spectra. These experiments and the data from them have been used to guide the 
experimental set-up in the subsequent studies in this thesis.  
 
H1: “1H and 13C NMR analysis of cerebral microdialysates can be used to identify and 
quantify a range of interstitial cerebral metabolites” 
Based on the data in this study the hypothesis is accepted. 
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4.1 Introduction 
4.1.1 Grey versus white matter 
 
Microdialysis is a focal technique and brain chemistry varies depending on the region of 
brain where the catheter is situated. This is particularly relevant when monitoring TBI 
patients given the heterogeneity of brain injury; chemistry is more perturbed in peri-lesional 
brain. (48) For the studies in this thesis I chose to place catheters with the aim of avoiding 
peri-lesional tissue to simplify interpretation of metabolite and NMR data. A previously 
unexplored influence on brain chemistry is the placement of the catheter into grey or white 
matter.  
 
Microdialysis catheters are typically inserted through a bolt device that anchors the catheter 
to the skull. The shaft length of the standard catheter (for example CMA71 catheters 
exclusively used for cerebral microdialysis in this thesis) is 130 mm. The catheter shaft 
traverses the length of the bolt, which measures 60 mm in length, and approximately 70 mm 
of catheter traverses the brain. The catheter passes tangentially through the brain 
perpendicular to the brain surface and the tip containing the microdialysis membrane 
typically sits within white matter. However, in some cases due to the flexibility of the 
catheter, the catheter can bend into a more acute angle and the tip can come to lie in grey 
matter. Catheters are also sometimes placed at the time of craniotomy and their placement 
into grey or white matter is variable depending on the location and angle at which the 
catheter is placed. The importance of catheter location in grey or white matter in terms of 
interpreting cerebral microdialysis data has not previously been explored. 
4.1.2 Brain versus muscle 
 
Microdialysis has been employed in tissues other than the brain including muscle. The 
methodological principles are the same although different catheter designs are typically 
used to allow for ease of insertion and monitoring. The CMA60 microdialysis membrane 
length is 30 mm in comparison to a membrane length of 10 mm in the CMA70 catheters. It 
also comes with an introducing needle allowing it to be passed subcutaneously into fat or 
muscle. I used muscle as a comparison tissue for cerebral metabolic studies in this thesis and 
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therefore conducted the studies in this chapter to assess baseline characteristics in muscle 
in comparison to brain.  
4.1.3 Aims 
 
The aims of this study were to assess the influence of catheter placement in grey or white 
matter on cerebral chemistry, to compare baseline microdialysis data between muscle and 
brain, and to assess the change in metabolite concentrations between resting muscle in 
anaesthetised patients and in awake patients.  
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4.2 Materials and methods 
4.2.1 Patients  
 
The Cambridge Central Local Research Ethics Committee approved this study. Informed 
consent was obtained from all participants in the muscle group and assent from the relatives 
of those patients who had suffered a TBI. The study was carried out in conformation with 
the spirit and the letter of the Declaration of Helsinki. 
 
TBI brain microdialysis patients: The TBI patients were defined as those suffering cranial 
trauma with consistent CT scan findings and requiring invasive intracranial monitoring as 
part of their clinical management. Patients were managed according to local TBI-
management protocols, which include endotracheal intubation, ventilation, sedation, 
muscular paralysis and maintenance of blood sugar (serum glucose) concentration within 
the target range 4-7 mmol/L. (82) 
 
Muscle microdialysis patients: Patients undergoing resections of acoustic neuromas that 
required thigh fat and fascia harvesting for dural closure were recruited for studying muscle. 
During the procedure to harvest fat and fascia a microdialysis catheter was placed under 
direct vision into quadriceps muscle.  
4.2.2 Microdialysis technique 
 
The microdialysis methodology described in section 2.1.1 was used for this study. 
 
Catheters in the TBI patients were perfused with CNS Perfusion Fluid (M Dialysis, AB; for 
composition see Section 3.2.1). Muscle microdialysis catheters were perfused with T1 
Perfusion Fluid (M Dialysis AB), composed of NaCl (147 mmol/L), KCl (4 mmol/L), and CaCl2 
(2.3 mmol/L) in water. Microdialysate collection vials from the TBI patients were changed 
hourly and analysed at the bedside using an ISCUS analyser (M Dialysis AB) employing 
enzymatic colorimetric assays for glucose, lactate, pyruvate, glutamate and glycerol. 
Microdialysate vials from muscle were also analysed with the ISCUS analyser at 2-hourly 
intervals. 
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4.2.3 Statistical Analysis 
 
Statistical analyses performed using SPSS21 for Mac (IBM SPSS Statistics, NY) included 
Mann-Whitney U test with a preselected p-value of 0.05 for statistical significance to 
compare median values for each patient of microdialysis data between groups. In muscle, 
changes of microdialysis parameters between anaesthesia and post-operative time periods 
were assessed for statistical significance with Wilcoxon signed rank test with a preselected p-
value of 0.05 for statistical significance. 
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4.3 Results 
4.3.1 Demography 
 
Fourteen TBI patients (12 M, 2 F) aged 20 - 59 y (median 29.5 y) were studied. These 
patients were sequentially recruited TBI patients who had sufficient baseline microdialysis 
data (more than 10 metabolite measurements with normal CNS Perfusion fluid) to allow 
meaningful analysis. The group included six patients also included in Study III who received a 
period of 1,2-13C2 glucose perfusion. All patients had CT scans available performed after 
microdialysis catheter insertion used to ascertain whether the catheter tip resided in white 
or grey matter (see Fig. 4.1). Four patients had catheters in grey matter (total 136 hours of 
microdialysis monitoring) and 10 patients had catheters in white matter (total 834 hours of 
microdialysis monitoring). Quadriceps muscle was studied in six patients (2 M, 4 F; age range 
26 - 82 y) who were undergoing surgery that included fat and fascia harvesting from the 
thigh permitting catheter insertion. Five of these patients formed the group undergoing 
unsupplemented microdialysis perfusion in Study III. Microdialysates were collected for 
analysis during operative anaesthesia and also for a period immediately post-operatively. 
Demographic details of all patients are presented in Table 4.1. 
 
 
 
Figure 4-1 CT scans of TBI patients after microdialysis catheter insertion.  
The red arrows indicate the tip of the microdialysis catheter, which are seen to reside in right frontal white 
matter (A) and in right frontal grey matter (B). 
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Table 4-1 
(Acute subdural haematoma, ASDH; road traffic collision, RTC; subarachnoid haemorrhage, SAH; --, missing data) 
 
TBI Patient Age Sex 
Injury 
mechanism 
GCS at 
scene/15 
Pattern of 
injury 
Catheter 
location (grey 
or white 
matter) 
TBG01 a 26 F RTC 6 
Diffuse, 
traumatic SAH G 
TBG04 a 59 F RTC 4 Diffuse, ASDH G 
TBG08 a 20 M RTC 4 Diffuse W 
TBG09 a 20 M RTC 5 Diffuse, ICH W 
TBG11 a 20 M RTC 4 Diffuse W 
TBG12 a 55 M RTC 8 Diffuse, ASDH G 
TBG13 27 M Assault 5 Diffuse, ASDH W 
TBG15 32 M RTC 12 Diffuse W 
TBG16 21 M RTC 12 -- G 
TBG17 61 M RTC 15 -- W 
TBG19 49 M Assault 9 -- W 
TBG20 47 M Fall 7 -- W 
TBG21 27 M Fall 4 -- W 
TBG27 36 M RTC 4 -- W 
       
Muscle 
Patient Age Sex 
Time under 
GA (hours) 
Time awake 
(hours) 
 
 MU01a 67 M 18.8b 8.3  
 MU02 a 82 M 10.3 14.7  
 MU03 a 63 F 9.5 16.0  
 MU04 a 26 F 6.7 14.0  
 MU05 a 48 F 7.6 15.0  
 MU06 67 F 6.8 16.0  
  
a patients also included in Study III 
b patient MU01 underwent an extended period of muscle microdialysis under anaesthesia due to the patient 
requiring post-operative anaesthesia 
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4.3.2 Comparison of metabolite concentrations in muscle and brain 
 
Microdialysate measurements of glucose, lactate, pyruvate, glutamate, glycerol and LP ratio 
are shown in Fig. 4.2 and in Table 4.2. Glucose, pyruvate, and glutamate concentrations were 
all higher in muscle than brain. There was no significant difference in lactate and glycerol 
concentration or the LP ratio between brain and muscle.  
 
 
Figure 4-2 Metabolite concentrations in muscle and TBI brain  
Median values for metabolites measured in muscle (red squares; 6 patients) and TBI brain (purple circles; 14 
patients). Red asterisks denote significant differences between TBI and muscle groups. Lines represent the 
median value for all patients in the muscle and TBI groups. 
 
Table 4-2  
(Median values with interquartile ranges in parentheses) 
 
 Muscle microdialysate 
concentrations 
Brain (TBI patients) 
microdialysate concentrations 
Glucose (mmol/L) 3.7 (3.4 - 5.1) 1.6 (0.9 - 2.2) p=0.001 
Lactate (mmol/L) 3.6 (3.2 - 4.0) 2.3 (1.5 - 3.1) p=0.051 
Pyruvate (μmol/L) 216.6 (191.2 - 226.5) 100.7 (79.3 - 123.6) p=0.001 
Glutamate (μmol/L) 12.2 (5.9 - 15.9) 2.9 (2.3 - 8.4) p=0.041 
Glycerol (μmol/L) 105.5 (81.3 - 135.4) 43.7 (31.5 90.5) p=0.106 
LP ratio 16.0 (13.7 - 18.6) 23.5 (17.4 - 29.1) p=0.076 
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4.3.3 A comparison of metabolite concentrations in grey and white matter 
of TBI brain. 
 
Microdialysate measurements of glucose, lactate, pyruvate, glutamate, glycerol and LP ratio 
are shown in Fig. 4.3. Lactate concentrations were lower in grey than white matter with 
concentrations of 1.7 (1.3 – 2.5) mmol/L and 2.7 (1.7 – 3.7) mmol/L although this did not 
reach statistical significance (p=0.84). Accordingly, the LP ratio was lower in grey matter than 
white matter with concentrations of 17.7 (16.4 – 20.9) and 24.9 (18.8 – 30.2) respectively 
(p=0.14). Overall, there were no significant differences in the metabolite concentrations 
measured between grey and white matter.  
 
Figure 4-3 Comparison of microdialysis in grey and white matter in TBI brain.  
Median values of metabolite concentrations measured with microdialysis with the catheters in grey matter (4 
patients; grey boxes) and in white matter (10 patients; yellow circles). 
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4.3.4 Muscle microdialysis under operative anaesthesia and post-
operatively 
 
Median concentrations for each of the six muscle patients of glucose, lactate, pyruvate, 
glutamate, glycerol and LP ratio during operative anaesthesia and during a period when the 
patient was awake are shown in Fig. 4.4. In the post-operative period patients were freely 
able to move their limbs whilst in bed although none of the patients had started to walk 
during microdialysis.  Glucose concentrations increased in all patients between anaesthesia 
and wakefulness with a mean difference of +81.6% (p=0.028). There were no other 
consistent trends in the other metabolites measured between anaesthesia and wakefulness. 
 
 
Figure 4-4 Change in metabolite concentrations from anaesthesia to wakefulness.  
The median concentration of glucose, lactate, pyruvate, glutamate, glycerol and the LP ratio measured during 
anaesthesia (GA) and in the immediate post-operative period (awake) for each patient is shown. Glucose was 
the only metabolite that showed a consistent and significant trend.  
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4.4 Discussion 
 
This study has confirmed the differences in baseline microdialysis metabolite concentrations 
between muscle and TBI brain and explored the impact of inadvertent brain microdialysis 
catheter placement into grey matter. 
4.4.1 Muscle 
 
The concentrations of microdialysis metabolites measured in muscle are comparable to 
those measured in other microdialysis studies of muscle. (83-90) Average glucose 
concentrations have been measured between 3.1 to 4.4 mmol/L, lactate between 1.6 to 2.5 
mmol/L, pyruvate between 20 to 370 umol/L and glycerol approximately 40 mmol/L in 
studies using similar microdialysis methodology with a perfusion flow rate of 0.3 μL/min. 
(84,86,87,89,90) In comparison to injured brain, glucose, pyruvate, and glutamate 
concentrations were higher in muscle. These differences in metabolite concentrations 
between brain and muscle are due to both differences in the actual concentrations of 
metabolites in the interstitium and also differences in metabolite recovery (see Section 
2.1.2).  The CMA60 catheter used for muscle microdialysis throughout this thesis contains a 
30 mm microdialysis membrane whereas the CMA70 catheter used for studying brain has a 
10 mm membrane. Recovery is proportional to the surface area of the dialysis membrane 
and so the larger dialysis membrane of the CMA60 catheter will result in greater recovery 
compared to the CMA71 catheter. Complete equilibration (i.e. recovery close to 100%) has 
been demonstrated using the CMA60 catheter in muscle to occur for glucose at a perfusion 
flow rate of 0.16 μL/min and for lactate at a flow rate of 0.33 μL/min (the differences in 
recovery between molecules relate to differences in their diffusivity). (84) In comparison in 
brain, a flow rate of 0.3 μL/min has been shown to equate to a mean relative recovery of 
approximately 65 to 72 % for these molecules. (57) In summary, the higher concentrations 
measured in muscle are due to both enhanced recovery and greater tissue concentrations.  
 
Muscle microdialysate glucose concentrations increased when patients were woken from 
anaesthesia. This likely reflects increased blood flow and increased delivery of glucose as 
muscle activity increases. In comparison to brain, muscle has a very variable metabolic rate 
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linked to activity. Consequently microdialysis measurements of energy metabolites vary 
depending on the level of muscle activity. For example, microdialysate lactate has been 
demonstrated to increase threefold following sustained trapezius muscle contraction. (87) 
The fact that I only observed a change in glucose concentration and not other metabolites 
probably reflects the minimal muscle activity performed by these patients in the immediate 
post-operative period. For the rest of the studies in this thesis where I used muscle as a 
control tissue for comparison with brain, in view of the metabolic variability of muscle, I 
chose to restrict muscle microdialysis experiments to periods where the patient undergoing 
muscle microdialysis was under anaesthesia. 
4.4.2 Metabolic differences between grey and white matter 
 
Grey and white matter differ in their energy requirements. Grey matter consists of neuronal 
cell bodies, their associated dendrites and axons in addition to glial cells. White matter is 
mostly made up of myelinated axons with far fewer cell bodies. Consequently cerebral blood 
flow (CBF) and the rate of glucose metabolism are higher in grey than in white matter. 
Regional CBF measured using intra-arterial Xenon 133 is on average 75 ml/100 g/min in 
human grey matter and 45 ml/100 g/min in white matter. (91) Regional cerebral metabolic 
rate of glucose (CMRglc) as measured by [14C]DG autoradiography in rats demonstrate that 
CMRglc in grey matter is on average about three times that of white matter. (51) Similarly in 
human brain the CMRglc measured using 18FDG-PET is significantly greater in grey compared 
to white matter. (92) Therefore, differences in microdialysis metabolites between grey and 
white matter would be expected reflecting the differences in CBF and energy metabolism. I 
did not demonstrate any statistically significant differences between grey and white matter 
brain chemistry likely due to the small number of patients, particularly the small number of 
catheters in grey matter.   
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4.5 Summary and context 
 
In this study I have determined the baseline concentrations of energy metabolites in muscle 
and explored the influence of muscle activity in awake patients after anaesthesia on 
microdialysis. These experiments have been used to guide the use of muscle as a control 
tissue in subsequent studies in this thesis. In TBI brain, I established that although most of 
the time microdialysis samples white matter it sometimes samples grey matter and 
evaluated the influence that this has on metabolite concentrations. 
 
H2: “Baseline tissue chemistry is the same in brain and muscle” 
Based on the data in this study the hypothesis is rejected. 
 
H3: “In TBI patients baseline tissue chemistry is the same in grey and white matter” 
There is insufficient data to accept or reject this hypothesis. 
 
  
Study III 
58 
5 Study III  
 
Glucose metabolism via glycolysis and 
the pentose phosphate pathway after TBI 
 	
5.1	 Introduction ........................................................................................................... 59	
5.1.1	 Aims ......................................................................................................................................... 60	
5.2	 Materials and methods .......................................................................................... 61	
5.2.1	 Patients .................................................................................................................................... 61	
5.2.2	 Microdialysis technique ............................................................................................................ 61	
5.2.3	 NMR analysis ............................................................................................................................ 62	
5.2.4	 Statistical Analysis ..................................................................................................................... 64	
5.3	 Results ................................................................................................................... 65	
5.3.1	 Demography ............................................................................................................................. 65	
5.3.2	 Baseline results compared with 1,2-13C2 glucose perfusion period ............................................. 67	
5.3.3	 NMR results for lactate production by glycolysis and PPP, and relationship with brain tissue 
oxygen 71	
5.4	 Discussion .............................................................................................................. 76	
5.4.1	 Glucose metabolism via glycolysis and the pentose phosphate pathway .................................... 76	
5.4.2	 Role of brain tissue oxygen concentration in brain metabolism ................................................. 77	
5.4.3	 The fate of lactate ................................................................................................................... 77	
5.5	 Summary and context ............................................................................................ 79	
  
Study III 
59 
5.1 Introduction 
 
An increase in the proportion of glucose undergoing ‘anaerobic’ (non-oxygen consuming) 
metabolism is observed after TBI. (44,55,56) This has been postulated to provide the energy 
in the form of ATP needed to restore ionic and neurochemical gradients, which become 
disturbed after TBI. (22,23) Up-regulation of the pentose phosphate pathway (PPP) has also 
been suggested as a possible contributor to increased anaerobic glucose metabolism after 
TBI, based on rat models and indirect (arteriovenous-jugular difference) studies in human 
patients. (93,94) 
 
The PPP, also termed the hexose monophosphate shunt, is a biosynthetic pathway that 
constitutes a complex detour bypassing some of the steps of glycolysis in the metabolism of 
glucose. The key enzyme for the PPP, glucose-6-phosphate dehydrogenase, which is 
responsible for the rate-limiting step, is present in most tissues and cell types, and is 
regarded as a “housekeeping” enzyme. (95,96) The PPP does not consume or produce ATP 
and does not require molecular oxygen. In the early “oxidative phase” of the PPP, during 
which the first carbon of the glucose skeleton is lost as carbon dioxide, nicotinamide 
adenine dinucleotide phosphate (NADP+) is converted to its reduced form NADPH. The latter 
is a reducing agent that participates in reductive biosynthetic reactions such as lipid and 
steroid synthesis, and in the production of the reduced form of glutathione and thioredoxin. 
Glutathione and thioredoxin are cofactors for glutathione peroxidase enzymes and 
peroxiredoxins respectively, both of which scavenge hydroperoxides thereby combatting 
oxidative stress. Among the many intermediates of the later “non-oxidative” phase of the 
PPP is ribose 5-phosphate used for nucleic acid synthesis. Hence, the proportion of glucose 
metabolised via the PPP is greatest in tissues with high lipid- and steroid-synthetic roles (e.g. 
liver and lactating mammary glands), also in cells with a high oxidative load (e.g. red blood 
cells), and is thought to be one of the mechanisms supporting high cell proliferation rates in 
cancer. (96) PPP activity after TBI has been postulated as playing a protective role, 
promoting synthesis of nucleic acids and fatty acids for tissue repair and combatting the 
oxidative stress that results from injured cells. (93,97) 
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5.1.1 Aims 
 
The aim of this study was to evaluate glycolysis and the PPP as routes of glucose 
metabolism, directly in TBI patients’ brains, by using microdialysis to perfuse the brain with 
1,2-13C2 glucose and analysing the ensuing labelling patterns in lactate collected in the 
emerging microdialysates. For comparison, the same technique was also carried out in 
‘normal’ brain, and in muscle as a non-CNS tissue.  
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5.2 Materials and methods 
5.2.1 Patients  
 
The Cambridge Central Local Research Ethics Committee approved this study. Informed 
consent was obtained from all participants in the control ‘normal’ brain and muscle groups 
and assent from the relatives of those patients who had suffered a TBI. The study was 
carried out in conformation with the spirit and the letter of the Declaration of Helsinki. 
 
TBI brain microdialysis patients: The TBI patients were defined as those suffering cranial 
trauma with consistent CT scan findings and requiring invasive intracranial monitoring as 
part of their clinical management. Patients were managed according to local TBI-
management protocols as per Study II (see Section 4.2.1). 
 
Control ‘normal’ brain microdialysis patients: Patients undergoing a craniotomy for the 
resection of a benign lesion whereby a microdialysis catheter could be safely placed into 
radiographically normal brain were selected as control subjects. The microdialysis catheter 
was placed via the craniotomy and tunnelled under the scalp. The control patients were 
awake for the duration of microdialysis perfusion. 
 
Muscle microdialysis patients: Patients undergoing resections of acoustic neuromas that 
required thigh fat and fascia harvesting for dural closure were recruited for studying muscle. 
During the procedure to harvest fat and fascia a microdialysis catheter was placed under 
direct vision into quadriceps muscle. The muscle microdialysis subjects were under general 
anaesthesia for the duration of the microdialysis perfusion, which was performed at the 
same time of day for each patient minimising the effect of diurnal variation. 
5.2.2 Microdialysis technique 
 
The microdialysis methodology described in section 2.1.1 was used for this study. 
 
Catheters in the TBI patients and the normal brain control subjects were perfused with CNS 
Perfusion Fluid (M Dialysis, AB; for composition see Section 3.2.1) supplemented with 4 
mmol/L 1,2-13C2 glucose (see below for details). Muscle microdialysis catheters were 
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perfused with T1 Perfusion Fluid (M Dialysis AB; for composition see Section 4.2.2) 
supplemented with 4 mmol/L 1,2-13C2 glucose. The concentration (4 mmol/L) of 13C-labelled 
substrate was chosen to be within the range found in brain and muscle microdialysates in 
unlabelled studies, to minimise perturbation. (83,98,99) 1,2-13C2 glucose (isotopic 
enrichment 99%, chemical purity 99%) was obtained from Cambridge Isotope Laboratories, 
Inc (Tewksbury, MA) and was formulated in CNS perfusion fluid or T1 perfusion fluid by the 
Manufacturing Unit, Department of Pharmacy, Ipswich Hospital NHS Trust (Ipswich, UK), 
who then tested the formulations to verify purity, sterility, freedom from endotoxins and 
absence of pyrogenicity, to comply with current regulations, before releasing them for use in 
patients. Microdialysate collection vials from the TBI patients were changed hourly and 
analysed at the bedside using an ISCUS analyser (M Dialysis AB) employing enzymatic 
colorimetric assays for glucose, lactate, pyruvate, glutamate and glycerol. Microdialysate 
vials from ‘normal’ brain and from muscle were also analysed with the ISCUS analyser at 4- 
and 2-hourly intervals, respectively. ICP, cerebral perfusion pressure, and brain tissue oxygen 
tension (PbtO2) data from TBI patients were recorded at the bedside using ICM+ software 
(ICM+, University of Cambridge, UK). Microdialysate samples were stored at 4°C (or at –80°C 
if storage for longer than a few days was necessary) prior to NMR analysis. 
5.2.3 NMR analysis 
 
Brain microdialysate samples were pooled into 24-hour periods for each individual patient. 
For NMR analysis 20 μL of D2O and 50 μL internal reference standard from a stock solution 
of 24.0 mmol/L DSS (Sigma-Aldrich, Poole, Dorset, UK) in CNS perfusion fluid were added to 
180 μL of the pooled microdialysate sample. Muscle microdialysate samples were pooled 
into 8-hour periods. 20 μL of D2O and 70 μL from a stock solution of 2.84 mmol/L DSS were 
added to 120 μL of the pooled microdialysate sample. Pooled samples, after addition of D2O 
and DSS, were stored at −80˚. For NMR analysis, samples were transferred into 3 mm NMR 
tubes (Hilgenberg GmbH, Malsfeld, Germany). 
 
13C and 1H NMR spectra were acquired as per Study I (see Section 3.2.2) using the pulse 
programmes noesypr1d and zgpg30 for 1H and 13C spectra, respectively. 
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To enable quantification of the signals in the 13C and 1H spectra, calibration was carried out 
with a series of known concentrations of standards including lactate, 3-13C lactate, glucose, 
1,2-13C2 glucose, and glutamine (from Sigma-Aldrich and Cambridge Isotope Laboratories). 
These standards were prepared in CNS Perfusion Fluid with the same fixed concentration of 
D2O and DSS as for the preparation of brain microdialysate samples as an internal standard 
and run under identical NMR conditions to the pooled microdialysates. Peak areas for DSS, 
glucose, lactate and glutamine signals identified on the 13C and 1H spectra were determined 
using Lorentzian line-shape fitting (see Section 3.2.2). Peak areas relative to the DSS internal 
standard were used with reference to calibration curves (see Section 3.3.4) for each signal 
derived from standards of known concentrations, which showed linear relationships 
between peak areas (ratio to DSS internal standard) and concentrations. Fractional 
enrichment (%) is defined as 100 x [13C] / ([13C] + [12C]) where square brackets indicate 
concentrations of the relevant species. [13C] was determined from the 13C NMR spectra and 
[12C] from the 1H spectra, using the calibration method above. The natural abundance of 13C 
is 1.1% of all carbon atoms; 13C results presented for lactate were expressed after 
subtracting this natural background from the 13C singlet signals. 13C doublet signals were not 
background-subtracted, because the probability of two 13C atoms occurring next to each 
other naturally is 0.01%.  
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Interpretation of the NMR results were based on biosynthetic pathways summarised 
schematically in Fig. 5.1, which shows the lactate labelling patterns corresponding to 
glycolysis, which produces 2,3-13C2 lactate, and the PPP, which produces 3-13C lactate.  
5.2.4 Statistical Analysis 
 
Statistical analyses performed using SPSS21 for Mac (IBM SPSS Statistics, NY) included non-
parametric tests (Mann-Whitney U test and Kruskal–Wallis one-way analysis of variance) 
with a preselected p-value of 0.05 for statistical significance. Results are presented as 
median values with the interquartile range (IQR) given in parentheses. Relationships 
between PbtO2 and the 13C labelling results were explored using linear regression, with 
Pearson’s correlation coefficient r and analysis of variance (ANOVA) p values.  
  
Figure 5.1	13C NMR labelling patterns in lactate derived from 1,2-13C2 glucose 
Simplified schematic of steps in glycolysis and the pentose phosphate pathway (PPP), showing 13C 
labelling patterns resulting from 1,2-13C2 glucose substrate. Red fills indicate 13C atoms. Abbreviations: 
Glc-6-P, glucose-6-phosphate; 6PGL, 6-phosphogluconolactone; F6P, fructose-6-phosphate; G3P, 
glyceraldehyde-3-phosphate; PYR, pyruvate.  
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5.3 Results 
5.3.1 Demography 
 
Fifteen severe TBI patients (10 M, 5 F) aged 16-59 y (median 27 y) were studied using 1,2-
13C2 glucose (4 mmol/L) perfusion via the microdialysis catheter, with simultaneous 
collection of microdialysates for NMR analysis. For comparison, macroscopically normal-
appearing brain was studied using the same 13C-labelled microdialysis method in six patients 
(age range 59-73 y; 3 M, 3 F) undergoing surgery for benign brain tumours. For a non-CNS 
tissue comparison, thigh (quadriceps) muscle was similarly studied in four patients (age 
range 20-61 y; 3 M, 1 F) who underwent surgery for acoustic neuroma resection. A further 
seven patients (2 ‘normal’ brain, 5 muscle) were studied by microdialysis but with plain 
unsupplemented perfusion fluid without 1,2-13C2 glucose. The 15 TBI patients who received 
1,2-13C2 glucose (see above) were also studied for a baseline period with plain 
unsupplemented perfusion fluid (without 1,2-13C2 glucose). Demographic details of all 
patients are presented in Table 5.1 and 5.2. 
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Table 5-1 
(Acute subdural haematoma, ASDH; Road traffic collision, RTC; P, propofol; F, fentanyl; M, midazolam; R, 
remifentanyl) 
 
 
  
TBI 
Patient Age Sex 
Injury 
mechanism 
GCS at 
scene/15 
Modified 
Marshall 
CT Grade 
(initial CT) 
Pattern of 
injury 
13C 
microdialysis 
start time 
after injury 
(hours) 
Sedative 
regime (P, 
propofol; 
F, 
fentanyl; 
M, 
midazola
m, 
GOS 
Outcome 
1 26 F RTC 6 2d Diffuse 17 P, F 4 
2 27 M RTC 7 3 Diffuse 45 P, F 5 
3 53 F RTC 6 2c Diffuse 41 P, F NA 
4 59 F RTC 4 6b ASDH, diffuse 60 Nil NA 
5 16 F RTC 4 2d Diffuse 47 F, M, T 5 
6 37 M RTC 8 2d Contusions, diffuse 49 P, F 5 
7 28 M RTC 3 6b ASDH, diffuse 104 P, F, M 5 
8 20 M RTC 4 2d Diffuse 132 P, F 4 
9 20 M RTC 5 6c Diffuse, ICH 51 P, F NA 
10 25 M RTC 8 1 Diffuse 26 P, F 4 
11 20 M RTC 4 2d Diffuse 88 P, F 5 
12 27 M Assault 5 3 ASDH, diffuse 17 P, F, M 3 
13 26 M RTC 5 2c Diffuse 47 P, F, R 3 
14 28 F Fall 11 6b ASDH, diffuse 104 P, F, R 3 
15 51 M Fall 8 6b 
ASDH, 
contusions, 
diffuse 
14 P, F 4 
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Table 5-2 
Normal 
brain 
subject 
Age Sex Benign tumour type Perfusion fluid   
Muscle 
subject Age Sex Perfusion fluid 
1 60 F Meningioma 1,2-13C2 glucose   1 45 M 1,2-13C2 glucose 
2 59 M Colloid cyst 1,2-13C2 glucose   2 20 M 1,2-13C2 glucose 
3 59 M Meningioma 1,2-13C2 glucose   3 61 M 1,2-13C2 glucose 
4 73 M Meningioma 1,2-13C2 glucose   4 45 F 1,2-13C2 glucose 
5 50 F Meningioma 1,2-13C2 glucose   5 67 M Unsupplemented 
6 67 F Meningioma 1,2-13C2 glucose   6 82 M Unsupplemented 
7 42 F Meningioma Unsupplemented   7 63 F Unsupplemented 
8 68 F Meningioma Unsupplemented   8 26 F Unsupplemented 
      9 48 F Unsupplemented 
 
5.3.2 Baseline results compared with 1,2-13C2 glucose perfusion period 
 
Microdialysate measurements (using the ISCUS analyser) of glucose, lactate, pyruvate, 
glutamate and glycerol are shown in Fig. 5.2. These were acquired in the 15 TBI patients 
during periods when the microdialysis catheter was perfused with plain unsupplemented 
CNS perfusion fluid and also during the 24 h period of perfusion with 1,2-13C2 glucose (4 
mmol/L). In ‘normal’ brain, ISCUS analysis was performed for two patients who received 
plain unsupplemented perfusion fluid and for six patients who received 24 h perfusion with 
1,2-13C2 glucose (4 mmol/L). In muscle, ISCUS analysis was performed for five patients who 
received plain unsupplemented perfusion fluid, and for four patients who received 8 h 
perfusion with 1,2-13C2 glucose (4 mmol/L). The 8 h period for muscle was necessitated due 
to clinical practicalities of limb movement - microdialysis was limited to periods during the 
acoustic neuroma surgery (see 4.4.1).  
 
 
 
 
 
Study III 
68 
 
 
Figure 5.2 ISCUS microdialysate results for baseline perfusion period versus 4 mmol/L 1,2-
13C2 glucose perfusion 
ISCUS clinical microdialysis analyser measurements: at baseline (light grey bars) with plain 
unsupplemented perfusion fluid and during 24 h perfusion (brain: TBI or normal) or 8 h 
perfusion (muscle) with 1,2-13C2 glucose (4 mmol/L) (dark grey bars). LPR is the 
lactate/pyruvate ratio. *p < 0.05 (Mann-Whitney U) for baseline vs. perfusion with 1,2-13C2 
glucose. Box and whisker plots represent pooled data. Numbers of patients with baseline 
(unsupplemented) measurements were 15 TBI, 2 ‘normal’ brain and 5 muscle. Numbers of 
patients who received 1,2-13C2 glucose were 15 TBI, 6 ‘normal’ brain and 4 muscle. ‘Normal’ 
brain was macroscopically normal-appearing brain in patients who underwent surgery for 
benign brain tumours. Muscle was leg quadriceps in patients undergoing acoustic neuroma 
resection surgery. 
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Significant increases (p < 0.05) in microdialysate glucose concentration (measured on the 
ISCUS analyser) between baseline (unsupplemented) and the 1,2-13C2 glucose perfusion 
period were seen for all three groups, as follows (medians): TBI brain (from 1.0 to 3.8 
mmol/L), ‘normal’ brain (from 1.9 to 3.9 mmol/L) and muscle (from 2.8 to 5.3 mmol/L). The 
only other statistically significant, but not thought to be biologically significant changes in 
ISCUS results between baseline and the 1,2-13C2 glucose perfusion period were for LP ratio in 
TBI brain (from 22.2 to 24.8), for glycerol in TBI brain (from 52.0 to 69.6 µmol/L), and for 
glutamate in TBI brain (from 3.4 to 4.4 µmol/L) and muscle (from 7.9 to 29.7 µmol/L).  
 
To explore further the significance of changes in baseline brain chemistry due to 
supplemental 1,2-13C2 glucose in TBI patients I compared changes of baseline metabolites 
within patients using each patient as his/her control i.e. a baseline period of 24 h 
microdialysis with unsupplemented perfusion fluid was compared with the 24 h period with 
1,2-13C2 glucose perfusion in each patient. An increase in microdialysate glucose between 
baseline and 1,2-13C2 glucose perfusion period was the only consistent and statistically 
significant result with a mean increase of +82 %  (p=0.005; Wilcoxon signed rank test)(see 
Fig. 5.3). 
 
Figure 5-3 ISCUS analyser measurements of baseline brain chemistry in TBI patients.  
Results presented are median values for each patient during 24 h period of unsupplemented perfusion 
microdialysis and during 24 h perfusion with 1,2-13C2 glucose (4 mmol/L). Changes between baseline and 
glucose perfusion were significant only for microdialysate glucose concentration by Wilcoxon's signed rank 
test. 
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Concentrations of 1,2-13C2 glucose (median and IQR) measured by 13C NMR in the 
microdialysates from TBI brain (24 h perfusion period), normal brain (24 h perfusion period) 
and muscle (8 h perfusion period) were respectively 2.14 (1.45-2.43), 0.93 (0.83-1.83) and 
0.95 (0.59-1.25) mmol/L, with TBI significantly different from normal brain (p = 0.008) or 
muscle (p = 0.016). 
 
Throughout the 24 h period during which the cerebral microdialysis catheter was perfused 
with 1,2-13C2 glucose, the median serum glucose concentration measured in TBI patients 
was 7.3 mmol/L and all values were within the range 4-12 mmol/L except for one time-point 
in patient 11 where glucose was 1 mmol/L. Median serum lactate concentration was 1.1 
mmol/L (min 0.7, max 3.0 mmol/L). See Fig. 5.4. 
 
Figure 5-4 Systemic (serum) glucose and lactate concentrations measured during the 24 h 
microdialysis perfusion with 1,2-13C2 glucose in the TBI patients.  
Data for systemic glucose concentration (upper panel) is for all 15 TBI patients, five of whom had a 
second 24 h period of 1,2-13C2 glucose microdialysis perfusion. Data for systemic lactate concentration 
(lower panel) is for 9 TBI patients, two of whom had a second 24 h period of 1,2-13C2 glucose 
microdialysis perfusion. First and second perfusion periods are designated ‘a’ and ‘b’ respectively. 
Circles indicate individual data points; lines indicate median values. 
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5.3.3 NMR results for lactate production by glycolysis and PPP, and 
relationship with brain tissue oxygen 
 
Illustrative examples of 13C NMR spectra of the microdialysates are shown in Fig. 5.5. As a 
result of 1,2-13C2 glucose perfusion, TBI brain and ‘normal’ brain microdialysates included a 
clearly visible doublet (red stars in expansion of 13C spectra) for the lactate C3 methyl group, 
and likewise a doublet for lactate C2, indicating glycolysis-derived 2,3-13C2 lactate, and a 
smaller C3 singlet (green stars in expansion of 13C spectra) representing PPP-derived 3-13C 
lactate plus endogenous lactate. Qualitatively similar-appearing spectra were seen for 
muscle microdialysates resulting from 1,2-13C2 glucose perfusion. Unlabelled TBI 
microdialysates (with plain unsupplemented perfusion fluid) showed singlets for 
endogenous lactate C3 and C2 (Fig. 5.5).  
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Natural abundance of 13C was assumed 1.1%, and 13C fractional enrichment values for 
lactate were expressed after subtracting this naturally occurring 13C background from the 13C 
singlet signals. In TBI brain microdialysates 13C fractional enrichment (%) in 2,3-13C2 lactate, 
indicative of glycolysis, was median 5.4% (IQR 4.6-7.5%) measured using the C3 doublet and 
this was significantly greater than in ‘normal’ brain (Fig. 5.6). Fractional enrichment was 
based on quantification of the lactate C3 doublet signal (13C spectrum) to measure 13C at the 
C3 position and the lactate methyl protons (attached to C3) triplet signal (1H spectrum) to 
quantify 12C at the C3 position. Similar 13C fractional enrichment to that of lactate C3 doublet 
Figure 5.5 Illustrative examples of 13C NMR spectra for microdialysates from patients who received 
perfusion with 1,2-13C2 glucose (4 mmol/L) 
TBI brain (uppermost two spectra, 24 h perfusion), ‘normal’ brain (third spectrum, 24 h perfusion) and 
muscle (bottom spectrum, 8 h perfusion). An example of brain microdialysate from an unlabelled TBI 
patient with plain (unsupplemented) perfusion fluid is shown for comparison (fourth spectrum). 
Examples of expansion of the lactate C3 signal are shown for TBI brain and ‘normal’ brain. Red stars 
indicate lactate C3 doublet (due to glycolytic 2,3-13C2 lactate) and green stars indicate C3 singlet (due to 
pentose phosphate pathway-derived 3-13C lactate plus endogenous lactate). Abbreviations: glucose 
(Glc), lactate (Lac), 4,4-dimethyl-4-silapentane-1-sulfonate sodium salt (DSS, the internal reference 
standard). Spectra were run from –20 ppm to +250 ppm. The main reference DSS signal at 0 ppm is not 
shown in the range illustrated. 
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was obtained using the lactate C2 doublet, as expected (Fig. 5.6). In muscle, 13C fractional 
enrichment in 2,3-13C2 lactate was lower than in TBI and ‘normal’ brain (Fig. 5.6). 
 
Based on the lactate C3 methyl group, 13C fractional enrichment (%) in 3-13C lactate 
indicative of the PPP in TBI brain microdialysates was median 0.24% (IQR 0.17-0.61%) (Fig. 
5.6) which was thus much less than the 13C fractional enrichment in glycolytic 2,3-13C2 
lactate (above). The ratio in TBI brain microdialysates of PPP-derived 3-13C lactate to 
glycolytic 2,3-13C2 lactate was median 4.9% (IQR 3.6-8.2%) (Fig. 5.6). Four of the 15 TBI 
patients exhibited ratios of PPP-derived to glycolytic lactate (11.4, 11.5, 11.9 and 14.0%) that 
were greater than the range observed in the present study in normal brain (min 5.9, max 
10.4%). 
Figure 5.6 Microdialysate NMR measurements of 13C labelling  
Results from perfusion for 24 h (brain: TBI or ‘normal’) or 8 h perfusion (muscle) with 1,2-13C2 glucose (4 
mmol/L). Red asterisks denote p < 0.01 for TBI vs. ‘normal’ brain (Mann-Whitney U); other comparisons 
asterisked in black denote p < 0.05. Individual data-points are shown by x symbols. Number of patients: 
15 TBI, 6 ‘normal’ brain, 4 muscle.  
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In muscle, microdialysis perfusion with 1,2-13C2 glucose (4 mmol/L, for 8 h) resulted in 
lactate C3 doublet and C2 doublet, indicating glycolytic 2,3-13C2 lactate, with 13C enrichment 
at C3 median 1.2% (range 1.0-1.4%). However, there was no 13C enrichment above 
background natural abundance for lactate C3 singlet, so PPP production of lactate was not 
detected in muscle.  
 
The concentration of 2,3-13C2 lactate (indicative of glycolysis) showed a non-significant 
inverse trend (r = -0.4, p = 0.1) with brain tissue oxygen concentrations (PbtO2 expressed in 
mm Hg) measured in the vicinity of the microdialysis catheter in TBI brain. A significant 
inverse correlation (r = -0.5, p = 0.04) was seen for the ratio of PPP-lactate to glycolytic 
lactate vs. PbtO2 (Fig. 5.7). Local tissue oxygen concentration was not measured in normal 
brain or muscle. 
 
Five TBI patients had a second 24 h period of 1,2-13C2 glucose (4 mmol/L) microdialysis 
perfusion. There were no significant differences in the production of glycolytic-lactate or 
PPP-derived lactate between these two time periods.  
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Figure 5.7 	Relationships in TBI brain for glycolytic lactate and pentose phosphate pathway (PPP)-
derived lactate vs. PbtO2.  
Concentrations of glycolytic 2,3-13C2 lactate (A) and PPP-derived 3-13C lactate (B) plotted vs. PbtO2. (C): 
ratio (%) of PPP-derived 3-13C lactate to glycolytic 2,3-13C2 lactate, plotted vs. PbtO2. Each data-point 
represents the results of NMR analysis of the combined contents of 24 x 1 h of microdialysate collection 
vials from one microdialysis catheter plotted against the corresponding PbtO2 concentration expressed 
in mm Hg, measured using a Licox oxygen probe placed alongside the microdialysis catheter in the 
brain. Lines are fitted by linear regression (statistics shown are Pearson’s correlation coefficient r and 
ANOVA p value). Data are from 13 TBI patients. Four of these 13 had a second period of monitoring, 
making 17 data-points in total for each correlation. 
 
Study III 
76 
5.4 Discussion 
 
This study has shown that 1,2-13C2 glucose infusion via the microdialysis catheter results in 
13C-labelling in lactate in the emerging microdialysates. This allowed me to compare 
glycolysis and PPP as routes by which lactate is derived. 
5.4.1 Glucose metabolism via glycolysis and the pentose phosphate 
pathway  
 
Clear evidence for glycolysis being the main route of lactate production from glucose, as 
expected, was seen as diagnostic doublet signals for both C3 and C2 of lactate (Fig. 5.5) 
indicating 2,3-13C2 lactate, a hallmark of the pathway (Fig. 5.1). These doublets were seen for 
all patients, in TBI brain, ‘normal’ brain and muscle.  This is in accord with the recognised 
glycolysis pathway consisting of the Embden-Meyerhof pathway from glucose to pyruvate, 
followed by conversion to lactate by the action of lactate dehydrogenase (Fig. 5.1). This 13C 
enrichment was significantly higher in TBI brain, suggesting greater glycolytic activity, than in 
‘normal’ brain and muscle. The doublet signals provide a distinctive signature that in effect 
avoids the issue of natural abundance 13C background (1% of all carbon atoms), since the 
probability of two endogenous 13C atoms occurring next to each other naturally is 0.01%.  
 
The PPP loses the first carbon of 1,2-13C2 glucose as carbon dioxide and thus gives rise to 3-
13C lactate with a singlet signal for C3 (Fig. 5.1). While 13C singlet signals for lactate C3 were 
clearly visible in all patients’ microdialysates (Fig. 5.5) these were smaller than the C3 
doublet. Furthermore, it emerged that much of the C3 singlet signal intensity (peak area) 
was due to endogenous natural abundance 13C. Small 13C fractional enrichments for lactate 
C3 singlet above this background were seen in microdialysates from TBI brain and ‘normal’ 
brain, indicating PPP-derived lactate, but negligible in muscle. While there was no 
statistically significant difference in 13C fractional enrichment for lactate C3 between 
‘normal’ brain and TBI brain, the higher upper range of the latter suggests that in certain TBI 
individuals lactate production via the PPP is elevated above that in ‘normal’ brain. In the four 
TBI patients with the most elevated PPP lactate the ratio (%) of PPP lactate to glycolytic 
lactate was 11.4 – 14.0%. 
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5.4.2 Role of brain tissue oxygen concentration in brain metabolism  
 
In this study PbtO2 was measured alongside the microdialysis catheter in the TBI patients and 
revealed that there was a non-significant trend towards greater glycolytically generated 2,3-
13C2 lactate with decreasing PbtO2. It is important to note that there were only 3 cases that 
could be described as hypoxic (defined as PbtO2 < 20 mm Hg) and the remaining 14 data-
points ranged from 22 to 43 mm Hg. Interestingly, the ratio of PPP-derived lactate to 
glycolytic lactate showed a significant inverse correlation with PbtO2 (r= -0.5, p = 0.04) (Fig. 
5.7). Thus, although PPP-derived lactate was always much less than glycolytic lactate, the 
balance between the two appeared to shift towards the PPP with lower PbtO2.  
5.4.3 The fate of lactate 
 
If the 2,3-13C2 lactate (produced from the substrate 1,2-13C2 glucose) entered the TCA cycle 
in brain cells, this would in theory have resulted in doublets in the 13C NMR spectra, due to 
4,5-13C2 glutamine (and/or glutamate) on the first turn of the cycle, and, on the second turn, 
doublets due to 1,2-13C2 glutamine and a singlet due to 3-13C glutamine. (100,101) 
Experimental models of brain injury in rodents using 1,2-13C2 glucose as substrate, with 
analysis of brain tissue extracts representing total intracellular and extracellular molecules, 
confirm double labelling in glutamate and glutamine. (93,100) In this study small singlet 
signals, but not doublets, corresponding to glutamine were seen in the 13C NMR spectra of 
some of the microdialysates from ‘normal’ brain (4/6 patients) and TBI (2/15 patients). In 
theory, pyruvate cycling (see Section 8.4.4) which breaks the 13C-13C bond might explain the 
glutamine singlets. Also, in theory, PPP-derived 3-13C lactate might enter the TCA cycle 
forming singly-labelled glutamine (and/or glutamate), although accompanied by doubly-
labelled glutamine from glycolytic 2,3-13C2 lactate, as found in vitro by Brekke et al. (2012). 
(102) However, in the present study, quantification of the small glutamine singlets revealed 
no significant 13C enrichment above natural abundance.  
 
Microdialysis only samples the extracellular compartment and therefore cannot measure 
the intracellular distribution of 13C. Even so, this 13C-labelled microdialysis method provides 
a useful means for measuring ‘early’ glucose metabolism (glycolysis and PPP) as sufficient 
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labelled lactate is exported into the extracellular compartment to allow detection. However, 
in the subsequent metabolism of lactate, the downstream dilution of 13C label with 
endogenous unlabelled intermediates probably explains why significant 13C enrichment of 
extracellular metabolites derived from the TCA cycle was not observed. 
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5.5 Summary and context 
 
In this study I have shown that the major pathway for lactate production is glycolytic. 
Glycolytic lactate production was significantly greater in the TBI brain than in the normal 
brain. The minor pathway, PPP-derived lactate production, was statistically not significantly 
different in the TBI brain than in normal brain. There was a shift in glucose metabolism from 
glycolysis to PPP with decreasing brain tissue oxygen concentrations.  
 
H4: “The relative contribution of the glucose metabolic pathways glycolysis and the 
pentose phosphate pathway differs for uninjured brain compared to injured brain. The 
contribution of the PPP is less in uninjured brain than in injured brain.”  
Based on the data in this study there is insufficient evidence to accept this hypothesis. Even 
though this study indicates a minor PPP-derived lactate it must be remembered that the PPP 
is a complex network of biosynthetic reactions and it is conceivable that if heavy recycling is 
operating within the PPP less lactate might emerge, though with elevated production of 
NADPH and intermediates utilised in neuroprotection and repair of cells. 
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6.1 Introduction 
 
Lactate has been perceived as a waste product of anaerobic metabolism, produced when 
oxygen provision is insufficient to meet demand. However, this cannot be the complete 
picture as elevated microdialysate lactate levels are observed after TBI despite seemingly 
adequate oxygen delivery. (44) There are several other potential explanations for the 
elevated lactate levels other than anaerobic metabolism. Firstly, as I showed in the previous 
study, the pentose phosphate pathway contributes to interstitial lactate. Secondly, a failure 
of mitochondrial enzymes, including pyruvate dehydrogenase which funnels pyruvate into 
the TCA cycle, increases the amount of lactate generated from pyruvate. (103) In support of 
this, evidence points towards the importance of mitochondrial dysfunction after TBI. (104-
106) Thirdly, elevated lactate levels may also reflect enhanced uptake of lactate from the 
circulation.  
 
Evidence for enhanced uptake of lactate from the circulation is provided by carbon-14 (14C) 
lactate autoradiography experiments which demonstrate accumulation of radiolabel at the 
injury site after fluid percussion injury in rats. (107) In humans evidence exists for lactate 
uptake from the circulation into the brain both in normal volunteers (with lactate infused 
intravenously and/or produced endogenously by exercise) (108,109) and in sedated, 
ventilated TBI patients. (110,111) Furthermore, lactate infused via a microdialysis catheter 
into the human brain after TBI has been shown using 13C labelling and NMR spectroscopy to 
be utilised via the TCA cycle. (16)  
 
The concept of lactate functioning as a cerebral energy source has been suggested by 
Pellerin and Magistretti, who in 1994 introduced the principles of a mechanism that later 
became known as the astrocyte-neuron lactate shuttle hypothesis (ANLS) as discussed in 
Section 1.2.3. (18,112) The ANLS model describes a metabolic relationship between neurons 
and astrocytes whereby neurons preferentially metabolise lactate (which is synthesized from 
blood-borne glucose by astrocytes) as an oxidative fuel. (18,112) As a logical extension of 
the hypothesis, the elevated lactate levels found in the brain after TBI may not only reflect 
increased generation due to hypoxia and mitochondrial dysfunction, but also increased 
uptake of lactate from the circulation for use as an energy substrate. (112) 
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6.1.1 Aims 
 
In this study my aim was to explore the uptake and release of endogenous lactate by the 
injured brain using a combination of AV concentration gradients and cerebral microdialysis 
in TBI patients. In particular, I investigated the inter-relationships between arterial lactate 
concentration, brain extracellular lactate concentration, and lactate import vs. export by the 
brain, as well as the time-variant nature of the process, during the first days following injury. 
6.1.2 Special Acknowledgement 
 
This chapter is based on work carried out in collaboration with Dr Adel Helmy. I carried out 
the sample preparation and analysis; Dr A Helmy recruited the patients and obtained the 
matched arterial and jugular venous samples. 
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6.2 Materials and Methods 
6.2.1 Patients  
 
This study was approved by the Cambridgeshire (2) Local Research Ethics Committee. 
Patients (over 16 years old) with severe TBI, defined as those suffering cranial trauma with 
consistent CT scan findings and with a post resuscitation GCS ≤ 8, were recruited. Patients 
were managed according to local TBI-management protocols, which include endotracheal 
intubation, ventilation, sedation, muscular paralysis and jugular bulb oximetry. For the 
purposes of this study, monitoring data were analysed for 5 days from recruitment.  
6.2.2 Invasive brain monitoring 
 
A triple lumen cranial access device (Technicam, Newton Abbot, UK) was used for each 
patient. This permitted placement of an intracranial pressure (ICP) monitor (Codman, 
Raynham, MA), a CMA 71 microdialysis catheter, and a Licox brain tissue oxygen sensor 
(GMS, Kiel-Mielkendorf, Germany) into right frontal white matter. The microdialysis catheter 
was perfused with CNS Perfusion Fluid (M Dialysis, AB; for composition see Section 3.2.1) 
which does not contain any lactate or any other additives, at a rate of 0.3 μL/min using CMA 
106 microdialysis pumps (M Dialysis AB). Microdialysis collection vials were changed hourly 
and analysed at the bedside using an automated enzymatic colorimetric analyser (ISCUS, M 
Dialysis AB) as per standard clinical protocols. ICP, CPP, jugular venous oxygen saturation 
(SjO2), and PbtO2 data were recorded at the bedside using ICM+ software (ICM+, University 
of Cambridge, UK).  
6.2.3 Plasma Sampling 
 
Plasma sampling was undertaken twice daily from an arterial line and from a right-sided 
jugular venous catheter. We chose to use the right jugular vein as this usually constitutes the 
dominant venous drainage of the brain. (113) The first 1 ml was discarded and then 5 ml was 
collected into an ethylene-diaminetetra-acetic acid (EDTA) tube and immediately centrifuged 
for 15 min at 1,500 g at 4˚C. The supernatant (plasma) was decanted and stored at -80˚C 
until further processing was performed. Thawed plasma was filtered through 10 kDa 
molecular weight cut-off Amicon Ultra centrifugal filters (Millipore, Cork, IRL) for 60 min at 
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8,700 x g at 4˚C, to remove large protein molecules. I analysed the resulting solution for 
glucose and lactate concentrations using an ISCUS analyzer.  
6.2.4 Statistical Analysis 
 
All statistical analyses were carried out using SPSS19 for Mac (IBM SPSS Statistics, NY). I 
compared microdialysate sample results with plasma sample results collected concurrently 
to provide a direct comparison in each patient at a specific time point. Statistical methods 
included non-parametric tests (Mann-Whitney U test and Kruskal–Wallis one-way analysis of 
variance) with a preselected p-value of 0.05 used to indicate statistical significance. Average 
values are presented as median values with the interquartile range given in parentheses. 
Plasma sampling and invasive brain monitoring data were pooled from multiple patients to 
calculate pre- and post-72 h median values.  
 
AV difference values for lactate (AVlac) were calculated as the arterial concentration minus 
the venous concentration and dichotomized into groups of uptake (positive values) and 
export (negative values). To ensure that positive and negative AVlac values robustly reflected 
uptake and export, respectively, I excluded values close to zero when dichotomizing the 
data. I conservatively selected an error margin of ±4% based on the precision of analysis for 
the ISCUS analyzer of 1.6 to 2.7%.(114) This resulted in the exclusion of AVlac measurements 
from −0.05 to +0.05 mmol/L (because 0.05 mmol/L is 4% of the mean arterial lactate 
concentration of 1.36 mmol/L found in these patients).  
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6.3 Results 
6.3.1 Patients 
 
Nineteen patients with TBI are included in this study (Table 6.1). Patients’ microdialysis 
monitoring commenced at a median of 18 hours (range 9 to 46 hours) from their injury. The 
first plasma samples were withdrawn a median of 30 hours (range 15 to 101 hours) from 
injury with 29% of measurements obtained during the first 72 hours after injury.  
 
Patient Age Sex 
Mechanism 
of Injury Post-resuscitation GCS Pattern of Injury 
1 44 F RTC E1 V1 M1 Diffuse 
2 25 M RTC E1 V1 M1 Diffuse 
3 27 F RTC E1 V1 M1 Diffuse 
4 58 F RTC E1 V1 M1 Diffuse 
5 61 F RTC E1 V1 M1 Diffuse 
6 49 M RTC E1 V2 M5 Contusions 
7 60 M RTC E1 V1 M5 ICH/IVH/Diffuse 
8 30 M Fall E1 V2 M2 Evacuated EDH/Diffuse 
9 39 F RTC E1 V1 M1 Diffuse 
10 41 F Fall E1 V1 M1 Diffuse 
11 37 M RTC E1 V1 M1 Diffuse 
12 43 M RTC E1 V1 M1 Diffuse 
13 22 M RTC E1 V1 M1 Diffuse 
14 18 F RTC E1 V1 M5 Evacuated EDH/Diffuse 
15 46 F RTC E1 V1 M2 Small SDH/Diffuse 
16 27 M RTC E1 V2 M5 Diffuse 
17 47 M RTC E1 V1 M3 Diffuse 
18 28 F Fall E1 V1 M1 Diffuse 
19 51 M Assault E1 V2 M5 Diffuse/contusions 
Table 6-1 Nineteen patients were recruited including 9 females. All patients presented 
with a diffuse injury and GCS from 3 – 8. GCS – Glasglow Coma Score, EDH – extradural 
hematoma; SDH – subdural hematoma, ICH – intracerebral hematoma; IVH – 
intraventricular hemorrhage, RTC – road traffic collision 
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6.3.2 Arterial glucose and lactate values 
 
Arterial glucose values ranged from 4.1 to 13.4 mmol/L with 65.7% of values between 4 and 
8 mmol/L reflecting the goal-directed management of blood glucose. Arterial glucose values 
were lower in the first 72 hours after injury with a median concentration of 6.97 (5.92 − 
7.85) and 7.46 (6.48 − 8.16) mmol/L after this period (p=0.049). Arterial lactate 
concentrations were stable, with median concentrations of 1.12 (0.87 − 1.68) in the first 72 
hours, and 1.02 (0.69 − 1.59) mmol/L after this period (p=0.074) (Table 5-2). 
 
 
First 72h - median (IQR) Beyond 72h - median (IQR) p Value 
Arterial Glucose (mmol/L) 6.97 (5.92 - 7.85) 7.46 (6.48 - 8.16) 0.049 
Arterial Lactate (mmol/L) 1.12 (0.87 - 1.68) 1.02 (0.69 - 1.59) 0.074 
AV difference Glucose (mmol/L) 0.16 (−0.24 - 0.41) 0.18 (−0.10 - 0.54) 0.299 
AV difference Lactate (mmol/L) −0.07 (−0.13 - 0.02) −0.05 (−0.11 - 0.04) 0.621 
Brain glucose (mmol/L) 0.77 (0.49 - 1.27) 0.54 (0.38 - 0.86) 0.018 
Brain lactate (mmol/L) 2.37 (1.67 - 2.87) 2.65 (1.79 - 3.25) 0.133 
Brain/Arterial glucose ratio 0.11 (0.07 - 0.18) 0.08 (0.05 - 0.11) 0.003 
LP ratio 26.5 (23.5 - 28.8) 26.1 (22.6 - 28.7) 0.883 
    PbtO2 (mm Hg) 20.4 (15.7 - 28.8) 26.3 (18.7 - 32.0) 0.019 
SjO2 (%) 77.5 (70.0 - 83.0) 78.0 (69.5 - 83.3) 0.982 
CPP (mm Hg) 76 (72 - 81) 74 (69 - 83) 0.485 
 
 
 
 
6.3.3 Glucose and lactate uptake into the brain 
 
The median AV difference in glucose (AVglc) was 0.17 (-0.15 − 0.50) mmol/L. Positive values 
for AVglc indicate net uptake of glucose into the brain. The median AVlac was −0.06 (-0.11 − 
0.02) mmol/L. Lactate uptake by the brain was demonstrated by positive AVlac values > 0.05 
mmol/L. This was observed in 17/19 patients and in 29% of samples. Greater AVlac values 
were associated with higher arterial lactate concentrations (Fig. 6.1A), significantly so at 
Table 6-2 Arterial glucose was significantly lower during the early period whilst brain glucose and 
the brain/arterial glucose ratio were significantly higher. P values refer to Mann-Whitney U tests 
of significance. IQR – interquartile range, AV – arteriovenous, PbtO2 – brain tissue oxygen, SjO2 - 
jugular venous oxygen saturation, CPP - cerebral perfusion pressure 
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arterial lactate concentrations > 1.5 mmol/L (p=0.001). A median arterial lactate 
concentration of 1.63 (0.99 − 2.24) mmol/L was associated with brain lactate uptake and 
0.89 (0.63 − 1.23) mmol/L with brain lactate export (p<0.001). Lactate uptake was associated 
with higher AVglc values with a median of 0.42 (0.03 − 0.67) during uptake and 0.07 (-0.19 − 
0.31) mmol/L during lactate export (p=0.003). The highest proportion of lactate uptake into 
the brain was observed on day 3 after injury (Fig. 6.1B). 
 
Figure 6.1 Lactate uptake at different arterial lactate concentrations and on different days 
following TBI. (A) The distribution of values for AVlac were significantly different across binned 
arterial lactate concentrations (Kruskal-Wallis p=0.004). Arterial lactate concentrations greater 
than 1.5 mmol/L were associated with significantly higher AV lac values, when compared to 
arterial lactate concentrations less than 1.5 mmol/L, as denoted by the asterisk (Mann-Whitney 
U p=0.001). (B) A greater proportion of lactate uptake (grey), as opposed to lactate export 
(white), was observed 3 days following the injury.  
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6.3.4 Brain glucose and lactate values 
 
Median brain glucose and lactate concentrations measured in microdialysis samples were 
0.66 (0.42 − 0.96) mmol/L and 2.46 (1.72 − 3.21) mmol/L, respectively. Brain glucose 
concentrations were statistically not significantly different during periods of lactate uptake 
or export with median concentrations of 0.72 (0.47 − 1.17) versus 0.57 (0.35 − 0.85) mmol/L, 
respectively (p=0.147). Brain lactate levels were also not significantly different during 
periods of lactate uptake or export with median concentrations of 2.46 (1.50 − 3.18) and 
2.19 (1.72 − 3.02) mmol/L, respectively (p=0.546). The LP ratio was also not significantly 
different with a median of 24.7 (22.9 − 28.6) during lactate uptake and 26.4 (23.4 − 28.7) 
during export (p=0.452). 
Figure 6.2 Brain glucose and lactate concentrations.  
(A) Median values of brain glucose concentrations earlier and later than 72 hours from injury (points 
and error bars represent median values and interquartile ranges for each patient). Brain glucose 
concentrations were significantly higher earlier, in the first 72 hours after injury compared to after 72 
hours and fell in the majority of patients (0.82 vs. 0.63 mmol/L; Wilcoxon signed rank test p=0.035). 
(B) Median values of brain lactate concentrations during periods of hypoxia and normoxia (squares 
represent median vales for each patient; lines are median values).  A brain tissue oxygen partial 
pressure of < 20 mm Hg was associated with slightly higher brain lactate concentrations although this 
did not reach statistical significance. Median brain lactate was 2.58 mmol/L when PbO2 < 20 mm Hg 
and 2.31 when PbO2 > 20 mm Hg (Mann-Whitney U p=0.605). 
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Brain glucose concentrations were higher in the first 72 hours after injury when compared 
with values measured after this period with median concentrations of 0.82 (0.49 − 1.4) and 
0.63 (0.30 − 0.89) mmol/L respectively (p=0.035) (Table 6.2 and Fig. 6.2A). This was despite 
lower arterial glucose values during the first 72 hours. Reflecting this, the ratio of 
brain/arterial glucose was higher although AVglc values did not change significantly between 
these time periods. 
6.3.5 Cerebral perfusion/oxygenation 
 
The majority of plasma and microdialysis samples were taken when either PbtO2 or SjO2 
indicated adequate cerebral perfusion. Insufficient perfusion, defined as the combination of 
SjO2 < 60% and PbtO2 < 20 mm Hg, was observed at 4/126 sampling periods in 3 patients. A 
PbtO2 < 20 mm Hg, suggestive of focal ischaemia in the region of the Licox probe, was 
associated with a median microdialysate lactate of 2.58 (1.62 − 3.07) mmol/L. The median 
microdialysate lactate was 2.31 (1.65 – 2.84) mmol/L when PbtO2 > 20 mm Hg (p=0.605) (Fig. 
6.2B). Brain glucose, brain LP ratio, AVglc and AVlac were not significantly different between 
instances of apparent ischaemia and non-ischaemia. 
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6.4 Discussion 
 
The key findings of this study are that the injured brain imports lactate from the circulation 
despite relatively high brain lactate concentrations and that glucose uptake is maintained 
during periods of lactate uptake. Periods of positive AVlac values, indicating net lactate 
uptake, were found in 17/19 patients following TBI, representing 29% of samples, peaking 
on day 3 after injury. A median arterial lactate concentration of only 1.63 mmol/L was 
associated with lactate uptake by the brain indicating that lactate uptake occurs against a 
concentration gradient (median brain extracellular lactate concentration in the patients was 
2.45 mmol/L, in agreement with other TBI microdialysis studies). (39,111) This suggests that 
lactate transporters must considerably up-regulate their capacity to transport lactate across 
the blood brain barrier (BBB) against a concentration gradient.  
6.4.1 Limitations of using AV measurements to study metabolism 
 
Arterial and venous measurements provided only a snapshot view of cerebral metabolism 
with sampling limited to twice daily. For the purposes of this study I was not able to make 
any CBF measurements. Uptake of glucose or lactate into the brain is influenced by CBF. 
Decrease in CBF would lead to a higher percentage extraction of blood-borne glucose and 
lactate by the brain, and potentially result in a higher AV difference, although the picture is 
complicated by the brain’s ability to produce and export lactate. I consider that my approach 
of simply dichotomizing the AV lactate data into net ‘uptake’ or ‘export’ diminishes the 
influence of CBF on my interpretation, and I regard this approach as producing a 
conservative assessment of net lactate uptake. If CBF were to fall to an ischaemic state, brain 
lactate production from anaerobic glycolysis would increase and export from the brain might 
be expected to increase venous levels of lactate, thereby reducing the chance of observing a 
positive lactate AV gradient.  
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6.5 Summary and context 
 
In this study I have shown that after TBI lactate uptake occurs despite relatively high brain 
lactate levels suggesting up-regulation of MCT transporters. Glucose delivery to brain cells 
appears to be maintained during periods of lactate uptake. Hence, lactate uptake may reflect 
an adaptive response to the increased energy demands and change in metabolic priorities of 
the injured brain.  
 
H5: “The brain after injury imports lactate from the circulation.” 
Based on the data in this study the hypothesis is accepted. 
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7.1 Introduction 
 
As an organ the brain relies on glucose. Other potential energy metabolites such as lactate, 
other monocarboxylic acids and ketone bodies are taken up into the brain under certain 
circumstances but do not appear to contribute significantly as energy substrate for the 
healthy brain. (5) However, at the cellular level there is an interchange of energy metabolites 
and lactate is postulated to act in this capacity. The best described metabolic relationship 
between cells in the brain is the astrocyte-neuron lactate shuttle (ANLS) hypothesis as 
discussed in Section 1.2.3 and in the previous chapter (Section 6.1). Supporting this 
hypothesis includes a study in human TBI patients in which microdialysis catheters were 
used to perfuse 3-13C lactate into the brain. (16) Subsequent 13C NMR analysis of returned 
microdialysates revealed 13C labeling in the TCA cycle derivatives glutamine and glutamate 
thereby demonstrating that the human injured brain can metabolise lactate through the TCA 
cycle. However, the ability of the normal, uninjured human brain to metabolise lactate in 
this way has yet to be established. Whether the TCA cycle in organs other than the brain 
metabolises lactate is also unclear.  
7.1.1 Aims 
 
The aims of this study were to determine whether lactate metabolism occurs in normal 
brain and in muscle, as well as injured brain, and to quantify the production of glutamine 
isotopomers from lactate in order to compare metabolism of lactate through the TCA cycle 
in these different tissues. 
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7.2 Materials and methods 
7.2.1 Patients  
 
The Cambridge Central Local Research Ethics Committee approved this study. Informed 
consent was obtained from all participants in the control ‘normal’ brain and muscle groups 
and assent from the relatives of those patients who had suffered a TBI. The study was 
carried out in conformation with the spirit and the letter of the Declaration of Helsinki. 
 
TBI brain microdialysis patients: TBI patients were defined as those suffering cranial trauma 
with consistent CT scan findings and requiring invasive intracranial monitoring as part of 
their clinical management. Patients were managed according to local TBI-management 
protocols as per Study II (see Section 4.2.1). 
 
Control ‘normal’ brain microdialysis patients: Patients undergoing a craniotomy for the 
resection of a benign lesion whereby a microdialysis catheter could be safely placed into 
radiographically normal brain were selected as control subjects. The microdialysis catheter 
was placed via the craniotomy and tunnelled under the scalp. The control patients were 
awake for the duration of microdialysis perfusion. 
 
Muscle microdialysis patients: Patients undergoing resections of acoustic neuromas that 
required thigh fat and fascia harvesting for dural closure were recruited for studying muscle. 
Microdialysis was performed as per Study II (see Section 4.2.1). 
7.2.2 Microdialysis technique 
 
The microdialysis technique was the same as that employed in Study II (see Section 4.2.2). 
Catheters in the TBI patients and the normal brain control subjects were perfused with CNS 
Perfusion Fluid (M Dialysis, AB; for composition see Section 3.2.1) supplemented with 8 
mmol/L 3-13C lactate. Muscle microdialysis catheters were perfused with T1 Perfusion Fluid 
(M Dialysis, AB; for composition see Section 4.2.2) supplemented with 8 mmol/L lactate. 8 
mmol/L lactate (isotopic enrichment 99%, chemical purity 99%) was obtained from 
Cambridge Isotope Laboratories, Inc (Tewksbury, MA) and was formulated in CNS perfusion 
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fluid or T1 perfusion fluid by the Manufacturing Unit, Department of Pharmacy, Ipswich 
Hospital NHS Trust, who then tested the formulations to verify purity, sterility, freedom from 
endotoxins and absence of pyrogenicity. Microdialysate collection vials from the TBI patients 
were changed hourly and analysed at the bedside using an ISCUS analyser (M Dialysis AB) 
employing enzymatic colorimetric assays for glucose, lactate, pyruvate, glutamate and 
glycerol. In TBI patients PbtO2 data was collected using a Licox brain tissue oxygen sensor 
(GMS, Kiel-Mielkendorf, Germany) and recorded at the bedside using ICM+ software (ICM+, 
University of Cambridge, UK). 
7.2.3 NMR analysis 
 
Microdialysate sample preparation and NMR analysis were performed as per Study II (see 
Section 4.2.3). Brain microdialysate samples were pooled into 24-hour periods for each 
individual patient. For NMR analysis 20 μL of D2O and 50 μL internal reference standard from 
a stock solution of 24.0 mmol/L DSS in CNS perfusion fluid were added to 180 μL of the 
pooled microdialysate sample. Muscle microdialysate samples were pooled into 8-hour 
periods. 20 μL of D2O and 70 μL from a stock solution of 2.84 mmol/L DSS were added to 
120 μL of the pooled microdialysate sample. Pooled samples, after addition of D2O and DSS, 
were stored at −80˚. For NMR analysis, samples were transferred into 3 mm NMR tubes 
(Hilgenberg GmbH). 
 
13C and 1H NMR spectra were acquired as per Study I (see Section 3.2.2) using the pulse 
programmes noesypr1d and zgpg30 for 1H and 13C spectra, respectively. 
 
Interpretation of the NMR results was based on biosynthetic pathways summarised 
schematically in Fig. 7.1, which shows the glutamine labelling patterns corresponding to TCA 
cycle metabolism of lactate.  
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In summary, 3-13C lactate is metabolised via pyruvate dehydrogenase to 4-13C glutamine on 
the first turn of the TCA cycle and to equal amounts of 2- and 3-13C glutamine on the second 
turn of the TCA cycle. When 3-13C lactate is metabolised via pyruvate carboxylase, 2-13C 
glutamine is produced on the first turn of the TCA cycle. 
 
Quantification of glutamine isotopomers was performed using the same methodology used 
in Study III (see Section 5.2.3). Calibration curves were defined as per Study I (see Section 
3.3.4) using glutamine standards of varying concentration prepared in CNS Perfusion Fluid 
with the same fixed concentration of D2O and DSS used for the preparation of brain 
microdialysate samples and run under identical NMR conditions. The peak areas of the 
glutamine NMR signals in the microdialysate samples relative to the DSS internal standard 
were used with reference to the calibration curves to calculate concentration. 
Figure 7.1 Schematic of 13C labelling patterns derived from 3-13C lactate. 
3-13C lactate is metabolised to 3-13C pyruvate, which then enters the TCA cycle via conversion to 2-13C 
acetyl CoA by pyruvate dehydrogenase (PDH) or via pyruvate carboxylase (PC) to 3-13C oxaloacetate. 2-
13C acetyl CoA is metabolised to citrate, isocitrate and then to 4-13C α-ketoglutarate where it can then 
‘spin out’ as 4-13C glutamate, which is then converted to 4-13C glutamine. Consequently 4-13C 
glutamine is produced on the ‘first turn’ of the TCA cycle. If 4-13C α-ketoglutarate remains within the 
TCA cycle it is metabolised to equal proportions of 2- and 3-13C malate due to randomisation of label 
between the carboxylic groups in the succinate to fumarate step. If malate continues within the TCA 
cycle equal amounts of 2- and 3-13C glutamine are produced on the 'second turn' of the TCA cycle. 
When 3-13C lactate is metabolised via PC to 3-13C oxaloacetate 2-13C α-ketoglutarate is produced, 
which results in 2-13C glutamine produced on the 'first turn' of the TCA cycle. 
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Fractional enrichment (%) is defined as 100 x [13C] / ([13C] + [12C]) where square brackets 
indicate concentrations of the relevant species. [13C] was determined from the 13C NMR 
spectra and [12C] from the 1H spectra. 
7.2.4 Statistical Analysis 
 
Statistical analyses performed using SPSS21 for Mac (IBM SPSS Statistics, NY). Changes of 
ISCUS microdialysis parameters between baseline and lactate perfusion periods were 
assessed for statistical significance with Wilcoxon signed rank test with a preselected p-value 
of 0.05 for statistical significance. Mann-Whitney U test was used to compare glutamine 
fractional enrichment between TBI and normal brain microdiaysates. 
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7.3 Results 
7.3.1 Demography 
 
Nine patients with severe TBI (8 M, 1 F) aged 22 - 64 y (median 45 y) were studied using 3-
13C lactate (8 mmol/L) perfusion via the microdialysis catheter for 24 hours. Eight of the 9 
patients had simultaneous collection of microdialysates for NMR analysis. One of these 
patients had 3-13C lactate perfusion via bilateral catheters, one placed at craniotomy into left 
frontal white matter and the other placed via a bolt into right frontal white matter. One 
patient underwent two 24-hour periods of 3-13C lactate perfusion. Thus, a total of 10 
samples from 8 TBI patients underwent NMR analysis. Six of the 9 patients underwent a 
baseline period with plain unsupplemented perfusion fluid (without 3-13C lactate). 
Demographic details of the TBI patients are presented in Table 6.1. 
 
Sample ID Patient Age Sex 
Injury 
mechanism 
GCS at 
scene/15 
Lactate perfusion 
period start time 
(hours from 
injury) 
Catheter 
location (right 
frontal - RF; left 
craniotomy - 
LC) 
PbtO2 at baseline 
and during 3-13C 
lactate perfusion 
(mmHg) 
TBG26b & 26c T1 51 M Fall E1 V2 M5 14 
RF & LC (2 
catheters) --  
TBG27a & 27b T2 36 M RTC E1 V1 M2 34 & 60 RF 19.5, 29.3 
TBG28a T3 17 M RTC E3 V4 M5 18 RF  -- 
TBG30a T4 48 M Fall E4 V4 M5 26 RF  -- 
TBG31a T5 45 M Assault -- 64 RF  -- 
TBG32a T6 22 F RTC E1 V2 M2 53 RF --, 23.9 
TBG35a T7 24 M RTC E1 V1 M5 83 RF 27.9, 26.0 
TBG38a T8 47 M RTC E1 V2 M5 37 RF 37.4, 31.4 
TBG29 T9 64 M Fall E3 V4 M6 98 RF 20.2, 35.1 
 
 
 
 
For comparison with TBI brain, macroscopically normal-appearing brain was studied using 
the same 13C-labelled microdialysis method in five patients (2 M, 3 F) aged 42 - 79 y (median 
69 y) undergoing surgery for benign brain tumours.  Thigh (quadriceps) muscle was similarly 
studied in five patients undergoing surgery for acoustic neuroma resection (2 M, 3 F) aged 
59 - 68 y (median 61 y). Muscle microdialysis was limited to periods of 8 hours during which 
the patients were anaesthetised undergoing acoustic neuroma surgery. 
Table 7-1 
Abbreviations: M, male; F, female; RTC, road traffic collision; GCS, Glasgow Coma 
Scale score; PbtO2, brain tissue oxygen tension (median values; -- not measured).  
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7.3.2 Baseline results compared with 3-13C lactate perfusion period in TBI 
patients.  
 
Microdialysate measurements (ISCUS analyser) of glucose, lactate, pyruvate, glutamate, 
glycerol and LP ratio are shown in Fig. 7.2 for six of the 9 TBI patients (the other three 
patients who underwent 3-13C lactate microdialysis did not undergo a period of normal 
perfusion fluid microdialysis). Median values and interquartile ranges are shown for a 24-
hour period with normal perfusion fluid and for a 24-hour period with 3-13C lactate 
perfusion (8 mmol/L). The 24-hour period with normal perfusion fluid immediately 
preceded (4 patients) or followed (2 patients) the 24-hour period with 3-13C lactate 
perfusion.  
 
4/6 patients demonstrated increases and 2/6 patients decreases in glucose between 
baseline and the 3-13C lactate perfusion period with a mean difference of +11.9 %. This 
increase was not significant (p = 0.463). As expected, lactate perfusion resulted in a 
significant increase in microdialysate lactate (p = 0.028); all patients demonstrated increases 
in lactate between baseline and 3-13C lactate perfusion periods with a mean difference of 
+174 %.  
 
Pyruvate increased significantly between baseline and 3-13C lactate perfusion period with a 
mean difference of 35.8 % (p = 0.028). The LP ratio was also observed to rise significantly 
with a mean difference of 101.8% (p = 0.028) 
 
Glutamate concentrations did not change significantly between baseline and 3-13C lactate 
perfusion periods with a mean difference of 51.1% (p = 0.60). Glycerol increased significantly 
between baseline and 3-13C lactate perfusion periods with a mean difference of 81.2% (p = 
0.043). 
 
 PbtO2 did not change significantly between perfusion periods although complete data was 
only available for 4 patients, 2 of which showed an increase and 2 a decline in PbtO2 during 
lactate perfusion compared to baseline (p = 0.465). 
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Figure 7.2 ISCUS microdialysate and PbtO2 data for baseline perfusion period versus 8 mmol/L 3-
13C lactate perfusion 
(A-F) ISCUS clinical microdialysis analyser measurements and (G) PbtO2 data: at baseline with plain 
unsupplemented perfusion fluid and during 24 h perfusion with 3-13C lactate (8 mmol/L). Error bars 
represent interquartile ranges. 
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7.3.3 Metabolic products derived from 3-13C lactate 
 
Illustrative examples of 13C NMR spectra of the microdialysates are shown in Fig. 7.3. As a 
result of 3-13C lactate perfusion TBI brain, ‘normal’ brain and muscle microdialysates 
included clearly visible peaks separate from the lactate peaks, which were not visible in 
microdialysates from patients receiving normal perfusion fluid (‘unlabelled patient’ in Fig. 
7.3), indicating cellular uptake and metabolism of the 3-13C lactate. The substrate lactate C3 
at 22.8 ppm produced the largest signal as expected.  
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A clearly visible singlet peak at 29.2 ppm for pyruvate C3, which was not visible in unlabelled 
TBI microdialysates, was present in TBI brain, ‘normal’ brain and muscle microdialysates as a 
result of 3-13C lactate perfusion. Labelling of other pyruvate isotopomers was not detected.  
 
Labelling of glutamine derived from 3-13C lactate was detected in 7/10 TBI and 4/5 ‘normal’ 
brain microdialysates, but not in muscle. In the TBI patients glutamine labelling was 
detected in the C4 position (33.7 ppm) in 6/10 samples, in the C2 position (57.1 ppm) in 
Figure 7.3	Illustrative examples of 13C NMR spectra for microdialysates from patients who received 
perfusion with 3-13C lactate 
TBI brain (uppermost two spectra, 24 h perfusion), ‘normal’ brain (third spectrum, 24 h perfusion), 
and muscle (fifth spectrum, 8 h perfusion). An example of brain microdialysate from an unlabelled TBI 
patient with plain (unsupplemented) perfusion fluid is shown for comparison (fourth spectrum). Blue 
arrows indicate pyruvate C3 enrichment and orange arrows indicate glutamine C4, C3 and C2 
enrichment. Abbreviations: glucose (Glc), lactate (Lac), 4,4-dimethyl-4-silapentane-1-sulfonate 
sodium salt (DSS, the internal reference standard). Spectra were run from –20 ppm to +250 ppm. The 
main reference DSS signal at 0 ppm is not shown in the range illustrated. The sixth spectrum is of a 
solution of 1,2-13C2 glucose and 3-13C lactate in CNS Perfusion fluid showing the peaks produced by 
these substrates. 
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6/10 samples, and in the C3 position (30.0 ppm) in 4/10 samples. In ‘normal’ brain 
microdialysates, C4 labelling was detected in 4/5, C2 labelling in 3/5, and C3 labelling in one 
patient. See Fig. 7.4. 
 
 
 
 
The greater fractional enrichment of C4 glutamine over C2 enrichment indicates that the 
entry of 13C to the TCA cycle was predominantly via pyruvate dehydrogenase (PDH) rather 
than pyruvate carboxylase (PC). This is because when 3-13C lactate enters the TCA cycle via 
PC it leads to the formation of C2 glutamine on the first turn of the TCA cycle (see Fig. 7.1). 
Figure 7-4 13C labeling of glutamine isotopomers  
13C enrichment values at the glutamine isotopomers C4, C3 and C2 (after 
subtraction of the 1.1% natural abundance background) represented by a 
heat map for each of the microdialysate samples. The numerical values are 
graphed in Figure 7-5. 
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(115) In contrast, entry of 3-13C lactate via PDH produces C4 glutamine isotopmers on the 
first turn of the TCA cycle and C2 and C3 glutamine isotopmers only on subsequent turns. In 
only one of the TBI patients (TBG28A) was C2 labelling greater than C4.  
 
Natural abundance of 13C was assumed to be 1.1%, and 13C fractional enrichment values for 
glutamine were expressed after subtracting this naturally occurring 13C background from the 
13C singlet signals. Overall there were no significant differences in glutamine fractional 
enrichment values for C4, C3 or C2 isotopomers between TBI and ‘normal’ brain 
microdialysates. See Fig. 7.5. C4 glutamine fractional enrichment was 5.1 (0 – 11.1) % in TBI 
and 5.7 (4.6 – 6.8) % in normal brain. C3 enrichment was 0 (0 – 5.0) % in TBI and 0 (0 - 0) % 
in normal brain. C2 enrichment was 2.9 (0 – 5.7) % in TBI and 1.8 (0 – 3.4) % in normal brain. 
No glutamine enrichment above that expected from natural abundance 13C was detected in 
muscle microdialysates. 
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Figure 7-5 Microdialysate NMR measurements of 13C labelling: glutamine enrichment 
(A) Total glutamine concentration measured using 1H NMR. (B-D) Results from perfusion for 
24 h (brain: TBI or ‘normal’) with 3-13C lactate (8 mmol/L). Although glutamine (13C+12C) was 
detectable in muscle (measured using 1H NMR) 13C fractional enrichment of glutamine above 
natural abundance was not detectable in muscle. Natural abundance of 13C was assumed to 
be 1.1% and 13C fractional enrichment values for glutamine were expressed after subtracting 
this naturally occurring 13C background from the 13C singlet signals. 
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7.4 Discussion 
 
In this study 3-13C lactate microdialysis of human muscle and brain with subsequent 13C 
NMR analysis of microdialysates demonstrates TCA cycle metabolism of lactate to glutamine 
in brain but not muscle although muscle metabolises lactate to pyruvate. TCA cycle 
metabolism of lactate produces similar amounts of glutamine in normal and injured brain. 
Inspecting the glutamine labelling pattern reveals that the principal entry of lactate to the 
TCA cycle is via pyruvate dehydrogenase.  
7.4.1 TCA cycle metabolism of lactate is detectable in human brain but not 
resting muscle.  
 
This study adds further evidence in support of lactate acting as an oxidative energy substrate 
in the human brain. 3-13C lactate administered to brain by the microdialysis catheter 
resulted in the production of glutamine, a product of the TCA cycle, labelled at the C4, C3 
and C2 positions.  
 
Glutamate released from neurons during synaptic transmission is taken up by astrocytes and 
converted to glutamine by the action of glutamine synthetase, which is present 
predominantly in astrocytes. Glutamine is released by astrocytes into the interstitial 
extracellular fluid where it is imported by neurons and converted to glutamate by 
phosphate-activated glutaminase. These processes are known as the glutamate-glutamine 
cycle. (116-120)  Consequently carbons released from neurons during the synaptic release of 
glutamate are thus recycled to neurons in the form of glutamine from astrocytes. In addition 
to the neuronal production of glutamate directly from glutamine, glutamate is also produced 
by the transamination of α-ketoglutarate, an intermediate of the TCA cycle. In summary, 
glutamine is derived from the TCA cycle either directly from the transamination of α-
ketoglutarate plus the action of glutamine synthetase in astrocytes or indirectly following 
the capture of glutamate from the synaptic cleft. Therefore the transfer of 13C from lactate 
to glutamine in this study indicates TCA cycle metabolism of lactate. 
 
In muscle, uptake and metabolism of 3-13C lactate was evident by the generation of 3-13C 
pyruvate. Further downstream metabolism in the form of TCA cycle intermediates was not 
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detected. The likelihood is that glutamine does not function as an intercellular metabolite in 
muscle in the same way as it does in brain. However, the fact that 3-13C lactate contributed 
to an extracellular pool of pyruvate indicates the activity of lactate dehydrogenase in 
metabolising lactate to pyruvate. This suggests contribution of lactate to an intracellular 
pool of pyruvate that could subsequently undergo mitochondrial oxidative metabolism. 
However, I was not able to demonstrate in this study whether or not lactate contributes 
significantly to oxidative metabolism. This might have in part been due to the shorter time 
periods that muscle underwent 3-13C lactate microdialysis (8 h) compared to brain 3-13C 
lactate microdialysis (24 h). 
7.4.2 TCA cycle metabolism of lactate occurs in normal as well as injured 
brain  
 
This study supports a previous 13C-labelling microdialysis study that demonstrated 
metabolism of lactate via the TCA cycle in the injured human brain. (16) In addition, I have 
demonstrated that TCA cycle metabolism of lactate is not limited to the injured brain but 
also occurs to a similar degree in normal brain. In this study no significant differences were 
observed in 13C enrichment values for any of the glutamine isotopomers between normal 
and injured brain.  
7.4.3 The effect of lactate on microdialysate glucose, pyruvate, glycerol, LP 
ratio and PbtO2 
 
Administration of lactate to the extracellular space resulted in significant increases in 
microdialysate pyruvate and glycerol concentrations measured on the ISCUS which 
measures total levels regardless of labelling.  
 
The increase in pyruvate concentrations is as expected through the action of lactate 
dehydrogenase. An alternative explanation for the increase in pyruvate is that lactate causes 
increased delivery of glucose to the cells with a subsequent increase in glycolytic pyruvate. 
Lactate is vasoactive and has been demonstrated both experimentally and in the human 
brain to increase CBF, mostly likely mediated via prostaglandins. (121-123) Hence, 
microdialysis perfusion with lactate might result in the increased delivery of glucose due to 
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regional increases in CBF. This might also be expected to increase PbtO2, which I observed in 
2/4 of the patients for whom I had complete data.  
 
Increased microdiaysate glycerol in the context of TBI patients has been previously 
attributed to the degradation of phospholipids due to cell death. (124) However, glycerol can 
also be formed from glucose in brain. (125) It follows that increased glycerol might result 
from greater metabolic production as a result of spared glycolytic glucose metabolism 
conferred by lactate perfusion. Microdialysate glycerol concentration decreased after 
cessation of lactate perfusion in the one patient (with complete glycerol data) whose 
baseline period was after the 24 h period with lactate perfusion (in the other four patients 
with complete glycerol data the baseline period preceded the lactate perfusion period) (see 
Fig. 7.2E). This suggests that the rise in glycerol concentration with lactate perfusion was 
metabolically-derived as opposed to caused by cell death. 
7.4.4 Pyruvate dehydrogenase versus pyruvate carboxylase activity 
 
The 13C labelling of C4 glutamine indicates metabolism of 3-13C lactate via entry to the TCA 
cycle through PDH and synthesis of α-ketoglutarate during the first turn (see Fig. 7.1). In this 
study, C4 glutamine exhibited the strongest 13C enrichment of the glutamine isotopomers 
indicating that PDH was the predominate route for 3-13C lactate metabolism in brain.  
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7.5 Summary and context 
 
In this study I have shown that lactate delivered by microdialysis is metabolised via the TCA 
cycle in both injured and normal brain. Lactate is initially metabolised to pyruvate before 
entering the TCA cycle via pyruvate dehydrogenase. This leads to elevated microdialysate 
concentrations of pyruvate. In muscle, evidence of TCA cycle metabolism of lactate is lacking 
although lactate is metabolised to pyruvate. 
 
H6: “The brain is able to oxidatively metabolise lactate.” 
Based on the data in this study the hypothesis is accepted. 
 
H7: “Muscle is able to oxidatively metabolise lactate.”  
Based on the data in this study there is insufficient evidence to accept this hypothesis.  
 
H8: “3-13C lactate metabolism through the TCA cycle differs between uninjured and injured 
brain.” 
Based on the data in this study there is insufficient evidence to accept this hypothesis. 
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8.1 Introduction 
8.1.1 The LP ratio as a marker of mitochondrial function 
 
Evidence for the metabolic perturbations observed to accompany TBI point towards a 
relative reduction in oxidative mitochondrial metabolism with a greater proportion of 
glucose metabolised anaerobically. (55,56) Consistent with this is an elevated LP ratio, 
measured in brain extracellular fluid of TBI patients using microdialysis and found to relate 
to clinical outcome. (39) As discussed in Section 1.5 the LP ratio reflects the balance of 
cytosolic NAD+ and NADH, the redox status. NAD+ is oxidised to NADH during glycolysis and a 
continued supply of NAD+ is required for glycolysis to continue. An elevated LP ratio in the 
context of TBI has been attributed to a reduction in oxidative mitochondrial metabolism due 
to hypoxia and/or structural and metabolic dysfunction. (39)  
8.1.2 Pathophysiology of mitochondrial dysfunction after TBI 
 
Several mechanisms have been implicated in the pathophysiology of mitochondrial 
dysfunction after brain injury. (103-106,126) Abnormal calcium influx and the oxidative 
modification of proteins, lipids and DNA due to oxidative stress impairs the electron 
transport chain, promotes the release of cytochrome c through the outer mitochondrial 
membrane leading to caspase-dependent apoptosis and increases the permeability of the 
inner membrane leading to a loss of NAD+. Furthermore, several of the mitochondrial 
enzymes and transporters involved in the TCA cycle and in shuttling intermediates into and 
out of the mitochondria are affected by these mechanisms. These structural and 
biochemical changes to mitochondria likely contribute to metabolic failure and ultimately 
cell death after TBI. 
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8.1.3 Transfer of reducing equivalents between the cytosol and 
mitochondrion 
 
A potential metabolic sequalae of mitochondrial dysfunction after TBI is disruption to the 
exchange of intermediates into and out of the TCA cycle, which is likely to have secondary 
effects on the redox balance and on neuronal-glial metabolic coupling. Normally, the 
mitochondrial membrane is impervious to NAD+ and NADH. Mechanisms that transfer 
reducing equivalents between the cytosol and the mitochondrion are integral to the 
maintenance of cytosolic redox. A series of enzymes and transporters that couple the 
interconversion of the TCA cycle intermediates malate and oxaloacetate, oxaloacetate and 
aspartate, and α-ketoglutarate and glutamate with the transport of aspartate, glutamate, α-
ketoglutarate and malate across the mitochondrial membrane, termed the malate-aspartate 
shuttle, is thought to be the principle mechanism for the transfer of reducing equivalents 
between the cytosol and mitochondria in the brain (see Fig. 8.1). (127-129) The overall 
effect of this shuttle is to deliver NADH from the cytosol to mitochondrial electron transport 
chains. In addition to the shuttling of intermediates between the TCA cycle and the cytosol, 
there is an exchange of metabolites between neuronal and glial TCA cycles although the 
exact nature and stochiometry of this is debated. (130-133)  
 
 
Figure 8-1 The malate-aspartate shuttle 
A series of enzymes and transporters that couple the interconversion of the TCA cycle intermediates 
malate and oxaloacetate, oxaloacetate and aspartate, and α-ketoglutarate and glutamate with the 
transport of aspartate, glutamate, α-ketoglutarate and malate across the mitochondrial membrane. 
Abbreviations: AGC1, aspartate-glutamate carrier 1; mAAT, mitochondrial aspartate aminotransferase; 
MAC, malate-α-ketoglutarate carrier; MDH, malate dehydrogenase.  
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8.1.4 Aims 
 
The aim of this study was to evaluate the substrate succinate delivered to the injured human 
brain by microdialysis as a potential metabolic rescue agent. Succinate is an energetically 
important molecule - it is a TCA cycle intermediate and moreover it provides a direct point of 
contact between the TCA cycle and the mitochondrial electron transport chains (ETC). 
Succinate is metabolised to fumarate in the TCA cycle by succinate dehydrogenase, also 
known as complex II of the ETC, which is located on the inner mitochondrial membrane. 
NADH produced from other steps of the TCA cycle delivers electrons to complex I of the ETC. 
Electron transport proceeds from complex I to Coenzyme Q (also termed ubiquinone), 
complex III, Cytochrome C and complex IV, bypassing complex II (succinate dehydrogenase). 
In contrast succinate bypasses complex I and electron transport proceeds via complex II to 
Coenzyme Q. Ultimately, the electrons in the ETC are deposited on molecular oxygen 
resulting in the conversion of oxygen to water. Complexes I, III and IV maintain the proton 
gradient across the inner mitochondrial membrane that drives ATP synthesis. Consequently 
succinate can provide energy support in compromised mitochondria as it bypasses Complex 
I of the ETC, which in some situations appears more vulnerable to inhibition and/or damage 
than Complexes II, III and IV (134). In addition succinate is likely to have an anaplerotic 
action directly furnishing the TCA cycle with intermediates. My use of 13C labelled 2,3-13C2 
succinate meant that I could explore the interchange of metabolites into and out of the TCA 
cycle. 
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8.2 Materials and methods 
8.2.1 Patients  
 
The National Research Ethics Service (NRES) Committee East of England - Cambridge Central 
approved this study, which was carried out in conformation with the spirit and the letter of 
the Declaration of Helsinki. Patients (more than 16 years old) with severe TBI, defined as 
those suffering cranial trauma with consistent CT scan findings and with a post-resuscitation 
GCS ≤ 8 were recruited. Patients were treated according to local TBI management protocols, 
as per Study II (see Section 4.2.1). 
8.2.2 Microdialysis technique 
 
The microdialysis technique was the same as that employed in Study II (see Section 4.2.2). 
Catheters were perfused with CNS Perfusion Fluid (M Dialysis, AB; for composition see 
Section 3.2.1)  supplemented with 12 mmol/L 2,3-13C2 succinate (isotopic enrichment 99%, 
chemical purity 99%) obtained from Cambridge Isotope Laboratories, Inc (Tewksbury, MA) 
and formulated in CNS perfusion fluid by the Manufacturing Unit, Department of Pharmacy, 
Ipswich Hospital NHS Trust. A baseline period with perfusion with unsupplemented CNS 
Perfusion Fluid was also obtained either before or after the succinate perfusion. 
Microdialysate collection vials were changed hourly and analysed at the bedside using an 
ISCUS analyser (M Dialysis AB) employing enzymatic colorimetric assays for glucose, lactate, 
pyruvate, glutamate and glycerol. Microdialysate samples were stored at 4°C (or at –80°C if 
storage for longer than a few days was necessary) prior to NMR analysis. 
8.2.3 NMR analysis 
 
Microdialysate sample preparation and NMR analysis was performed as per Study II (see 
Section 4.2.3). Brain microdialysate samples were pooled into 24-hour periods for each 
individual patient. For NMR analysis 20 μL of D2O and 50 μL of 24.0 mmol/L DSS in CNS 
perfusion fluid  were added to 180 μL of the pooled microdialysate sample. Pooled samples, 
after addition of D2O and DSS, were stored at −80˚. For NMR analysis, samples were 
transferred into 3 mm NMR tubes (Hilgenberg GmbH, Malsfeld, Germany). 
 
Study VI 
115 
Interpretation of the NMR results was based on biosynthetic pathways summarised 
schematically in Fig. 8.2. Succinate is metabolised to fumarate by succinate dehydrogenase. 
Fumarate is metabolised to malate, which can exit the mitochondrion via the malate-α-
ketoglutarate carrier (MAC). Malate, within the TCA cycle, is converted to oxaloacetate that 
can cycle around the TCA cycle and then spin out via α-ketoglutarate to glutamate and 
subsequently glutamine. Oxaloacetate can also leave the TCA cycle following conversion to 
aspartate which is transported to the cytosol by the aspartate-glutamate carrier (ACG). In 
the cytosol aspartate is metabolised back to oxaloacetate and then to malate, which can re-
enter the mitochondrion via MAC. Malate can undergo decarboxylation to pyruvate either 
directly via malic enzyme (ME) or indirectly via phosphoenopyruvate carboxykinase (PEPCK) 
and pyruvate kinase (PK). 
 
 
8.2.4 High-Performance Liquid Chromatography (HPLC) 
 
Total glutamine concentration (12C and 13C, regardless of labelling) was quantified by 
reverse-phase HPLC analysis of microdialysate samples (derivatised in-needle using ortho-
Figure 8-2 Schematic of TCA cycle, malate-aspartate shuttle and pyruvate recycling pathway.  
See text in Sections 8.2.3 and 8.4 for further details. Filled circles represent 13C labelling of metabolites derived 
from 2,3-13C2 succinate. 2,3-13C2 malate results from metabolism of 2,3-13C2 succinate via the TCA cycle. 
Subsequent metabolism of 2,3-13C2 malate within the TCA cycle results in 2,3-13C2 glutamate spinning out on 
the 'first turn', which is then metabolised to 2,3-13C2 glutamine. 2,3-13C2 malate undergoes decarboxylation to 
2,3-13C2 pyruvate either directly via malic enzyme or indirectly via phosphoenopyruvate carboxykinase and 
pyruvate kinase. 2,3-13C2 pyruvate is converted to 2,3-13C2 lactate by lactate dehydrogenase. 
 
Abbreviations: LDH, lactate dehydrogenase; mAAT, mitochondrial aspartate aminotransferase; ME, malic 
enzyme; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PEPCK, phosphoenopyruvate 
carboxykinase; PK, pyruvate kinase. 
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pthalaldehyde and mercaptopropionic acid) on an Agilent 1100 series HPLC system with a 
fluorescence detector (Agilent Technologies, Waldbronn, Germany), using a published 
method (135) based on technical information from Agilent (136). 
 
8.2.5 Statistical Analysis 
 
Statistical analyses performed using SPSS21 for Mac (IBM SPSS Statistics, NY). Changes of 
ISCUS microdialysis parameters between baseline and succinate perfusion periods were 
assessed for statistical significance with Wilcoxon signed rank test with a preselected p-value 
of 0.05 for statistical significance.  
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8.3 Results 
8.3.1 Demography 
 
Nine severe TBI patients (7 M, 2 F) aged 18-60 y (median 47 y) were studied using 2,3-13C2 
succinate (12 mmol/L) perfusion via the microdialysis catheter. These patients were also 
studied for a baseline period with plain unsupplemented perfusion fluid (without 2,3-13C2 
succinate). Demographic details, catheter positions and PbtO2 measurements are presented 
in Table 8.1. 
 
Patient Age Sex 
Injury 
mechanism 
GCS at 
scene/15 
Succinate perfusion 
period start time 
(hours from injury) 
Marshall 
grade 
Admission 
Catheter 
location CT Description 
PbtO2 
at baseline and 
during 2,3-13C2 
succinate 
perfusion 
(mmHg) 
1 56 F Fall 10 26.0 6a L frontal EDH, contusions 25.3, 31.1  
2 52 M RTC 4 121.3 3 R frontal DAI -- 
3 18 M RTC 8 41.9 3 R frontal DAI, contusions 21.8, 20.4 
4 47 M RTC 8 36.9 2b R frontal DAI,  contusions 19.9, 27.4 
5 41 F Fall 3 67.5 6b R frontal R ASDH --, 35.7 
6 20 M Assault 14 83.0 3 R frontal DAI, contusions --, 15.8 
7 60 M Fall 11 103.9 2d R frontal DAI, contusions 18.6, 17.9 
8 47 M RTC 9 160.4 2b R frontal DAI -- 
9 46 M RTC 6 79.5 3 R frontal L ASDH 34.9, 34.9 
 
 
8.3.2 Baseline results compared with 2,3-13C2 succinate perfusion period 
 
Microdialysate measurements (using the ISCUS analyser) of glucose, lactate, pyruvate, 
glutamate and glycerol are shown in Fig. 8.2. These were acquired in nine TBI patients for a 
24-hour period during which the microdialysis catheter was perfused with plain 
unsupplemented CNS perfusion fluid immediately before or after a 24 h period of perfusion 
with 2,3-13C2 succinate (12 mmol/L). 
Table 8-1  
Abbreviations: M, male; F, female; RTC, road traffic collision; GCS, Glasgow Coma Scale score; L, 
left; R, right; EDH, extradural haematoma; DAI, diffuse axonal injury; ASDH, acute subdural 
haematoma; PbtO2, brain tissue oxygen tension (median values; -- not measured).  
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Decreases in microdialysate glucose concentration (measured on the ISCUS analyser) 
between baseline (unsupplemented) and the 2,3-13C2 succinate perfusion period were seen 
for 7/9 patients. The greatest fall in microdialysate glucose between baseline and succinate 
perfusion was observed in those patients where the microdialysate glucose concentration 
was greater than 3 mmol/L during the baseline period. Overall the mean difference was -
15% (p=0.038). In 7/9 patients there was an increase in microdialysate pyruvate 
concentration with a mean difference of +17% although this missed significance (p=0.11). 
Microdialysate glutamate concentrations fell in all patients (7/7) between baseline and 
succinate perfusion periods with a mean difference of -43% (p=0.038). There was no 
consistent trend for a change in microdialysate lactate concentration between perfusion 
Figure 8-3	ISCUS clinical microdialysis analyser measurements  
Results are for during 24 h perfusion with plain unsupplemented fluid and during 24 h perfusion with 2,3-
13C2 succinate. Symbols joined by lines represent individual patients (TBI patients 1-9). Each pair of data-
points indicates median levels at baseline and during succinate perfusion respectively for that patient. For 
patients TBI 1 and TBI 2 the baseline period was post-succinate while for the other seven patients the 
baseline period was pre-succinate. Red asterisks denote significant changes between baseline and 
succinate perfusion judged by Wilcoxon's signed rant test.  
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periods rising in 4 and falling in 5 patients. Overall the mean difference was -3% (p=0.86). 
The LP ratio fell in all but one of the patients (8/9) between baseline and succinate perfusion 
periods with mean difference of -12% (p=0.015). The LP ratios of the two patients with the 
highest baseline LP ratios fell from 31.3 to 21.5 and from 26.8 to 23.3 during succinate 
perfusion bringing them below 25, regarded as a crucial threshold. (39)  5/6 of the patients 
demonstrated a rise in glycerol concentration during succinate perfusion although the 
overall change did not reach significance (p=0.075). 
  
8.3.3 NMR results after 2,3-13C2 succinate perfusion 
 
NMR analysis of brain microdialysates was performed for six TBI patients who received 2,3-
13C2 succinate microdialysis perfusion. Illustrative examples of 13C NMR spectra of the 
microdialysates are shown in Fig. 8.4. In summary, the strongest peaks observed were 
Figure 8-4 Illustrative examples of 13C NMR spectra for microdialysates from patients who received perfusion with 
2,3-13C2 succinate (12 mmol/L).  
TBI brain (uppermost two spectra, 24 h perfusion) and an example of brain microdialysate from an unlabelled TBI 
patient with plain (unsupplemented) perfusion fluid is shown for comparison (fourth spectrum). Expansions of the 
glutamine C2, glutamine C3 and lactate C3 signals are shown for TBI brain. Spectra were run from –20 ppm to +250 
ppm. The main reference DSS signal at 0 ppm is not shown in the range illustrated. Abbreviations: glucose (Glc), 
lactate (Lac), glutamine (Gln), Mal (malate), 4,4-dimethyl-4-silapentane-1-sulfonate sodium salt (DSS, the internal 
reference standard).  
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doublets for malate C2 and C3, a singlet peak at 138 ppm for 2,3-13C2 fumarate, and a singlet 
peak at 36.9 ppm for 2,3-13C2 succinate. 2,3-13C2 fumarate and 2,3-13C2 succinate produce 
singlet peaks because both these molecules are symmetrical and so the C2 and C3 positions 
are equivalent. There was no discernable singlet for malate, which indicates that the double-
labeled malate observed was entirely derived from the 2,3-13C2 succinate that was 
administered.  
 
Clearly visible doublets for the lactate C3 methyl group and for the lactate C2 were observed 
together with smaller singlets in all 6 patients.  
 
Doublet/singlet peaks were observed at 57.3 and 30.3 ppm, which represent glutamine C2 
and C3 groups respectively. Of note, no labelling was observed for other glutamine 
isotopomers nor for glutamate, GABA, aspartate or pyruvate. The presence of C2 and C3 
glutamine doublets indicates metabolism of 2,3-13C2 succinate by the TCA cycle with the 
production of glutamate as a spin-off that is subsequently metabolised to glutamine. C2 and 
C3 glutamine doublets were present in 5/6 TBI patients.  
 
Fractional enrichment in 2,3-13C2 glutamine was (median; IQR) 16.2 (5.3-22.6) %. Fractional 
enrichment was based on quantification of the glutamine C3 doublet signal (13C spectrum) 
to measure 13C at the C3 position and total glutamine concentration based on HPLC. Similar 
13C fractional enrichment to that of glutamine C3 doublet was obtained using the glutamine 
C2 doublet (23.9%), as expected. Quantification of the C3 and C2 glutamine singlets (after 
subtracting naturally occurring 13C) revealed only a modest amount of enrichment with 
more enrichment at the C3 position than C2 with median fractional enrichments of 3.5 (1.1-
6.9) and 1.1 (0-3.6) % respectively. 
 
Fractional enrichments of the lactate C3 and C2 doublets were 2.3 (1.1-4.5) and 2.0 (0.8-4.4) 
% respectively. Singlets for lactate C3 and C2 revealed no significant 13C enrichment above 
background natural abundance 13C. In 5/6 patients enrichment was greater in 2,3-13C2 
glutamine than in 2,3-13C2 lactate, while in the remaining patient (TBI Patient 1) 2,3-13C2 
glutamine was undetectable although 2,3-13C2 lactate was present (see Fig. 8.5). The median 
2,3-13C2 lactate/2,3-13C2 glutamine enrichment ratio was 19.9 (12.9-21.7) %.  
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Figure 8-5 13C enrichment in glutamine and lactate.  
Fractional enrichment values (%) for microdialysate 2,3-13C2 glutamine (green bars; based on the glutamine C3 
doublet signal) and 2,3-13C2 lactate (blue bars; based on the lactate C3 doublet signal).  
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8.4 Discussion 
 
This study has shown that 2,3-13C2 succinate infusion via the microdialysis catheter can be 
used to directly interrogate mitochondrial metabolism in TBI patients and that the TCA cycle 
synthesises glutamine, lactate and malate. I postulate that delivery of succinate to the 
injured brain led to improved redox providing a permissive environment for glycolysis. 
8.4.1 Uptake and mitochondrial metabolism of 2,3-13C2 succinate 
 
Evidence for the cellular uptake and mitochondrial metabolism of 2,3-13C2 succinate is 
demonstrated by the appearance of characteristic doublet peaks in the NMR spectra arising 
from contiguous 13C atoms reflecting downstream metabolites derived from 2,3-13C2 
succinate. The microdialysis methodology used in this study delivers 2,3-13C2 succinate to 
the interstitium from where cellular uptake occurs. This is achieved through transporters 
that belong to the SLC13 family of membrane secondary active transporters, of which three 
have been identified in humans that function to transport di- and tricarboxylates coupled 
with sodium. (137-139) The subsequent metabolism of succinate takes place in the 
mitochondria by complex II (also termed succinate dehydrogenase) of the mitochondrial 
electron transport chain, located on the inner membrane. Succinate dehydrogenase is found 
at high concentrations only within the mitochondria. (140) Hence, the presence of 
metabolites with characteristic doublet signals (2,3-13C2 malate, 2,3-13C2 glutamine and 2,3-
13C2 lactate) derived from 2,3-13C2 succinate, indicates the successful uptake and 
mitochondrial metabolism of succinate.  
8.4.2 2,3-13C2 succinate metabolism via the TCA cycle produces 2,3-13C2 
glutamine 
 
Microdialysis perfusion of the brain with 2,3-13C2 succinate resulted in 2,3-13C2 glutamine in 
5/6 of the TBI patient’s microdialysates. There are two theoretically likely routes for this 
pattern of labelling. See Fig. 8.2. Firstly, 2,3-13C2 succinate is metabolised to fumarate by 
succinate dehydrogenase and then continues within the TCA cycle to α-ketoglutarate, which 
is metabolised to 2,3-13C2 glutamate. 2,3-13C2 glutamate is then metabolised to 2,3-13C2 
glutamine by glutamine synthase located in astrocytes. An alternative route is that the 2,3-
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13C2 malate produced from 2,3-13C2 succinate undergoes decarboxylation to 2,3-13C2 
pyruvate either directly via malic enzyme or indirectly via phosphoenopyruvate 
carboxykinase (PEPCK) and pyruvate kinase (see below). 2,3-13C2 pyruvate then enters the 
TCA cycle via pyruvate dehydrogenase, which results in 4,5-13C2 glutamate on the first turn 
of the TCA cycle. Alternatively 2,3-13C2 pyruvate enters the TCA cycle via pyruvate 
carboxylase, which converts 2,3-13C2 pyruvate to 2,3-13C2 oxaloacetate. 2,3-13C2 
oxaloacetate’s continued metabolism within the TCA cycle results in the production of 2,3-
13C2 glutamate from the first turn and thence 2,3-13C2 glutamine. In summary, our 
observation of 2,3-13C2 glutamine is consistent with succinate metabolism within the first 
turn of the TCA cycle and/or carboxylation of pyruvate derived from malate. The latter 
seems less likely as 4,5-13C2 glutamine was not detected, which would be expected from 
entry of 2,3-13C2 pyruvate to the TCA cycle via pyruvate dehydrogenase. (93,100) Hence, 
direct metabolism of 2,3-13C2 succinate within the TCA cycle to 2,3-13C2 glutamine is the 
most likely source of labelled glutamine. The greater fractional enrichment in 2,3-13C2 
glutamine observed than in 2,3-13C2 lactate (see Fig. 8.5) further supports the early 
generation of labelled glutamine via direct metabolism of 2,3-13C2 succinate by the TCA 
cycle. 
 
8.4.3 2,3-13C2 succinate metabolism via the TCA cycle produces 2,3-13C2 
malate 
 
There are two potentially likely sources of 2,3-13C2 malate derived from the perfused 2,3-13C2 
succinate. The 2,3-13C2 malate may have emerged following metabolism of succinate to 
fumarate and then to malate, which leaves the mitochondrion via the malate-α-
ketoglutarate carrier. See Fig. 8.1. Alternatively, malate might remain within the TCA cycle 
being converted to oxaloacetate (OAA). A spinout product of OAA is aspartate, which can 
exit the mitochondria (via the glutamate/aspartate carrier) as part of the malate-aspartate 
shuttle mechanism. (141) In the cytosol, aspartate is converted to OAA and thence to 
malate. 
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8.4.4 2,3-13C2 succinate metabolism via the TCA cycle produces 2,3-13C2 
lactate, which indicates ‘partial pyruvate recycling’ 
 
The synthesis of 2,3-13C2 lactate from 2,3-13C2 succinate is evidence for the generation of 
pyruvate from TCA cycle intermediates. The synthesis of lactate from the TCA cycle is 
achieved through the action of two pathways that lead to the generation of pyruvate from 
intermediates of the TCA cycle. Malate can be decarboxylated to pyruvate via malic enzyme, 
and oxaloacetete decarboxylated to pyruvate via the combined action of PEPCK and 
pyruvate kinase. Both malic enzyme and PEPCK have been shown to be active in brain. (142) 
Malic enzyme exists as cytosolic and mitochondrial isoforms, both of which have been 
identified in rat brain. (143,144) Malic enzyme activity is observed in cultured astrocytes but 
not cultured neurons although it is abundantly expressed in synaptosomes. (144) PEPCK is 
found to be mainly mitochondrial and, in contrast to malic enzyme, has been identified in 
both primary cultures of neurons and astroyctes as well as in whole rat brain. (145,146)  
 
The production of pyruvate from TCA cycle intermediates, through malic enzyme and/or 
PEPCK, with subsequent re-entry of pyruvate into the TCA cycle constitutes what has been 
termed ‘pyruvate recycling’ whereby pyruvate is produced from the TCA cycle and then later 
consumed by the TCA cycle through its entry via pyruvate dehydrogenase. The labelling 
patterns in this study indicate ‘partial pyruvate recycling’ as the pyruvate spun out from the 
TCA cycle does not re-enter it but proceeds to lactate that exits from cells. Full pyruvate 
recycling, involving re-entry of 2,3-13C2 pyruvate into the TCA cycle via PDH would have 
resulted in 4,5-13C2 glutamine, which I did not detect. 
8.4.4.1 Pre-clinical evidence for pyruvate recycling 
 
Pyruvate recycling was first described as occurring in the brain by Cerdan et al. (1990) as an 
explanation for the unexpected synthesis of singly-labelled glutamate and glutamine, in 
addition to 4,5-13C2 glutamate and 4,5-13C2 glutamine, after the intravenous administration 
of 1,2-13C2 acetate to rats. (147) The synthesis of singly labelled glutamate and glutamine in 
this experiment indicates decarboxylation of doubly labelled malate, which breaks the 13C-
13C bond, to 3-13C pyruvate which is then metabolised via pyruvate dehydrogenase. A similar 
13C-labelling experimental paradigm examining brain extracts from rats after administration 
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of 1,2-13C2 acetate was used by Cruz et al. (1998) and also demonstrated pyruvate recycling. 
(144)  Several groups have incubated primary cultures with uniformly labelled glutamate and 
found evidence for pyruvate recycling from the labelling patterns in glutamate and 
glutamine and other TCA cycle derivatives. In these experiments, pyruvate derived from 
decarboxylation of uniformly labelled TCA cycle intermediates re-enters the TCA cycle as 1,2-
13C2 acetyl CoA, which leads to characteristic labelling patterns in subsequent TCA cycle 
derivatives. (148-150) Other experiments in animals support these findings from cell culture.  
Ex vivo NMR of brain extracts after infusion of 2-13C acetate into rodents leads to 3-13C 
lactate, indicative of 3-13C pyruvate production from the TCA cycle, but also produces 2-13C 
lactate due to entry of 3-13C pyruvate into the TCA cycle and scrambling of 13C label in the 
succinate-to-fumarate step. (151) 
8.4.5 Succinate perfusion improves redox balance and glycolysis 
 
Comparison of microdialysate glucose and pyruvate concentrations between periods of 
normal perfusion and succinate perfusion suggest that succinate perfusion led to a boost in 
glycolysis. Microdialysate glucose concentrations fell during succinate perfusion and this fall 
was particularly pronounced in those patients who started with a relatively high (> 3 
mmol/L) baseline glucose concentration. In all but one of the patients, there was a modest 
increase in microdialysate pyruvate. Interestingly, the patient who demonstrated a fall in 
microdialysate pyruvate was one of the two patients in which the microdialysate glucose 
increased between baseline and succinate perfusion periods. The combination of a 
reduction in microdialysate glucose and a reciprocal increase in pyruvate suggests an 
increase in uptake and glycolytic metabolism of glucose.  
 
The LP ratio was modestly but significantly reduced in all patients during succinate perfusion 
in comparison to the period with unsupplemented perfusion fluid. This reduction in LP ratio 
appears to relate to a rise in pyruvate rather than a fall in lactate. The patient with the 
largest LP ratio reduction had the largest rise in pyruvate. The microdialysate LP ratio reflects 
the cytosolic redox status, the balance of NAD+ and NADH. Lactate dehydrogenase catalyses 
the reversible conversion of pyruvate to lactate and NADH to NAD+. A higher LP ratio 
indicates a shift in balance of this reaction such that more pyruvate is converted to lactate to 
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maintain the same NAD+ to NADH ratio. A continued supply of NAD+ is required for 
glycolysis. Hence, succinate infusion leads to a shift in the redox with increased cytosolic 
NAD+, resulting in a redox balance that is favourable for glycolysis.  
 
I postulate that this favourable shift in redox is due to improved shuttling of NADH from the 
mitochondrion to the cytosol. The mitochondrial membrane is impervious to NADH and so 
hydrogens and electrons are transferred indirectly by shuttles, the principle mechanism 
being the malate-aspartate shuttle (see Fig. 8.1) (127-129), which concurs with the 
observation of 2,3-13C2 malate in microdialysates. Furthermore, the fall in microdialysate 
glutamate concentration observed with succinate perfusion is consistent with increased 
activity of the malate-aspartate shuttle, drawing glutamate into mitochondria which is then 
consumed by the TCA cycle. 
 
8.5 Summary and context 
 
In this study I have shown that 2,3-13C2  succinate delivered by microdialysis can be used to 
interrogate the role of the TCA cycle in producing labelled metabolites that are exported into 
the interstitium. This has demonstrated that the TCA cycle is a source of lactate. Succinate 
appears to influence the redox balance by boosting mitochondrial shuttles, lowering the LP 
ratio. 
 
 H9: “Administration of succinate by microdialysis will enhance energy metabolism and 
have a favourable impact on the lactate / pyruvate ratio.”  
Based on the data in this study the hypothesis is accepted. 
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9.1 General statement of conclusions 
 
In this thesis I have developed and applied NMR methodology to human microdialysis for 
the reliable quantification of cerebral interstitial metabolites and identification of 13C 
labelling patterns in metabolites. This enabled me to use microdialysis-delivered 13C-labelled 
substrates to interrogate aspects of energy metabolism in the normal and injured brain and 
to compare cerebral metabolism with metabolism in muscle. I recruited a total of seventy-
one patients: 44 TBI patients and 27 control subjects for analysis of brain or muscle. 
 
I have demonstrated that glycolytic production of lactate is increased as a result of injury 
and that the pentose phosphate pathway also contributes to glucose metabolism and lactate 
generation. I found that the injured brain has periods where it imports lactate from the 
circulation. I have demonstrated that lactate is metabolised by the TCA cycle in both normal 
and injured brain. I have demonstrated in injured brain that the TCA cycle can generate 
lactate. Hence, lactate appears to function as an important intercellular metabolite being 
both produced by and consumed by the TCA cycle. I have demonstrated the ability to 
improve redox and potentiate energy metabolism using microdialysis-delivered succinate. 
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9.2 The metabolic fate of glucose  
 
An increase in the proportion of glucose undergoing ‘anaerobic’ (non-oxygen consuming) 
metabolism is observed after TBI. (44,55,56) Whether this is due to increased glycolysis or 
due to other pathways that metabolise glucose, notably the PPP, was explored in Study III 
using 1,2-13C2 glucose.  
9.2.1 Increased glycolysis after TBI 
 
I demonstrated that TBI is associated with increased glycolytic production of lactate. 
Diagnostic doublet signals for both C3 and C2 of lactate (see Fig. 5.5) indicating 2,3-13C2 
lactate, were observed for all patients in Study III, including microdialysates from TBI brain, 
‘normal’ brain and muscle. The 13C enrichment in the doublet signals was significantly higher 
in TBI brain, suggesting greater glycolytic activity, than in ‘normal’ brain and muscle. This is 
consistent with evidence from FDG-PET data, discussed in Section 1.5.3, which indicates that 
a greater proportion of glucose is anaerobically metabolised after TBI.  
9.2.2 Increased pentose phosphate pathway after injury 
 
I confirmed that the PPP contributes to the metabolism of glucose in injured and 'normal' 
brain although I did not find sufficient evidence to conclude that PPP activity is significantly 
increased after injury. However, some TBI patients appeared to have relatively high levels of 
PPP-derived lactate. The finding of increased PPP activity in some patients as a result of 
brain injury is supported by experimental studies. In rat models relevant to TBI, Bartnik et al. 
infused 1,2-13C2 glucose intravenously after fluid percussion injury and cortical contusion 
injury, and performed NMR analysis of brain tissue extracts. They found an increase in the 
proportion of 3-13C lactate (indicative of PPP) relative to 2,3-13C2 lactate (indicative of 
glycolysis), in brain-injured rats compared to control rats though with glycolysis remaining 
dominant. (93) In humans, Dusick et al. infused 1,2-13C2 glucose intravenously, with 13C 
labelling in lactate assessed by arteriovenous-jugular difference. (94) This study in TBI 
patients and controls, although it did not sample the brain directly and could only yield 
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information on brain lactate labelling during periods when the brain was a net exporter of 
lactate into the vasculature, led to similar conclusions to the rat studies above.  
9.2.3 Significance of the PPP 
 
The PPP is a complex biosynthetic network generating many other species besides lactate 
(see Fig. 5.1) and the balance between these species can potentially shift depending on the 
local biology and pathology. Some PPP-derived species are potentially reparative, e.g. ribose 
(for nucleic acid synthesis) and NADPH (to provide reducing equivalents for fatty acid 
synthesis), and neuroprotective e.g. NADPH, used for producing the reduced form of 
glutathione and thioredoxin, which are cofactors for glutathione peroxidases and 
peroxiredoxins respectively, enzymes that combat oxidative stress. Accordingly, Herrero-
Mendez et al. (2009) demonstrated that If one of the key regulatory enzymes of glycolysis, 
phosphofructokinase, is activated in neurons so that more glucose is funnelled through 
glycolysis at the expense of the PPP, apoptosis soon ensues due to oxidative stress. (151) The 
PPP, which does not involve molecular oxygen and does not generate ATP, can thus be 
regarded as sacrificing some of the cells’ supply of glucose molecules, which might 
otherwise have been used for ATP synthesis via glycolysis and the TCA cycle, for the sake of 
generating more reducing power (NADPH) and the ability to protect, repair or build cells.  
9.2.4 Role of brain tissue oxygen concentration on glycolysis and pentose 
phosphate pathway 
 
In Study III, PbtO2 was measured alongside the microdialysis catheter in the TBI patients, and 
revealed that the ratio of PPP-derived lactate to glycolytic lactate showed a significant 
inverse correlation with PbtO2 (r= -0.5, p = 0.04) (Fig. 5.7). So, at lower PbtO2 levels, the 
balance between glycolysis and PPP shifted towards the PPP, although PPP-derived lactate 
was always much less than glycolytic lactate. Like glycolysis, the PPP does not utilise oxygen. 
Studies in adult rats and in brain slices have also suggested that hypoxia increases the PPP. 
(152) In contrast, Brekke et al. (2014) found evidence for a decrease in PPP in neonatal rats 
after hypoxic-ischaemic injury. (101) They postulated that the apparent inability to up-
regulate the PPP in this situation might render the neonatal rats vulnerable. An analogous 
situation might conceivably exist in human TBI, whereby low ability to up-regulate the PPP 
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might result in those individuals’ brain tissue (either globally or locally) having increased risk 
of damage. Therapeutic up-regulation of the PPP in this context might be beneficial.  
 
9.2.5 Summary 
 
Glucose is predominantly metabolised via glycolysis. The glycolytic production of lactate is 
increased after TBI. The PPP also generates lactate from glucose and there is a shift in 
glucose metabolism from glycolysis to PPP with decreasing brain tissue oxygen 
concentrations.  
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9.3 Cerebral lactate metabolism 
9.3.1 TCA cycle metabolism of lactate occurs in normal as well as injured 
brain  
 
I explored the role of lactate as a metabolic fuel in Study V. 3-13C lactate was delivered by 
microdialysis to TBI brain, ‘normal’ brain and muscle. Enrichment of glutamine isotopomers 
above background natural abundance was similar in TBI and normal brain (see Fig. 7.3) 
confirming that TCA cycle metabolism of lactate is not limited to the injured brain but also 
occurs to a similar degree in normal brain. In support of this is recent evidence from Glenn 
et al. (2015) demonstrating equivalent cerebral lactate metabolism by healthy control 
subjects and TBI patients. (17) They used a dual tracer technique that involved injecting 6,6-
2H2 glucose and 3-13C lactate intravenously and measuring 13C-carbon dioxide (13CO2) 
sampled from the jugular bulb. Although they did not measure downstream TCA cycle 
metabolism of lactate, they demonstrated similar production of 13CO2 in controls and TBI 
patients (after accounting for 13C glucose produced from 3-13C lactate undergoing 
gluconeogenesis systemically). The cerebral metabolism of 3-13C lactate in this study 
occurred despite a net release of lactate by the brain i.e. a negative AV gradient. 
Furthermore, lactate uptake and metabolism by the injured brain was maintained despite a 
significant depression in the cerebral metabolic rate (CMR) of glucose in TBI patients. (17) 
9.3.2 The metabolic fate of lactate 
 
I examined the downstream metabolic products of 3-13C lactate and found that the 
dominant metabolic pathway for lactate involves pyruvate dehydrogenase entry to the TCA 
cycle as opposed to pyruvate carboxylase entry. C4 glutamine exhibited the strongest 13C 
enrichment of the glutamine isotopomers indicating synthesis of 4-13C α-ketoglutarate 
during the first turn of the TCA cycle.  
 
Pyruvate carboxylase activity is thought to mediate the most important anaplerotic pathway 
in the brain, replenishing carbon stock to the TCA cycle by fixing carbon dioxide. Pyruvate 
carboxylase activity is predominantly found in astrocytes and not in neurons. The fact that 
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pyruvate dehydrogenase activity dominated the metabolism of lactate is consistent with the 
idea that lactate is predominantly a neuronal as opposed to astrocytic substrate. (10,12)  
9.3.3 Sources of brain lactate – the circulation 
9.3.3.1 Periods of net lactate uptake from the circulation into the brain after TBI 
 
In Study IV, periods of positive AVlac values, indicating net lactate uptake, were found in 
17/19 patients following TBI. The observation of net lactate uptake into the injured brain 
was found to be maximal on day 3 after injury.   
 
A switch to lactate uptake may be important after TBI due to a change in the metabolic 
priorities of glucose. As discussed above, a greater proportion of glucose might be 
metabolised by the PPP in some patients after TBI. Hence, alternative fuel substrates may 
become recruited in an effort to maintain adequate cellular energy reserves. In hippocampal 
slices, lactate can support normal synaptic function even in the absence of glucose, (14) and 
in humans, lactate uptake may be associated with a concomitant reduction in glucose 
uptake. (108,153) Hence, it appears that, not only can the brain take up lactate, but it can in 
at least some cases also be used preferentially over glucose for the purposes of energy 
generation.  
 
Lactate uptake into the injured brain may also reflect differing susceptibilities of neurons 
and astrocytes to injury i.e. uncoupling of neuronal and glial metabolism. The astrocyte-
neuron lactate shuttle hypothesis describes how neurons preferentially metabolise lactate, 
which is provided by astrocytes. (18) Hence, increased lactate demand from the injured 
brain may reflect a neuronal energy deficit that astrocytes are not able to support, especially 
if the astrocytes themselves are injured or compromised by TBI.  
9.3.3.2 Time-dependent changes in energy metabolism after injury 
 
The significance of a peak in lactate uptake on day 3 in the group of patients in Study IV is 
not entirely clear. Many of the pathophysiological mechanisms identified in TBI, such as cell 
swelling and membrane disruption, inflammatory response, mitochondrial dysfunction and 
electrophysiological disturbances, place demands on cellular energy metabolism. Changes 
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with time in brain extracellular concentrations of glucose, lactate and other small molecules 
occur in the course of days post-injury, demonstrated in a microdialysis study of 223 TBI 
patients. (39) The overall pattern in this study was a decline in glucose and a rise in lactate 
during the course of a week of monitoring. Comparing these TBI data to “normal” brain 
extracellular physiological ranges, (98) by Day 3 post-injury brain extracellular glucose 
appears to have declined to a critical point, to which the injured brain responds by importing 
more lactate from the bloodstream, presumably to act as a complementary energy source. 
There were also time-dependent post-TBI changes in the brain microdialysate cytokine and 
chemokine profile, in a detailed 42-plex study of 12 patients. (154,155) Day 3 post-injury 
appears to be in a transition period, in terms of identified cytokines and chemokines that 
are produced in defined time frames (e.g. IL-6 at 24–48 hours, IL-10 at 96–144 hours) and 
discriminate between different temporal phases of the inflammatory response. Therefore, it 
is reasonable to speculate that Day 3 post-injury represents the period when different 
pathophysiological mechanisms combine to exert the greatest metabolic demand.   
9.3.3.3 The brain imports lactate against a concentration gradient 
 
Lactate uptake into the brain is observed in several situations other than TBI. If arterial 
lactate concentrations are elevated sufficiently, a concentration gradient is established so 
that lactate is transported from the blood to the brain. Arterial lactate concentrations can be 
elevated experimentally by administering a lactate infusion or can dramatically rise during 
intense exercise. (108,156-158) Exercise-induced arterial lactate elevation to 2.5 − 3.5 
mmol/L results in lactate uptake by the brain as measured using AV concentration 
differences. (157,158) Interestingly, in Study IV I found that the median arterial lactate 
concentration was lower than the median brain extracellular lactate concentrations 
indicating uptake of lactate against a concentration gradient and suggesting up-regulation of 
lactate transport mechanisms. 14C-labelled lactate autoradiography and 13C-labelled lactate 
NMR experiments support the evidence here that the injured brain takes up more lactate 
even at normal circulating systemic concentrations. (16,159) 
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9.3.3.4 Lactate transport 
 
Lactate transport in the brain is facilitated by a series of monocarboxylate transporters 
(MCTs) that co-transport protons. MCT1 transporters are mainly expressed on endothelial 
cells and astrocytes, MCT2 transporters are predominantly neuronal and MCT4 
predominantly glial. (47,158,160) The behaviour of MCTs is complex and multifactorial. 
Movement of lactate “uphill” by MCT1 against a lactate concentration gradient may be 
facilitated by a “downhill” proton concentration gradient. (161) I was not able to measure 
cerebral extracellular pH to test this hypothesis due to there not being a clinically usable 
sensor. Various physiological and pathological conditions have been shown to induce the 
expression of MCT transporters. Following cortical contusion injury in rats, 
immunohistochemistry and western blot analysis demonstrated a 26-28% increase in 
expression of MCT2 transporters. (162) This induction of MCT2 expression occurred acutely; 
apparent at 3 hours following TBI. The induction of MCT2 expression was found primarily 
within the vasculature. This potentially correlates with the increase in lactate transport 
across the BBB that I observed. It is unclear how TBI might trigger up-regulation of MCT 
transporters. Conceivably, it may be driven by metabolism such that cellular demand for 
energy, at a time when glucose uptake is insufficient to meet this demand, promotes 
increased MCT activity. In addition, mediators that increase after TBI may induce MCT 
transporter expression. VEGF, HIF1 and noradrenaline are found to be elevated after TBI and 
have all been implicated in affecting MCT transporter expression. (160,163)  
9.3.4 Sources of brain lactate – the TCA cycle 
 
In Study VI, where I used 2,3-13C2 succinate perfusion, characteristic 13C doublet signals were 
produced for C3 and C2 isotopomers of lactate indicating that delivery of 2,3-13C2 succinate 
leads to 2,3-13C2 lactate. The synthesis of doubly-labelled lactate from 2,3-13C2 succinate is 
evidence for the generation of lactate from TCA cycle intermediates. 
 
The synthesis of lactate from the TCA cycle is achieved through the action of two pathways 
that lead to the generation of pyruvate from intermediates of the TCA cycle. Malate can be 
decarboxylated to pyruvate via malic enzyme and oxaloacetete decarboxylated to pyruvate 
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via the combined action of PEPCK and pyruvate kinase. (142-146) Demonstration that 
lactate can both feed and be derived from the TCA cycle is a novel finding in human brain.  
9.3.4.1 The significance of pyruvate recycling 
 
The decarboxylation of TCA cycle intermediates to pyruvate and subsequent generation of 
lactate that can then potentially be metabolised by the TCA cycle is perhaps an important 
mechanism for linking neuronal and glial TCA cycles. The cycling of TCA cycle intermediates 
in this way has been termed the ‘pyruvate recycling pathway’ although the potential role of 
lactate in this pathway, as defined in this thesis, has not previously been appreciated.  
 
Pyruvate recycling is thought to be important for the complete oxidation of glutamate, 
contributing to the energy needed by astrocytes to clear the synaptic cleft of glutamate. 
(142) Glutamate uptake into astrocytes is expensive requiring one mole of ATP per mole of 
glutamate, which is transported along the sodium gradient maintained by Na+-K+-ATPases. 
(164) Glutamate is oxidised by the astrocytic TCA cycle following its conversation to α-
ketoglutarate by mitochondrial aspartate aminotransferase, which also contributes to the 
malate-aspartate shuttle and therefore the transfer of reducing equivalents between the 
cytosol and mitochondria. TCA cycle metabolism of α-ketoglutarate followed by 
decarboxylation and metabolism in the pyruvate recycling pathway allows all the carbons of 
the glutamate molecule to be fully oxidised for energy (142) and for this energy to be passed 
back to neurons in the form of lactate.  
9.3.4.2 The utility of pyruvate recycling at times of metabolic stress 
 
Evidence for pyruvate recycling from cultured cerebellar neurons incubated with medium 
containing 1,6-13C2 glucose after a period (12 hr) without glucose suggested that pyruvate 
recycling permitted energy metabolism when glucose was low. (165) In a study examining 
brain extracts from a rat diabetic model after 2-13C acetate infusion, 2-13C lactate was 
observed indicative of pyruvate recycling. (166) Hence, pyruvate recycling has been 
proposed as a mechanism that protects against metabolic disturbances associated with 
diabetes. In a study where 1,2-13C2 acetate was infused into rats after permanent occlusion 
of the right middle cerebral artery and transient occlusion of both common carotid arteries, 
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which results in focal ischaemia within the right hemisphere, increased pyruvate recycling 
led to increased metabolism of 13C glutamine. Taken together, these results point towards 
the utility of pyruvate recycling for maintaining energy generation by the complete oxidative 
metabolism of glutamate and other metabolites derived from the TCA cycle, particularly at 
times of metabolic stress. In addition, both PEPCK decarboxylation and malic enzyme activity 
lead to the formation of NADPH, a reducing agent that participates in reductive biosynthetic 
reactions and in the production of the reduced form of glutathione and thioredoxin, which 
are cofactors for enzymes that scavenge hydroperoxides. (167) Hence, increased PEPCK 
decarboxylation might play a protective role after TBI combatting the oxidative stress that 
results from injured cells. 
9.3.5 Summary 
 
There are periods when lactate is imported from the circulation in TBI patients likely due to 
up-regulation of lactate transport. Both TBI and normal brain are able to metabolise lactate 
via the TCA cycle. TCA cycle intermediates can be decarboxylated to pyruvate and then to 
lactate, which is exported from the cell. Lactate, being both produced by and consumed by 
the TCA cycle, might function as an important intercellular metabolite linking neuronal and 
glial TCA cycles.  
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9.4 Potentiating cerebral metabolism after TBI 
9.4.1 Succinate perfusion improves redox balance and glycolysis 
 
In Study VI, a comparison of brain chemistry during baseline and during 2,3-13C2 succinate 
perfusion demonstrated a fall in glucose concentration suggesting greater utilisation, a fall in 
the LP ratio due to a rise in pyruvate, and fall in glutamate. Therefore succinate perfusion 
induces a shift in redox with increased cytosolic NAD+. This stimulates glycolysis causing a 
fall in glucose and a reciprocal increase in pyruvate. The shift in cytosolic redox reflects 
increased transfer of reducing equivalents (hydrogens and electrons) between the cytosol 
and mitochondria.  
9.4.2 Succinate’s contribution to the malate-aspartate shuttle shifts 
cytosolic redox 
 
The principle mechanism identified in brain that shuttles reducing equivalents between the 
cytosol and mitochondrion is known as the malate-aspartate shuttle. (168) In the cytosol, 
electrons from NADH are transferred to oxaloacetete through the action of malate 
dehydrogenase, which results in the production of malate that is then transported into 
mitochondria in exchange for α-ketoglutarate by the malate-α-ketogutarate carrier. The 
subsequent mitochondrial metabolism of malate in the TCA cycle to oxaloacetate results in 
the transfer of electrons to NAD+ forming NADH. Oxaloacetate can be transanimated to 
aspartate by mitochondrial aspartate aminotransferase, which also catalyses the conversion 
of glutamate to α-ketoglutarate. Aspartate is able to leave the mitochondria in exchange for 
glutamate and a proton from the cytosol via the Ca2+-sensitive aspartate-glutamate carrier, 
aralar1 (AGC1), which is found in brain; evidence from immunochemistry studies 
demonstrate its highly enriched presence in neurons. (169) In the cytosol, aspartate is 
metabolised to oxaloacetate by cytosolic aspartate aminotransferase, which also converts α-
ketoglutarate to glutamate (see Fig. 8.1). The overall rate-limiting step of the shuttle is the 
exchange of aspartate for glutamate by aralar1 and this transporter favours entry of 
glutamate and efflux of aspartate. Administration of succinate, which is metabolised to 
malate within the mitochondria, likely contributes to this shuttle. Hence, 2,3-13C2 succinate 
is metabolised to 2,3-13C2 oxaloaceate within the TCA cycle and then converted to 2,3-13C2 
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aspartate, which exchanges with glutamate via AGC1. 13C labelling in these intermediaries of 
the malate-aspartate shuttle were not detected in microdialysates, likely owing to their 
short-lived existence outside the cell. Aspartate functions as a neurotransmitter and is 
rapidly imported from the extracellular space. Contribution to the malate-aspartate shuttle 
in this way leads to a shift in the cytosolic redox balance as demonstrated by the fall in LP 
ratio.  
 
In support of succinate perfusion causing an increase in malate-aspartate shuttle activity 
was a significant fall in extracellular glutamate during succinate perfusion. Increased activity 
of AGC1, the rate-limiting step of the malate-aspartate shuttle, favours import of glutamate 
into the mitochondria. Therefore, the malate-aspartate shuttle draws glutamate into 
mitochondria for consumption by the TCA cycle and potentially prevents excitotoxic 
glutamate build-up. 
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9.5 General limitations 
9.5.1 Microdialysis 
9.5.1.1 Normal control tissue 
 
Cerebral microdialysis is generally restricted to patients with brain injuries given its invasive 
nature. Consequently there is limited data on normal ranges for metabolite concentrations. I 
chose to use patients undergoing surgery for resection of benign tumours with microdialysis 
catheters inserted into macroscopically normal brain as control subjects. Although this 
enabled qualitative conclusions to be drawn about the activity of metabolic pathways, 
namely glycolyitc activity, PPP activity and lactate metabolism, more quantitative 
comparisons between my control subjects and TBI patients is difficult due to the few 
patients available as control subjects. It must also be acknowledged that the very act of 
undergoing a craniotomy might influence cerebral chemistry in areas remote to the 
operative site.  
9.5.1.2 The use of pooled data from TBI patients 
 
TBI is a heterogeneous disorder and is commonly associated with injuries to other organs 
with systemic consequences that might be expected to influence brain metabolism. The 
number of patients I recruited is probably too small to allow meaningful analysis of systemic 
factors. Furthermore I was not able to collect complete data on all the systemic parameters 
that might influence brain metabolism such as systemic glucose, lactate and oxygen 
concentrations. However, microdialysis sampling was limited to sedated and ventilated 
patients with protocol-directed management of oxygenation and serum glucose; the impact 
of systemic changes in physiology is likely to be less than the perturbations to cerebral 
metabolism caused by the brain injury itself.  
 
I used pooled data of multiple samples from each patient to compare groups. The pooling of 
data for a particular epoch simplifies comparative analysis at the expense of reducing 
temporal information.  The future use of more sophisticated statistical methods as well as 
larger sample sizes would improve the reliability of the inferences made in this thesis. 
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9.5.1.1 Interpreting the effects of metabolite supplementation on brain chemistry 
 
Pooled microdialysis data from large series of TBI patients show significant associations with 
tissue and clinical outcomes (e.g. (39)). However, microdialysis data are found to be highly 
autocorrelated such that subject identity explains 52 to 75% of variance, as determined in a 
large study (90 patients) using statistical pattern recognition methods. (170) Therefore, 
caution must be applied when interpreting an individuals brain chemistry or when the 
sample size of pooled data is small, particularly when trying to evaluate the association of 
brain chemistry with clinical outcomes and with other physiological parameters such as ICP 
and PbtO2. In view of this, I chose to assess the impact of supplementary metabolites 
(glucose, lactate, succinate) on local brain chemistry by using each patient as their own 
control, assessing the change in metabolite concentrations, as opposed to looking for 
differences between pooled data.  
9.5.1.1 Catheter location 
 
TBI produces a heterogeneous injury pattern. Microdialysis is a focal technique and so brain 
chemistry is subject to catheter location particularly in relation to traumatic lesions such as 
contusions. I tried to avoid the influence of catheter location by placing microdialysis 
catheters away from lesions. I explored the influence that catheter location in grey or white 
matter has on brain chemistry in Study II. This study revealed that microdialysis catheters 
sometimes come to lie in grey matter and that differences in metabolism between grey and 
white matter might impact brain chemistry in TBI patients. This emphasises the importance 
of confirming catheter position on post-insertion imaging. Although I collected this data for 
all the patients studied in this thesis the numbers were insufficient to allow meaningful 
analysis of the impact of catheter location on metabolism. I would also argue that the 
influence of catheter location was less important when making qualitative inferences about 
metabolism based on 13C-labelling data. 
9.5.1.2 Relative recovery 
 
The concentration of a metabolite measured in the microdialysate is determined by the 
relative recovery of that molecule, which is determined by tissue properties, metabolite 
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properties and by microdialysis methodology including perfusion flow rate and the 
membrane properties (see Section 2.1.2). I maintained the same microdialysis method for all 
the studies in this thesis, using the same flow rate and catheter, varying only the 
supplementation of the perfusion fluid with 13C-labelled substrates. This is unlikely to have 
affected recovery given the small molecular size of the 13C-labelled molecules. Moreover, my 
qualitative interpretation of 13C-labelling in downstream metabolic products, assessment of 
13C fractional enrichment and measurement of the LP ratio are not subject to the effects of 
recovery. 
 
9.5.2 NMR spectroscopy as a tool to explore the metabolic profile of 
human brain microdialysates 
9.5.2.1 NMR quantification 
 
The methods used for this thesis include 1H and 13C NMR of microdialysates collected from 
human brain and muscle. Both 1H and 13C NMR allowed identification and quantification of a 
number of metabolites; the limit of detection using my 1H NMR methodology is 27 μmol/L. 
The optimum experimental conditions were defined in Study I. A high presaturation power, 
greater than -66 dBW, combined with a relaxation delay longer than 16 seconds were found 
to provide the most accurate results in terms of quantification. 13C NMR is not directly 
quantifiable in the same way as 1H NMR due to the unpredictable effect that NOE imposes 
on different 13C nuclei. Moreover, the relaxation times required to generate quantifiable 
spectra are in the order of several minutes (as opposed to the few seconds it takes 1H nuclei 
to fully relax) and it is thus not practical to run NMR experiments with the aim of quantifying 
13C nuclei directly. Study I confirmed the linear response produced by different 13C nuclei 
over a range of concentrations and thus enabled the generation of calibration curves that 
could be used for accurate quantification in the subsequent studies. 
 
The most significant limitation of my methodology is the inherent low sensitivity of 13C NMR 
and the small sample volumes acquired using microdialysis. I attempted to overcome this by 
pooling microdialysates over a 24-hour period, which limits biological information on more 
dynamic physiology, and by using an NMR experimental set-up with a high number of scans 
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per experiment to increase signal-to-noise ratio. However, despite this, observation of the 
metabolites derived from 13C-labelled substrates, which become progressively more and 
more dilute as they proceed through biochemical pathways, is likely limited to the early 
steps of metabolism. For example, 1,2-13C2 glucose administration by microdialysis leads to 
reliably quantifiable 13C-labelled lactate. However, in the subsequent metabolism of lactate, 
the downstream dilution of 13C label with endogenous unlabelled intermediates probably 
explains why I did not observe significant 13C enrichment of extracellular metabolites 
derived from the TCA cycle. Furthermore, microdialysis samples the extracellular interstitial 
fluid and so only those metabolites that are exported from the cell are sampled.  
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10.1 Microdialysis NMR methodology 
 
The delivery of 13C-labelled metabolic tracers by microdialysis is a safe and convenient 
method for interrogating metabolism in patients. Developments in superconductor and 
cryprobe technology will result in more sensitive NMR instruments. Improvements in 13C 
NMR sensitivity will allow smaller microdialysate volumes to be analysed and also improve 
signal-to-noise. Smaller sample volumes and thus better time resolution would be useful 
from a biochemical perspective allowing time course evaluation of metabolic processes. In 
the future it might be possible to derive rate data for metabolic kinetic modelling of local 
glucose consumption rates and glycolytic- and PPP-production rates of lactate.  
10.2 Complimentary methods for measuring cerebral metabolism 
 
The microdialysate LP ratio in combination with the pyruvate concentration provides a 
surrogate marker of mitochondrial metabolism. A more direct measure of mitochondrial 
function would be useful for future clinical studies on cerebral metabolism. Phosphorus (31P) 
in vivo magnetic resonance spectroscopy (MRS) has been used to interrogate human 
cerebral energy metabolism. An important advantage of MRS techniques is their ability to 
yield biochemical information non-invasively without the need for tracers (although, unlike 
microdialysis, they do not provide continuous data). 31P MRS can be used to measure ATP 
and phosphocreatine, a readily mobilised store of high-energy phosphate, which are 
indicators of oxidative phosphorylation status and mitochondrial function. Hence, 31P MRS 
would be a useful adjunct to the studies in this thesis particularly serving as an end-point for 
future studies on interventions that boost energy metabolism. 
10.3 Strategies to improve energy metabolism after TBI 
 
The findings in this thesis raise interesting questions about potential strategies to improve 
energy metabolism in TBI patients. The PPP is potentially protective and reparative for the 
injured brain; therapeutic up-regulation might prove clinically beneficial. The injured brain’s 
capacity to metabolise endogenous lactate implies that exogenous lactate may be 
therapeutic in TBI patients. Succinate improves energy metabolism by influencing the redox 
balance most likely by boosting malate-aspartate shuttle activity. In addition to these 
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beneficial effects on metabolism in the injured brain, succinate might improve ATP 
generation more directly through its action on oxidative phosphorylation.  
10.3.1 PPP up regulation 
 
Various up-regulators of the PPP have been identified. Insulin has been shown to increase 
the expression of glucose-6-phosphate dehydrogenase mRNA in primary rat hepatocytes. 
(171) Dehydroascorbate, the oxidised form of vitamin C, has been shown to stimulate the 
activity of several PPP enzymes, increase glutathione levels and inhibit hydrogen peroxide-
induced changes in mitochondrial transmembrane potential in Jurkat cells (a cancer cell 
line). (172) Although these two latter studies were not performed in brain, they nevertheless 
illustrate the principle that the PPP can be deliberately up-regulated with measurable 
biochemical and biological effects. 
10.3.2 Mitochondrial rescue agents 
 
In addition to improving redox and providing a more permissive environment for glycolysis 
succinate might also improve mitochondrial ATP generation more directly. Succinate can 
provide energy support in compromised mitochondria as it bypasses Complex I of the 
mitochondrial electron transport chain, which in some situations appears more vulnerable 
to inhibition and/or damage than Complexes II, III and IV (134). Once permanent 
mitochondrial dysfunction has developed, cellular optimisation of any residual ability to 
produce energy may prevent the ATP level from dropping below the threshold that 
stimulates initiation of cell death pathways. The strategy of administering agents to ‘bypass’ 
defective components of the mitochondrial electron transport chain to sustain ATP synthesis 
has successfully been demonstrated (by 31P magnetic resonance spectroscopy of muscle) in 
a patient with a genetic defect in Complex III, for which the appropriate bypass agents were 
vitamins C and K (173). In an experimental model of sepsis (a pathology involving energy 
dysfunction), infusion of succinate prevented the fall in liver ATP content (174) and 
prolonged survival time (175). Administering succinate in TBI may thus support the activity 
of the electron transport chain and oxidative phosphorylation. Future proof-of-concept 
studies investigating succinate and other ‘mitochondrial rescue’ agents using 13C-tracers, 
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microdialysis and other metabolic markers such as 31P MRS will hopefully identify novel 
treatment strategies for TBI patients. 
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